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Abstract  
Clostridium difficile is the leading cause of hospital acquired diarrhoea. With extended 
hospitalisation, a high mortality rate and the risk of recurrence, C. difficile infection presents 
a burden to both patients and the healthcare system. Symptoms of disease are primarily 
mediated by the two major toxins released by C. difficile and are the focus of current 
vaccine studies. Little is known of surface proteins in C. difficile, their role in colonisation 
and their potential as antigens to reduce severity of disease. The surface of C. difficile is 
composed of a peptidoglycan cell wall and an external S-layer. In many Gram positive 
bacteria a membrane bound enzyme, sortase, covalently attaches specific proteins to the 
cell wall.  
In this study, seven potential sortase substrates were identified and shown to be expressed 
in C. difficile 630, and at least four were shown to be localised to the cell wall. The substrate 
CD0183 was shown to need its LPxTG like domain for correct sorting onto the cell wall by 
sortase, which was shown to be a probable cysteine protease. An efficient cell wall 
extraction protocol was developed alongside two novel assays for studying the sortase 
mechanism which could provide future insights into this mechanism of protein sorting. The 
highly conserved S-layer protein Cwp2 is co-transcribed with CD2790 and cwp66 and its 
promoter is important for the expression of cwp66, especially during exponential growth. S-
layer proteins were shown to potentially reduce colonisation and disease in a multi-
component vaccine, with Cwp2 in particular identified as an antigen which can prevent 
diarrhoeal symptoms of disease in hamsters. Thus S-layer proteins are potentially important 
components of a vaccine against C. difficile infection.   
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1Chapter 1 Introduction 
1.1 Clostridium difficile infection and disease 
1.1.1 An antibiotic associated nosocomial infection 
 
Clostridium difficile infection, termed CDI, is caused by colonisation of the human intestine 
by a Gram-positive bacterium known as C. difficile.  CDI accounted for 1% of all hospital 
deaths in England and Wales during 2009-2011 (www.statistics.gov.uk), with 2,053 deaths 
involving C. difficile in 2011 compared with 364 deaths caused by MRSA, another major 
nosocomial infection. C. difficile can cause severe enteric infections resulting in a range of 
gastrointestinal diseases (Rupnik et al. 2009). These include mild diarrhoea, debilitating 
diarrhoea, pseudomembranous colitis and death. Studies show that antibiotic use increases 
the risk of a patient acquiring CDI, even in the 3 month period after cessation of antibiotic 
therapy (Hensgens et al. 2012). C. difficile is therefore a major nosocomial pathogen, being 
the leading cause of hospital acquired diarrhoea (Kuipers and Surawicz 2008). 15 – 20 % of 
cases of antibiotic associated diarrhoea are a result of CDI (Bartlett and Gerding 2008) and 
CDI is the cause of the majority of cases of colitis associated with antibiotic use (Kelly et al. 
1994b). Antibiotic use causes disruption of the commensal flora of the intestine and 
provides a niche in which C. difficile can colonise and flourish before producing toxin and 
causing disease symptoms (Buffie et al. 2012). This was elegantly shown by Pultz and 
Donskey using the mouse model of CDI, where different antibiotics were administered to 
mice, and C. difficile quantified 3 days after the final dose (Pultz and Donskey 2005). 
Colonisation by C. difficile was observed with neither saline controls, nor mice treated with 
aztreonam, an antibiotic associated with minimal disruption of the anaerobic gut flora. C. 
difficile is resistant to aztreonam, so it was not due to antibiotic sensitivity that C. difficile 
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did not colonise the gut. Additionally, treatment with piperacillin-tazobactam to which C. 
difficile is sensitive and which disrupts the gut flora showed colonisation by C. difficile only 
once the drug had reduced to levels which no longer inhibited C. difficile growth (while 
colonisation 2 hours after the final dose of this antibiotic was minimal). Finally, using 
ceftriaxone, an antibiotic to which C. difficile is resistant and which disrupts the gut flora 
resulted in colonisation by C. difficile. This provided evidence that C. difficile is an 
opportunistic pathogen which colonises the gut upon reduction of the natural flora within 
the gut. This has been shown with other antibiotics, with clindamycin shown to induce a 
“super-shedder” state in mice asymptomatically colonised with C. difficile (Lawley et al. 
2009a) and with cefaperazone which can result in severe colitis in mice challenged with C. 
difficile (Theriot et al. 2011). 
1.1.2 Community infection 
 
In addition to being a major nosocomial pathogen, approximately 1-3% of the healthy 
population carries C. difficile as a commensal bacterium (Kuipers and Surawicz 2008). 
Analysis in Ireland in elderly subjects found that while there was 21% carriage for patients in 
short or long term care hospital, there was 9.5% carriage in outpatient settings and 1.6% 
carriage in the community (Rea et al. 2012). Despite the prevailing knowledge that C. 
difficile is a hospital acquired infection, since the 1990s community acquired infection by C. 
difficile has been increasingly reported. Community infection is determined by either toxin 
or C. difficile positive specimens collected as outpatients or within 3 days of admission of a 
patient who has not had an overnight stay in a healthcare-facility 12 weeks prior to the 
detection of the positive specimen (http://www.cdc.gov/hai/eip/cdiff_techinfo.html). In a 
study in North America in 2010 encompassing eight diverse geographic areas, it was 
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observed that 32% of cases of CDI were community associated, with the most common C. 
difficile strain being NAP1 at 23.5% (Lessa 2013). The study found that a quarter of patients 
with community acquired infection were hospitalised from the infection, but that 
complications and recurrence were less prevalent than in studies of hospital acquired C. 
difficile infections. Additionally, a study in Sweden showed 28% of cases of C. difficile 
associated diarrhoea could be defined as community acquired, with a larger proportion of 
patients aged 0-4 years developing community acquired diarrhoea (52%) compared with the 
over 60s (18%) (Karlstrom et al. 1998). The incidence of community colonisation appears to 
further decrease in elderly subjects (median age 81 years) in the United Kingdom with only 
4% of subjects in the community positive for C. difficile, and symptom free with no prior 
history of CDI or antibiotic use in the 3 months preceding analysis (Miyajima et al. 2011). 
Community associated colonisation by C. difficile is therefore increasing but its significance 
remains to be determined. It affects a younger population than observed in the hospital 
environment, is less likely to follow exposure to antibiotics but is generally less likely to 
cause a severe infection (Khanna et al. 2012).  
1.1.3 At risk groups of CDI  
 
As previously discussed, patients undergoing antibiotic treatment for a primary infection are 
at risk of C. difficile infection. Elderly patients have long been associated with a greater risk 
of CDI, and a study by Louie et al showed that patients above the age of 40 have decreased 
clinical cure and increasing risk of recurrence of infection (Louie et al. 2013). Risk factors 
were suggested to have been due to infection with potentially more virulent strains, the 
status of the patient prior to CDI and renal insufficiency, amongst others. It has also been 
previously suggested that the increase in frequency and severity of infections in elderly 
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patients is a consequence of immunosenescence, such that the immune system shows a 
decline in production of new lymphocytes causing difficulties fighting infections (Hakim and 
Gress 2007). In a study of C. difficile associated diarrhoea in Sweden (Karlstrom et al. 1998), 
39% of patients who developed symptoms in hospital were in the internal medicine wards, 
18% in surgery/orthopaedic wards, 17% in infectious diseases wards and 13% in 
geriatric/rehabilitation wards. However, of the proportion of patients developing diarrhoea 
in each ward, the highest incidence was in the geriatric/rehabilitation wards (95 per 10,000 
admissions). This was followed by wards for infectious diseases, internal medicine and 
oncology, showing that patients with compromised immune systems and undergoing 
antibiotic treatment were at high risk of infection.  
Additional risk factors include use of proton-pump inhibitors (Cunningham and Dial 2008), 
although this research is controversial. Briefly, proton-pump inhibitors greatly reduce the 
production of gastric acid which is a known host defence against gastrointestinal infections. 
However, spores are resistant to the action of gastric acid so the role of these inhibitors in 
CDI is still ambiguous.  
1.1.4 Toxins of C. difficile  
 
There is now overwhelming evidence that the symptoms of C. difficile infection are 
mediated by the action of enterotoxins. Early studies with Clostridium sordellii antitoxin 
showed neutralisation of the C. difficile toxins in cell rounding assays (Bartlett et al. 1978; 
Chang et al. 1978; Willey and Bartlett 1979) and removed the symptoms of C. difficile 
infection in hamsters, with a reduction in mortality by 75% and reduction in toxicity in faecal 
filtrates (Allo et al. 1979). These studies implicated the toxins in disease symptoms of C. 
difficile infection. There are three known C. difficile toxins; Toxins A, B and binary toxin. 
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Strains of C. difficile contain within their genomes variations in the sequences of these 
toxins, with not all strains containing binary toxin, and some not expressing a copy of the 
toxin A gene (A-/B+ strains) and some expressing no toxins (A-/B-). There are also variations 
in the level of toxin expression between strains of C. difficile.  
Pathogenesis is principally based upon the production of two highly related cytotoxins, toxin 
A (TcdA – 308 kDa) and toxin B (TcdB – 269 kDa). The genes for toxins A (tcdA) and B (tcdB) 
are found on a 19.6 kb pathogenicity locus (PaLoc) (Braun et al. 1996) which also includes 
three other genes: tcdR, tcdC and tcdE (Figure 1.1a). Due to its homology to DNA-binding 
proteins, TcdR is predicted to be a positive regulator of toxin expression, with its presence 
enhancing toxin promoter activity in E. coli (Moncrief et al. 1997). TcdE is speculated to be a 
holin-like protein involved in the release of toxin from C. difficile (Govind and Dupuy 2012). 
tcdC shows high expression during exponential phase, and a decrease in transcription when 
the rest of the PaLoc is upregulated, suggesting it to be a negative regulator of toxin 
production (Hundsberger et al. 1997; Carter et al. 2011; Saujet et al. 2011). Mutation in 
TcdC in some strains, such as in R20291, was believed to cause constitutive expression of 
toxins and make strains “hypervirulent” (Curry et al. 2007). However, through genetic 
manipulation of tcdC in R20291 one study has shown no link between tcdC mutations and 
toxin production (Cartman et al. 2012). It is hypothesised that tcdA and tcdB genes may 
have arisen by a duplication event. 
Some strains produce binary toxin (Stubbs et al. 2000), homologous to binary toxins in other 
Clostridial species which are actin-specific-ADP-ribosyltransferases (Popoff and Boquet 
1988; Perelle et al. 1997). Binary toxin genes, ctdA and ctdB are located away from PaLoc on 
the chromosome and toxin production is controlled by ctdR (Carter et al. 2007). Toxin A-/B- 
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strains which express binary toxin are non-pathogenic in hamsters and do not cause the 
same level of mucosal damage in the rabbit ileal loop as toxin positive strains (Geric et al. 
2006). Despite this, Toxin A-/B- Binary Toxin positive strains have been isolated from 
symptomatic patients, though frequency is low (Geric et al. 2003) and some studies have 
found more severe diarrhoea when binary toxin is present (Barbut et al. 2005; Bacci et al. 
2011). One study shows that binary actin ADP-ribosylating toxins increase the length of 
microtubules and cause protrusions from epithelial cells which embed bacteria, possibly 
allowing for increased colonisation by Clostridia (Schwan et al. 2009).  
The structures of toxins A and B are very similar, with four distinct domains which perform 
the same functions in each toxin (Figure 1.1b). These are the enzymatic, cysteine protease, 
translocation and cell binding domains. Cell binding activity is contained in the C-terminal 
domain of each toxin and consists of repeated motifs. In toxin A this domain is 38 repeats 
long (Dove et al. 1990), and 24 repeats long in toxin B. The receptor on host cells is as yet 
unknown; however studies suggest these repeat domains bind to carbohydrate (von Eichel-
Streiber and Sauerborn 1990). Many studies have linked these repeat domains with binding 
receptors in animal models, however, most of these receptors are not found in the human 
intestine. Interaction with a receptor allows for toxin uptake via host mediated endocytosis 
and without this domain the toxins do not cause cytotoxicity (Frisch et al. 2003). There has 
been recent speculation that an additional receptor binding domain may exist which 
incorporates the C-terminal region of the translocation domain, as this region is not 
necessary for toxin translocation (Genisyuerek et al. 2011). 
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Upon endocytotic uptake of the toxins into host endosomes, acidification of the endosome 
causes the protein to undergo an allosteric structural change that exposes hydrophobic 
residues (Qa'Dan et al. 2000; Pruitt et al. 2010). The translocation domain is a hydrophobic 
domain which is predicted to span the endosome membrane, allowing for toxin processing 
and release of the catalytic enzymatic domain alone into the cell cytoplasm (Pfeifer et al. 
2003). Without this domain the toxins show reduced activity (Zhang et al. 2013) and this 
domain has been indicated to be important for release of components from large lipid 
vesicles, with two glutamate residues potentially involved in pH sensing for membrane 
insertion (Genisyuerek et al. 2011). The cysteine protease domain allows for self processing 
Figure 1.1 PaLoc and toxin structure in C. difficile 
A: Pathogenicity locus (PaLoc) of C. difficile toxins A (tcdA) and B (tcdB). PaLoc also includes a 
putative positive regulator of toxin production, tcdR, a holin-like protein, tcdE, and a putative 
negative regulator of toxin production, tcdC. 
B: General structure of toxins A and B. N-terminal enzymatic domain contains catalytic and 
cysteine protease activity regions, translocation domain which contains an additional putative 
receptor binding domain, and the receptor binding domain contains repeat motifs (black lines). 
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of the toxins to allow for detachment of the enzymatic domain from the host endosome. 
Following binding of inositol hexakisphosphate this cysteine protease domain mediates 
autocatalytic processing of the toxins (Egerer et al. 2009). This further supports the theory 
that the translocation domain spans the endosome membrane as this would expose the 
cysteine protease domain to cytoplasmic inositol hexakisphosphate.  
The 543 amino acid N-terminal catalytic domain of the toxins is the portion of these proteins 
that mediates tissue damage leading to symptoms of disease (Rupnik et al. 2005) and it 
alone is exported into the host cell (Pfeifer et al. 2003). This enzymatic domain is released 
from the endosome into the host cytoplasm (Pfeifer et al. 2003; Rupnik et al. 2005) and 
targets small GTPases such as Rho, Rac and Cdc42, acting as a glucosyltransferase to 
irreversibly inactivate these eukaryotic proteins (Just et al. 1995a; Just et al. 1995b). This 
prevents downstream signalling from these proteins, causing disruption of the actin 
cytoskeleton (Mitchell et al. 1987). Cell morphology is disrupted due to a decline in F-actin 
in cells (Chang et al. 1979; Fiorentini et al. 1990) which also leads to the disruption of tight 
junctions between intestinal epithelial cells (Nusrat et al. 2001). It is believed that apoptosis 
of cells treated with C. difficile toxins is independent of their action on the actin 
cytoskeleton. In CHO cells, the enzymatic domain of toxin A accumulated in the 
mitochondria, a sign of impending apoptosis, before glucosylation of Rho proteins (He et al. 
2000). However some studies do show a link between the alterations in Rho activity and 
activation of caspase apoptotic pathways (Brito et al. 2002). There appears to possibly be 
both actin dependent and independent pathways to apoptosis stimulated by the action of 
toxins (Qa'Dan et al. 2002). Both toxins A and B induce the influx of neutrophils which 
causes the inflammation associated with pseudomembranous colitis (Kelly et al. 1994a). This 
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is probably partly due to disruption of tight junctions, but additionally through stimulation 
of chemokine expression (Kim et al. 2002) and macrophage derived TNF-α (Kelly et al. 
1994a). 
The role of both proteins in pathogenesis has long been disputed, but it is known that toxin 
negative strains do not commonly induce severe disease (Polage et al. 2012). Toxin A-/B+ 
strains cause similar disease to A+/B+ strains, but in nature no toxin A+/B- strains have been 
discovered. Both toxins have been shown to be important in virulence (Lyras et al. 2009; 
Kuehne et al. 2010), but there is still dispute over the relevance of each. However, it is 
certain that the toxins of C. difficile play a key role in pathogenesis, regardless of the role of 
each individual toxin.  
1.1.5 Asymptomatic colonisation  
 
Patients can be asymptomatically colonised with C. difficile, even with virulent ribotypes 027 
and 078, and subjects asymptomatically colonised show no dramatic difference in 
microflora diversity from subjects who were not colonised by C. difficile, although as 
previously noted, those who later succumbed to CDI showed marked reduction in microbial 
diversity (Rea et al. 2012). A study of asymptomatic patients in a Veterans Medical Centre in 
the US showed 51% were carriers of C. difficile and that asymptomatic carriers were more 
likely to have had a previous episode of C. difficile associated diarrhoea and antibiotic 
exposure than the non-carriers (Riggs et al. 2007). 20% of asymptomatic patients then later 
developed C. difficile associated diarrhoea. There were high levels of spores on patient’s 
skin and in the environment, and the study suggested that these asymptomatic carriers 
could contribute to transmission of disease. However, none of the non-carriers developed C. 
difficile associated diarrhoea, and in another study comparing colonisation in a geriatric 
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unit, only those patients who were asymptomatically colonised at the start of the study 
were colonised at the end of the study (Schoevaerdts et al. 2011). However, patients with 
asymptomatic colonisation by C. difficile are still at risk of later developing C. difficile 
associated diarrhoea and could prove a risk of transmitting infection to other people. 
Despite this, a study in hamsters suggested that asymptomatic colonisation with non-
toxigenic strains of C. difficile can act as a prevention of colonisation of toxigenic strains 
(Sambol et al. 2002) suggesting why patients asymptomatically colonised are at less risk of 
developing CDI associated diarrhoea.  
1.1.6 Recurrence of CDI 
 
Rates of recurrence cited range from 15-35% (Lowy et al. 2010; Louie et al. 2011) and are 
described as a recurrence of symptoms 3-21 days after CDI treatment is discontinued. 
Patients who experience recurrent infections are usually treated with the same antibiotics 
as used in the initial infection, however this is occasionally ineffective and multiple relapses 
of infection occur. Recurrence can be due to a failure to eradicate C. difficile from the 
patient, or due to re-infection from the environment. A study in 1998 found that the risk of 
relapse increases if antibiotics for a primary infection, which resulted in CDI, were continued 
or restarted following treatment of CDI (Nair et al. 1998). A study in 2000 using data from 
patients in 20 different hospitals found that nearly 50% of recurrences were due to re-
infection with a different strain of C. difficile from the original infection, and that re-
infections occurred later than relapses from the initial infection (Barbut et al. 2000). 
Another study found that 80% of recurrent infections are caused by the same strain as the 
initial infection, while 20% were found to be re-infection with a different strain (Oka et al. 
2012). However, this second study was conducted in only two hospitals, with many 
23 
 
recurrences occurring within the same hospital environment as the initial infection, such 
that many relapses could be re-infections with the same strain as the initial infection, rather 
than persistence in the gut following initial treatment (Wilcox et al. 1998). This is almost 
impossible to clarify. These studies show that many recurrences of CDI could be prevented 
with shorter hospital stays for patients, confirming the increased risk of CDI from longer 
hospital stays. Additionally better management of the primary infection and its treatment 
could prevent relapses when treatment is restarted. Increasing age and hospital exposure 
increase the risk of recurrent CDI (Eyre et al. 2012). Other suggested risk factors have been 
binary toxin expression (Stewart et al. 2013) and ribotype of the initial infection, such as 
ribotype 027 (Marsh et al. 2012).  
1.1.7 Strains of C. difficile are highly variable 
 
As mentioned in 1.1.4 there is a high degree of variation in toxin production, either through 
variations in the toxins encoded by a strain or from the level of toxins produced. This 
variation is also evident in surface proteins, such as SlpA (Calabi and Fairweather 2002), 
Cwp66 (Waligora et al. 2001) and CwpV (Reynolds et al. 2011) as well as antibiotic 
resistance (Pepin et al. 2007). Due to this high level of variation between strains of C. 
difficile it has been important to organise and group strains based on shared characteristics. 
There are already numerous methods for doing so, but from these analyses disease-causing 
strains always arise from multiple lineages, with subtle differences between strains likely 
due to horizontal gene transfer and large-scale recombination of important genes (Sebaihia 
et al. 2006); (He et al. 2010). C. difficile populations can be divided into 4 genetic groups or 
clades (Stabler et al. 2006), and there is both grouping within and crossover between clades 
of different genotypes determined by toxinotyping, ribotyping, multi-locus sequence typing 
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(MLST) and restriction endonuclease analysis. One study showed that with the exception of 
occasional recombination events, there is a degree of accordance between C. difficile clade 
and the variation between PaLoc tcdB-receptor binding domains and tcdC sequences (Dingle 
et al. 2011a). Other methods of typing also generally link strains which have similarities such 
as antibiotic resistance and toxin production (Killgore et al. 2008). Methods of typing C. 
difficile include methods amplifying or digesting DNA. PCR ribotyping (Bidet et al. 1999; 
Stubbs et al. 1999) and multilocus variable-number tandem-repeat analysis (MLVA) (van den 
Berg et al. 2007) make use of PCR amplification of genome targets, 16S rRNA intergenic 
sequences and seven regions with short tandem repeats, respectively. Amplified fragment 
length polymorphism (AFLP) uses a combination of DNA digestion and PCR (Mohammadi et 
al. 2005). Meanwhile, MLST (Lemee et al. 2004; Griffiths et al. 2010) and Surface layer 
protein A gene sequence typing (slpAST) (Kato et al. 2005) sequence selected gene 
segments, with SlpAST sequencing the variable region of slpA and comparing the predicted 
amino acid sequences (Karjalainen et al. 2002). Pulsed-field gel electrophoresis (PFGE) 
(Killgore et al. 2008) and restriction endonuclease analysis (REA) (Clabots et al. 1993) involve 
enzymatic digestion of total genomic DNA, using SmaI and HindIII restriction enzymes 
respectively.  
Between 1999 and 2004 there was a marked increase in mortality associated with CDI in the 
US, Canada and the UK (Redelings et al. 2007). This increased mortality was in part due to 
the emergence of fluoroquinolone antibiotic resistant strains of C. difficile determined as 
ribotype 027. These strains produced elevated levels of toxins A and B, and were termed 
“hypervirulent” (O'Connor et al. 2009). With the emergence of these hypervirulent 027 
strains, primary antibiotic treatment with both vancomycin and metronidazole has had 
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limited efficacy against CDI (Pepin et al. 2007). Meanwhile, PCR ribotype 078 was found to 
be one of the most prevalent PCR ribotypes in Europe in 2008 along with ribotypes 001, 014 
and 020 (Bauer et al. 2011). A study in the Netherlands found 078 strains to be associated 
with younger patients and community-associated disease compared with 027 strains, with 
both ribotypes showing similar disease phenotypes and morbidity (Goorhuis et al. 2008). 
Additionally, finding an effective treatment for disease recurrence for these hypervirulent 
strains has proven difficult (Kuipers and Surawicz 2008).  
What is clear from all these studies is that C. difficile is a highly variable organism which is 
constantly evolving. There is not a global trend in the strains causing CDI so multifaceted 
approaches are needed to combat infection and transmission. 
1.1.8 Sporulation and germination 
 
The infectious agent of C. difficile is the spore which is capable of germination and is heat 
resistant (Nakamura et al. 1985). Spores are resistant to many physical and chemical 
treatments, such as disinfectants (Lawley et al. 2009b) and have been shown to frequently 
contaminate the hospital environment, mostly in the rooms of patients suffering from CDI 
(Dubberke et al. 2007). Spores are highly infectious, with the presence of only a few spores 
in the environment capable of infecting exposed antibiotic treated mice (Lawley et al. 
2009b). Studies have shown that non-infectious mice asymptomatically colonised with C. 
difficile treated with antibiotics enter a highly contagious “supershedder” state whereby the 
mice shed large numbers of spores, which are capable of infecting non-colonised, cohabiting 
mice (Lawley et al. 2009a). Additionally, this study showed that transmission to 
immunocompromised mice (Myd88-/-) results in a severe intestinal disease which is 
uncommon in immunocompetent mice.  
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1.1.8.1 Germination of spores 
Sodium taurocholate, the main component of bile, enhances germination of spores into 
vegetative cells (Wilson et al. 1982) as do other chlorine derivatives with the amino acid 
glycine. Enhanced germination is often seen on agar rather than in liquid broth (Sorg and 
Sonenshein 2008) with an optimum germination pH of 6.5-7.5 (Wheeldon et al. 2008), 
suggestive that the spores must germinate in the neutralised region of the intestine and 
may require adhesion to semi-solid surfaces. Rich media such as BHIS can also induce 
germinate in the absence of taurocholate (Heeg et al. 2012).  
One study has shown that isolates recovered from relapse cases have a higher rate of 
germination without sodium taurocholate stimulation than isolates from single infections 
(Oka et al. 2012) such that germination efficiency of strains could be an indicator of a risk of 
recurrent infection. Germination is not ribotype specific, with strains within ribotype 027 
having different rates and extents of germination in response to taurocholate (Heeg et al. 
2012), although studies suggest that strains linked to severe CDI have higher germination 
efficiencies (Moore et al. 2013).  
1.1.8.2 Sporulation 
SpoOA mutants of C. difficile are defective in sporulation (Underwood et al. 2009).  This is 
consistent with the known essential role of SpoOA as the master response regulator in the 
related bacterium Bacillus subtilis (Olmedo et al. 1990). SpoOA mutants are unable to 
persist and cause transmission between mice, suggesting an essential role of sporulation in 
infection, recurrence and transmission of C. difficile (Deakin et al. 2012). It has been 
suggested that there is a link between toxin production and SpoOA expression, highlighted 
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in one study where high toxin production was observed in strains producing high levels of 
spores (Vohra and Poxton 2011a).  
Higher rates of sporulation have been suggested as a phenotype that could contribute to 
the survival and spread of certain strains (Akerlund et al. 2008), however there seem to be 
conflicting studies to date as to whether “hypervirulent” strains sporulate more or less than 
less virulent strains (Burns et al. 2010; Vohra and Poxton 2011a). 
 
1.2 Control, treatment and prevention of C. difficile infection  
1.2.1 Control of C. difficile infection in the hospital environment 
 
Rooms containing both symptomatic and asymptomatic patients are often contaminated 
with C. difficile spores (McFarland et al. 1989), as well as C. difficile being culturable from 
the hands of hospital personnel which could easily be acquired on sterile gloves (Riggs et al. 
2007). This suggests that spores of C. difficile can easily be transmitted from both 
symptomatic and asymptomatic patients by skin and environmental contact.  
Alcohol based hand hygiene is ineffectual against C. difficile spores (Wullt et al. 2003) and 
recent guidelines suggest visitors and healthcare workers should wash their hands with soap 
and water after coming into contact with patients CDI (Cohen et al. 2010). The use of gloves 
which are disposed of following patient contact has been shown to reduce the incidence of 
CDI from 7.7/1000 patient discharges to 1.5/1000 in one hospital and also reduced 
asymptomatic colonisation (Johnson et al. 1990). Studies suggest the use of gloves should 
be coupled with further hand washing following disposal of contaminated gloves for 
physical removal of any remaining spores (Oughton et al. 2009).  
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Patients with CDI should also be isolated, but many hospitals do not include 
asymptomatically colonised patients as repeat screening is not cost effective (Aichinger et 
al. 2008). Delays can often occur between taking samples and completing testing for CDI, 
such that patients are not necessarily isolated swiftly enough, causing the risk of spreading 
of disease. It has therefore been suggested that patients with suspected CDI should be 
isolated before results from tests return to prevent the risk of transmission (Sunkesula et al. 
2013). 
Environments should be thoroughly cleaned during and after a patient has developed CDI. 
Hypochlorite reduces surface contamination with C. difficile spores (Kaatz et al. 1988) as 
strong oxidising active ingredients in disinfects such as hydrogen peroxide and chlorine 
(Vohra and Poxton 2011b) are effective at preventing spore transmission after 5 minutes of 
exposure. Hydrogen peroxide vapour treatment could be for as little as 1 minute for 
effective disinfection of heavily contaminated surfaces (Lawley et al. 2010), with oxidizing 
agents such as Perasafe being more effective than other oxidizing agents such as Virkon 
(Dawson et al. 2011). It has also been shown that for fully effective removal of spores from 
the hospital environment, both chemical and physical removal of spores is necessary (Rutala 
et al. 2012). UV radiation for 50 minutes has been shown to reduce C. difficile spores in the 
environment by 99.8% (Rutala et al. 2010). 
1.2.2 Current treatment methods for CDI 
 
Guidelines in the USA suggest minimising the frequency and duration of antibiotic treatment 
for the primary infection to reduce the risk of CDI (Cohen et al. 2010) and continuation of 
this primary treatment following recovery from CDI is not recommended due to the risk of 
recurrence of CDI.  
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Two antibiotics are commonly used for treatment of CDI. For mild to moderate CDI 
metronidazole is used orally at 500 mg 3 times per day for 10–14 days. For severe CDI 
vancomycin is used orally at 125 mg 4 times per day for 10–14 days. During severe, 
complicated CDI a more aggressive therapy is used with oral vancomycin at 500 mg 4 times 
per day, 500 mg in approximately 100 ml saline administered rectally every 6 hours, with 
intravenous metronidazole at 500 mg every 8 hours (Cohen et al. 2010). With emergence of 
vancomycin resistant enterococci and the expense of this antibiotic, metronidazole is often 
the antibiotic of choice (1995) Recommendations for preventing the spread of vancomycin 
resistance). Metronidazole is usually not recommended for recurrent infections, while a 
tapered vancomycin regime is preferred for recurrence of CDI (McFarland et al. 2002). Use 
of fidaxomicin or a tapered vancomycin regime has been found to be associated with a 
lower risk of recurrence than treatment with normal vancomycin doses (Louie et al. 2013). 
Primary infection treatments need to be monitored closely as new antibiotic resistant C. 
difficile have been emerging over the past 15 years.  
1.2.3 Antibiotic resistance in C. difficile 
 
Treatment with a large number of antibiotics including clindamycin, cephalosporins and 
fluoroquinolones has been linked to development of CDI (Settle et al. 1998; Johnson et al. 
1999; Yip et al. 2001; Spigaglia et al. 2008). This is often due to antibiotic resistance of C. 
difficile, or the robust nature of the antimicrobial for depleting the indigenous flora. 
Antibiotic resistances amongst C. difficile strains seem to be numerous but not global, with 
resistances differing between countries (Huang et al. 2009). Metronidazole sensitivity 
appears to be decreasing amongst common but not all strains (Moura et al. 2013), though 
completely resistant C. difficile are uncommon (Baines et al. 2008), and this slight reduction 
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in sensitivity has also been observed for some strains towards vancomycin (Pelaez et al. 
2002). Vancomycin has also been observed to have reduced efficacy against “hypervirulent” 
027 strains (Pepin et al. 2007). Additionally these treatments may be partially ineffective as 
recurrence of CDI commonly occurs (Musher et al. 2005). Novel treatments and preventions 
are therefore being sought after such as C. difficile specific therapies.  
1.2.4 The human intestine and mucosal immune responses 
 
The intestine is a complex system including epithelial cells, immune system cells, defensins, 
mucins and microflora. It exists in a fine balance of symbiosis, with unwanted 
microorganisms becoming trapped in the mucus layer and ejected from the body by 
peristalsis while useful microorganisms remain (Johansson et al. 2011) and aid in digestion, 
priming the immune system and stimulating gene expression for many important intestinal 
functions (Hooper et al. 2001). The intestine needs to distinguish between allowing uptake 
of nutrients and tolerance of commensal flora, and expulsion of unwanted pathogens. The 
immune system must have suppressive mechanisms to prevent hypersensitivity against 
innocuous substances or the commensal flora.  
The immune system of the human intestine can be divided into two broad systems: the 
mucosal inductive site and the mucosal effector site (Brandtzaeg 2002). The inductive site 
contains membrane cells (M cells) which are thin epithelial cells in the intestine that 
transport particulates or antigens (dead or alive) from the luminal face of the 
gastrointestinal epithelium to present to antigen presenting cells (APCs); macrophages and 
dendritic cells. This uptake for transcytosis is mediated either non-specifically or by a 
receptor for mucosal antigens, shown to be glycoprotein 2 (GP2) (Hase et al. 2009). These 
cells then present antigens to T cells, leading to specific IgA responses from B cells (reviewed 
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in (Hathaway and Kraehenbuhl 2000)). These cells make their way to the mucosal effector 
sites, directed by adhesion molecules and chemokines on endothelial cells, in this case the 
intestine, which express mucosal addressin cell adhesion molecule-1 (MAdCAM-1), binding 
an integrin on the lymphocytes (Shyjan et al. 1996). IgG, IgA and IgM are generated and 
released into the gut lumen, acting as the first line of defence against exogenous pathogens 
by inhibiting colonisation (Menzel and Rowley 1975; Brandtzaeg 2002). M cells are thin and 
are a weak point in the intestine, often exploited by pathogens (Baumler et al. 1996).  
In addition to immune system priming from M cells, the immune system can directly 
recognise and act upon bacteria, with macrophages and dendritic cells utilising toll like 
receptors (TLRs). LPS (lipopolysaccharide) from Gram negative bacteria has been shown to 
be recognised by TLR4 in mouse models, with TLR4 defective mice more susceptible to 
Gram negative infection (Poltorak et al. 1998). TLR4 stimulates NFκB for innate immune 
responses and induces molecules required for naïve T cell activation by antigen presenting 
cells (Medzhitov et al. 1997). Meanwhile, TLR2 has been shown to be important for Gram 
positive bacteria recognition, with mutations within this protein preventing an inflammatory 
response to Gram positive but not Gram negative bacteria (Underhill et al. 1999a) with 
many cell wall components of Gram positive bacteria and mycobacteria stimulating TLR2 
signalling (Underhill et al. 1999b). Thus the immune system is capable of distinguishing 
between different classes of bacteria. 
Lactic acid species of bacteria have been shown to be important for stimulating and 
enhancing immune responses to pathogens (Gill et al. 2000). A study of Salmonella 
typhimurium found that though secretary antibody IgA (sIgA) prevented pathogen access to 
the mucosal surface and protected the gut from inflammation, it was in fact the microbiota 
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of the gut that were the main players in the kinetics of pathogen clearance, with mice 
harbouring a low complexity of gut flora but a normal sIgA response unable to clear 
infection unless a normal microbiota was transferred to them (Endt et al. 2010).  
1.2.5 The role of indigenous flora 
 
There is a mutually beneficial relationship between the host and its intestinal microbiota, 
the multitudes of bacteria that have colonised the intestine. The bacteria obtain a steady 
supply of nutrients, while the host also gains from their presence. The gut flora has been 
shown to have a role in developing the host’s intestine, with angiogenesis and signal 
regulation in epithelial cells dependent on interactions with the flora (Lopez-Boado et al. 
2000; Stappenbeck et al. 2002). Bacteria in the intestinal mucosa have been shown to be 
important in stimulating the mucosal immune system, with an increased number of 
lymphoid cells and IgA secreting cells, particularly due to the presence of segmented, 
filamentous bacteria (Klaasen et al. 1993), although this stimulation of the immune system 
can lead to inflammatory bowel disease (IBD) (Nell et al. 2010).  Additionally, indigenous 
flora have been shown to be very important in colonisation resistance, best shown by C. 
difficile infection where disease symptoms are induced predominantly by the use of 
antibiotics which drastically reduce the diversity of the microbiota (Lawley et al. 2009a). 
Organisms in the colonic flora may affect toxin production or activity as well as potentially 
affecting C. difficile adhesion to the epithelium; while a large amount of indigenous flora is 
present they may also limit nutrients available to C. difficile and prevent infection (Wilson 
1993). Interestingly, it seems that diversity within the microbiota is necessary to prevent 
colonisation by pathogens, with a study in mice finding that groups with low complexity 
microbiota were more susceptible to colonisation by pathogens, whereas co-housing with 
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mice that had normal microbiota increased the first group’s microbiota diversity and 
reduced colonisation by the pathogen S. enterica (Stecher et al. 2010).  
Some pathogens, such as Salmonella enterica, manipulate the host immune system to 
change the composition of the microbiota and suppress its growth, allowing the pathogen 
to proliferate and overcome colonisation resistance (Lupp et al. 2007; Stecher et al. 2007).  
1.2.6 Faecal transplants for treatment of CDI 
 
Following this understanding of the role of indigenous microbiota within the human 
intestine, faecal transplants have begun to emerge as a treatment for CDI, especially 
recurrent CDI. Faecal transplants involve the administration of stool from a healthy donor 
usually by nasogastric tube into the patient suffering from CDI as a lower-gastrointestinal 
route holds the risk for bowel perforation (Agito et al. 2013). A study over the course of 9 
years following 18 patients who had received donor stools found that only 1 patient 
experienced a recurrence in CDI (Aas et al. 2003). A large scale study that compared 
vancomycin treatment with vancomycin treatment plus bowel washout and faecal 
transplants, showed that with a transplant of healthy donor stool the resolution of C. 
difficile infection rose from 31% to 81%, with increased faecal bacterial diversity in those 
patients who had received the transplant (van Nood et al. 2013). With this suggestion that 
re-colonisation can aid in recovery from CDI, research has begun in defining the bacterial 
species necessary for this recovery, to produce a more palatable treatment. Pre-colonisation 
of germ-free mice with murine Lachnospiraceae has been shown to aid colonisation 
resistance to C. difficile infection, suggesting that this family of bacteria could be used to aid 
recovery from CDI (Reeves et al. 2012). Following successful studies in mice where healthy 
mouse faeces restored microbiota diversity and resolution of CDI, 6 phylogenetically distinct 
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bacterial species were shown to be sufficient to regain microbial diversity and clear an 
established C. difficile infection in mice (Lawley et al. 2012). Translated to human subjects, 
one small study with just two patients suffering from recurrent CDI showed that a saline 
inoculum containing just 33 species of bacteria isolated from a healthy donor was able to 
revert these patients to normal bowel patterns with no return of CDI (Petrof 2013). These 
latter two studies are especially of interest as the infecting strains of C. difficile were 027 
and 078 respectively, which have been termed “hypervirulent” and often cause epidemics.  
1.2.7 The economics of C. difficile infections 
 
The cost of treating patients for CDI, especially for recurrent infection, is high – in the USA a 
case of recurrent CDI in 2010 could cost up to $18,000 (Ghantoji et al. 2010). Annual costs of 
CDI are estimated to be approximately $800 million in the USA and €3000 million in Europe, 
with the cost of recurrent infections exceeding the cost of initial infections (Bouza 2012). 
This high cost is partly due to increased length of hospitalisation, medications and 
laboratory testing, as CDI patients have been shown to stay in hospital on average 4 days 
longer than non CDI patients (Magalini et al. 2012; Monge et al. 2013). Thus procedures 
which reduce the length of hospitalisation or prevent initial onset of CDI would be far more 
economical and would allow patients to return home more swiftly, and safely, after a stay in 
hospital. For this, the immune response to C. difficile needs to be understood.  
1.2.8 The immune response to C. difficile 
 
Clostridium difficile colonises the large intestine and can remain here without giving rise to 
symptoms of CDI in 1-3% of the population (Kuipers and Surawicz 2008) and up to 20% of 
patients in hospital environments (McFarland et al. 1989). The immune system mounts a 
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response to C. difficile, which is a balance between a severe inflammatory response and a 
more protective antibody response.  
Both toxins and surface proteins have been shown to induce inflammatory responses in the 
host. As previously described, toxins of C. difficile have been shown to cause an influx of 
neutrophils to the intestine which has been linked to the disease phenotype, but this 
response may also aid clearance of infection with regulation by Nod1 (Hasegawa et al. 
2011). Additionally, toxins have been shown to stimulate the release of IL-8 from colonic cell 
lines (Branka et al. 1997) and appear to reduce T-cell proliferation stimulation by monocytes 
(Daubener et al. 1988). Surface proteins have also been implicated in stimulating an 
immune response from cells, with S-layer proteins (SLPs) capable of activating resting 
monocytes, inducing MDDC (monocyte derived dendritic cells) maturation to similar, if not 
greater levels, than LPS (lipopolysaccharide) and can enhance T cell proliferation which may 
contribute to pathogenicity (Ausiello et al. 2006). This appears to be a standard reaction to 
SLPs from all strains of C. difficile regardless of the strains ability to cause an epidemic or to 
be hypervirulent, thus SLPs are unlikely to be involved in the differences observed in 
severity of infections (Bianco et al. 2011). Additionally, SLPs have been indicated in 
activation of innate and adaptive immunity through TLR4 (Ryan et al. 2011). 
In addition to generating an inflammatory response, the host also raises antibodies against 
the infection.  A study by Kyne et al of 271 patients infected with C. difficile showed that 
those patients asymptomatically colonised had significantly higher levels of serum anti-toxin 
A IgG than those patients who developed diarrhoea (Kyne et al. 2000). Additionally, patients 
who had a single episode of diarrhoea had higher serum anti-toxin A IgM on the third day of 
diarrhoea, and higher serum anti-toxin A IgG on day 12 than patients who developed 
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recurrent diarrhoea (Kyne et al. 2001). IgG neutralising antibodies against toxin B have also 
been observed at higher levels in patients who experienced only a single episode of 
diarrhoea (Aronsson et al. 1985). Recurrent disease has also been significantly associated 
with low levels of serum antibodies against the receptor binding domain of toxin B (Leav et 
al. 2010). Studies have also investigated the antibody response to the surface proteins of C. 
difficile as these proteins have been shown to be shed during growth of C. difficile 
(Mukherjee et al. 2002) and patients who have a strong immunological reaction to C. 
difficile appear to be protected against disease. However, some studies have suggested that 
differences in antibody levels are not significant between symptomatic and asymptomatic 
patients (Sanchez-Hurtado et al. 2008); though this study was conducted in elderly patients 
and may reflect their reduced ability to mount immune responses to infection. Antibodies 
against FliC, Cwp66 and Cwp84 (flagella and surface proteins) have also been observed in 
patients suffering from CDI, with increased antibody responses to some of these surface 
proteins in controls compared with patients suffering from CDI (Pechine et al. 2005), 
suggesting a host response to these proteins prevents infection. However, despite showing 
antigenic properties, these surface proteins are often variable between strains, with 
antibodies unable to cross react between some strains (Spigaglia et al. 2011). Such variation 
may indeed be beneficial in facilitating evasion of the host immune system.  
1.2.9 Vaccination  
 
Vaccination has been a vital development in medicine for prevention of infectious disease. 
The conventional approach to development of vaccines involves attenuating live bacteria or 
creating detoxified or sub-unit vaccines from antigens discovered through biochemical 
methods, all of which can be time consuming and costly (Rappuoli 2000). With bacterial 
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genome sequencing increasing each year there is now a large volume of genomic 
information from which antigens can be identified without lengthy biochemical study. This 
bioinformatic approach, termed “reverse vaccinology” (Rappuoli 2000), can uncover 
additional novel vaccine candidates which may otherwise have been missed. Despite its 
advantages, this approach also has limitations. For example, genome data provides no 
information for antigen expression, abundance or immunogenicity, so there is a need for 
high-throughput systems to screen for potential antigens.  Additionally this method would 
only identify protein candidates, ignoring, for example, polysaccharide antigens. A 
significant example of the strength of reverse vaccinology is the development of a vaccine 
against serogroup B Meningococcus (Pizza et al. 2000). Using bioinformatics followed by 
screening, expression and immunisation, 7 antigens were selected for further study. The 
initial work took less than two years to be accomplished and a vaccine developed from this 
work is now being approved for licensing in Europe, Canada and Australia (Vesikari et al. 
2013).  
1.2.10 Vaccine studies against CDI 
 
Early experiments using formalin inactivated C. difficile culture filtrate toxoid antigens for 
vaccination showed markedly enhanced survival of hamsters and reduced levels of 
diarrhoea following C. difficile infection (Torres et al. 1995), which was improved to 100% 
survival with no diarrhoea following rectal immunization in conjunction with intramuscular 
vaccination (Giannasca et al. 1999). This later study additionally found that passive 
administration of IgG circulating mouse anti-toxin antibodies conferred resistance to CDI in 
hamsters despite C. difficile causing a mucosal disease. This suggests that an intravenous 
immunotherapy could be effective in humans. Despite protecting hamsters from lethal 
38 
 
challenge with toxin A-B+ C. difficile, vaccination with just toxoid B alone does not prevent 
colonisation (Siddiqui et al. 2012). In humans, following four doses of a C. difficile toxoid 
preparation (toxoid A and toxoid B), test subjects showed serum anti-toxin A IgG levels 
greater than 3 EU (elisa units) (Aboudola et al. 2003), a level shown in clinical studies to 
have a protective effect from CDI (Kyne et al. 2000). These elevated levels of antibody were 
also higher than levels observed after “natural” encounter of the toxin. A recent Phase I trial 
by Sanofi Pasteur with formalin-inactivated purified toxoids A and B has shown a good IgG 
response to immunisation after 3 doses of the toxoid vaccine, which is now entering Phase II 
trial (Greenberg et al. 2012). An initial study with 3 patients suffering from multiple 
recurrences of CDI showed that vaccination with a toxoid vaccine prevented any further 
recurrence following discontinuation of vancomycin treatment (Sougioultzis et al. 2005).  
Toxoid vaccines require purification and inactivation of whole toxins, thus research has been 
undertaken to produce recombinant subunit vaccines. Immunisation of mice with the C-
terminal binding domain of toxin A has been shown to protect mice against a lethal dose of 
toxin A (Sauerborn et al. 1997), while in hamsters immunisation with 33 of the 38 C-terminal 
repeats of toxin A prolonged survival in over 60% of hamsters compared with controls that 
did not survive (Lyerly et al. 1990). 14 of the 38 C-terminal repeats of toxin A have been 
shown to generate anti-toxin A neutralising antibodies in mice (Ward et al. 1999a). 
Immunisation with C-terminal domains of both toxins A and B fused with Salmonella 
typhimurium flagellin as an innate immune agonist protected mice from C. difficile challenge 
compared with controls (Ghose et al. 2013). Additionally, a chimeric toxin molecule 
consisting of a  glucosyltransferase-deficient toxin A with its C-terminal repeats replaced 
with those of toxin B showed protective effects in mice against multiple challenge strains 
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(Wang et al. 2012), while a recombinant fusion protein  of toxin A and B C-terminal domains 
reduced disease severity in hamsters (Tian et al. 2012). A subunit recombinant vaccine is 
undergoing Phase I testing for safety and immunogenicity in volunteers in two groups; 18-65 
year olds and over 65s. This consists of truncated toxins A and B (Intercell Oct. 24, 2011. 
http://www.intercell.com/main/forvaccperts/products/clostridium-difficile-vaccine/). 
Some studies have investigated the use of vector organisms for vaccine delivery as a means 
of stimulating a local mucosal immune response to C. difficile. A study with live, attenuated 
Vibrio cholerae expressing 720 amino acids of the C. difficile toxin A receptor binding 
domain administered orally to rabbits found that animals produced large levels of anti-toxin 
A IgG and prevented fluid secretion and histological changes in a toxin A ileal loop challenge 
assay (Ryan et al. 1997). 14 of the 38 C-terminal receptor binding repeats of toxin A were 
expressed by attenuated Salmonella typhimurium BRD509 in rabbits and were shown to 
induce generation of anti-toxin A antibodies capable of neutralizing the full length toxin 
(Ward et al. 1999b). Adenovirus has also been used as a delivery mechanism for a toxin A 
vaccine and has shown 100% protection in mice with rapid humoral immunity produced 
(Seregin et al. 2012). The use of Bacillus subtilis spores as a delivery vehicle expressing C-
terminal domains of either toxin A or both toxins A and B on the spore surface highlighted 
the possibility that toxin A alone may generate antibodies capable of neutralising both 
toxins A and B, as neutralising antibodies against toxin A were able to cross-react with the C-
terminal of toxin B but not vice versa (Permpoonpattana et al. 2011). It will be interesting to 
see if this toxin A-based vaccine is effective at preventing disease from toxin A-/B+ C. difficile 
strains as vaccines must be able to provide protection against a wide range of strains.  
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Novel therapies against C. difficile include DNA vaccine studies; one using the receptor 
binding domain of toxin A in mice found that vaccination conferred protection from death 
(Gardiner et al. 2009), while a DNA vaccine expressing the N-terminal enzymatic domain of 
toxin B has also been shown to provide protection from CDI in mice, especially in 
combination with anti-toxin A antibodies (Jin et al. 2013). Human monoclonal antibodies 
(HuMAbs) have also been investigated as a novel therapy for CDI. Initial work by Babcock et 
al showed that toxin A-directed HuMAb CDA1 was able to neutralise in vitro cytotoxicity, 
neutralize systemic toxicity in the mouse, and prevented toxin A-induced hemagglutination 
of rabbit erythrocytes (Babcock et al. 2006). Additionally, toxin B-directed HuMAb MDX1388 
was able to neutralise toxin B in vitro but was unable to protect mice from a lethal challenge 
with toxin B. CDA1 and MDX1388 recognise the C-terminal receptor binding domain of their 
respective toxin. Combination of the two HuMAbs in the hamster models of primary disease 
and relapse showed significant protection. These HuMAbs were then investigated as 
therapies for patients with symptomatic C. difficile infection (Lowy et al. 2010). Only 7% of 
patients who were administered MAbs developed recurrent disease, compared with 25% of 
the control group. The MAbs did not decrease the severity of the initial episode of C. difficile 
infection however, but in recurrent episodes of disease only 2 of the 7 MAb treated patients 
had severe diarrhoea compared with 16 of the 25 patients in the control group.  
In the hamster model of infection, passive immunisation with anti-surface layer protein 
antibodies significantly prolonged survival following challenge with C. difficile compared 
with the control group (O'Brien et al. 2005). However, a follow-up study using the SLPs as 
vaccine components showed highly variable antibody stimulation and incomplete protection 
of hamsters (Eidhin et al. 2008). However, in mice immunised intra-rectally, FliD and 
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flagellar components, FliD with Cwp84 and FliD with a cell wall extract were shown to 
reduce long term colonisation compared with controls (Pechine et al. 2007), and rectal 
immunisation with Cwp84 has been shown to increase survival of hamsters, though not to 
100% (Pechine et al. 2011).   
Toxin-based vaccines will neutralise toxins produced from C. difficile that have already 
colonised but will not target the bacterium. This could allow symptomatic C. difficile 
infection in patients, albeit briefly, or asymptomatic infection, and could therefore still allow 
transmission of disease and potentially recurrent disease. A more novel approach would be 
to prevent colonisation of C. difficile with a multi-component vaccine incorporating anti-
toxin and anti-bacterial (or anti-spore) elements. It could potentially enable the immune 
system to fight C. difficile from multiple angles, with a higher success rate and lower 
economic costs of CDI.  
 
1.3 The surface of C. difficile  
1.3.1 Gram positive cell walls 
 
The Gram positive cell envelope consists of a cytoplasmic membrane and, external to this, a 
variety of glycan polymers and proteins. The composition and structure of components 
varies between species, which can have markedly different cell walls. These contain a 
variety of surface polymers and proteins which can be utilised for host interaction, invasion, 
movement, and bacteria-bacteria interactions.  
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1.3.1.1 Peptidoglycan of Gram positive bacteria  
The cell wall, external to the membrane, of Gram positive bacteria is a complex matrix of 
peptidoglycan and other polymers, including anionic polymers such as teichoic acids and 
lipoteichoic acids polymers (Weidenmaier and Peschel 2008). Peptidoglycan surrounds the 
entire cell, contributing to the rigid structure of the bacterium and provides a framework for 
attachment of surface proteins and other polymers (Hancock and Baddiley 1976)}. It has 
also been implicated in activating the immune system in some species (Qiu et al. 2013; 
Sukhithasri et al. 2013; Sun et al. 2013). The structure of gram positive peptidoglycan 
follows similar patterns but each species has its own variation. 
A typical structure of peptidoglycan is a glycan backbone consisting of N-acetylglucosamine, 
GlcNAc, and N-acetylmuramic acid, MurNAc, alternating residues, with peptide strands 
attached to the MurNAc (Figure 1.2). The glycan backbone is typically linked by a β1-4 
linkage between GlcNAc and MurNAc (Vollmer et al. 2007). The peptide strands vary 
between species but are commonly composed of alternating L and D amino acids such as L-
Ala – D-Gln – L-Lys – D-Ala – L-Ala (Vollmer et al. 2007). There are bonds between proximal 
peptide strands forming cross-links that enable the cell wall to have a rigid structure. In 
Staphylococcus aureus this is a pentaglycine cross-link from the D-Ala4 residue of one strand 
to the L-Lys3 of another strand, a bond which is formed during incorporation of 
peptidoglycan precursors into the cell wall (Gally and Archibald 1993). Meanwhile in Bacillus 
anthracis and Listeria monocytogenes this crosslink is a direct covalent bond between 
diaminopimelic acid residues within the peptide chain of two strands (Perkins 1969).  
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The biosynthesis of peptidoglycan starts within the cell with phosphorylated sugars 
modified to MurNAc containing a UDP molecule. To this an L-Ala is linked, and the peptide 
strand extended. Undecaprenyl-P then replaces the UDP molecule to form Lipid I before 
GlcNAc is added to form Lipid II. This lipid peptidoglycan precursor is then translocated to 
the external face of the cytoplasmic membrane by flippase FtsW (Mohammadi et al. 2011) 
where the peptidoglycan precursor is then incorporated into the cell wall (reviewed in (van 
Heijenoort 2007). 
Peptidoglycan can be cleaved by a number of enzymes, which are utilised either by the 
organism itself for manipulating its cell wall, such as during growth of the organism, by host 
defences or competitors. These include lysozyme, mutanolysin, lysostaphin and amidases 
The GlcNAc-(β1-4)-MurNAc bond is cleaved by the muramidases lysozyme and mutanolysin 
Figure 1.2 Typical Gram positive peptidoglycan structure 
Typical peptidoglycan structure from Staphylococcus aureus; MN-GN denote the MurNAc GlcNAc 
glycan backbone, and amino acids show peptide chains. Gly5 denotes pentaglycine cross bridge 
which connects L-Lys to D-Ala or to surface proteins.  
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(Yokogawa et al. 1975; Calandra and Cole 1980) and the pentaglycine crossbridge of S. 
aureus is the target of lysostaphin (Schindler and Schuhardt 1964; Schindler and Schuhardt 
1965). Amidases, otherwise known as N-acyl muramyl-L-alanine amidases, cleave between 
the L-Ala and MurNAc to release the peptide chain from the glycan backbone (Young 1966). 
A number of Gram positive bacteria, such as Bacillus subtilis, Bacillus cereus and C. difficile 
contain a high degree of N-glucosamine deacetylation (Araki et al. 1972; Vollmer 2007; 
Peltier et al. 2011), which commonly accounts for lysozyme resistance in Gram positive 
bacteria (Hayashi et al. 1973). Mutanolysin is still able to cleave these deacetylated MurNAc-
GlcNH2 bonds (Psylinakis et al. 2005). Additionally, spore peptidoglycan can contain the 
addition of a β-lactam group on muramic acid, while in mycobacteria muramic acid can by 
glycolated (Vollmer 2007).  
In Staphylococcus aureus, the peptidoglycan is arranged on the surface in concentric circles 
when viewed by SEM and in an electron micrograph of freeze etched whole cells (Amako et 
al. 1982). This circular pattern was only observed on part of the cell, the newly generated 
cell wall, with rougher and irregular patches deemed to be the “older” surface of the cell 
wall. 
1.3.1.2 Teichoic acids in Gram positive bacteria 
The other major polymers within the cell wall are the anionic teichoic acids (Coley et al. 
1975). These are typically either membrane bound to glycolipids, termed lipoteichoic acids 
(LTA) (Lambert et al. 1977), or linked to the peptidoglycan cell wall, termed wall teichoic 
acids (WTA) (Hancock and Baddiley 1976). WTAs are linked through a phosphodiester bond 
between the MurNAc sugar of peptidoglycan and a linkage unit typically composed of a 
ManNAc(β14)GlcNAc disaccharide, with glycerol phosphates attached to the ManNAc 
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residue (Araki and Ito 1989). The structure of teichoic acids varies between species but are 
typically polymers of sugar monomers containing phosphate groups such as 1,3-glycerol 
phosphate (Gro-P) or 1,5 D- ribitol-phosphate (Rbo-P) (Neuhaus and Baddiley 2003). These 
polymers can have side chains, for example in Bacillus there can be side chains of α-GlcNAc 
or α-Gal to a Gro-P monomer (Iwasaki et al. 1986).  
Commonly teichoic acids are anionic due to the negatively charged phosphate groups. They 
can however become zwitterionic due to the addition of groups such as D-alanine which 
provides a free positively charged amino group (Weidenmaier and Peschel 2008). The 
negative charge of phosphate groups in the cell wall is thought to contribute to the 
association of other proteins such as S-layer proteins which are non-covalently attached to 
the surface of the bacterium (Kern et al. 2010). These anionic properties also allow the 
binding of cations (Marquis et al. 1976) which may influence the rigidity and porosity of the 
cell wall (Silhavy et al. 2010). 
WTA has been shown to play a role in colonisation in S. aureus, with deficient mutants 
unable to colonize the nasal region of rats (Weidenmaier et al. 2004) and possibly play a role 
in endovascular S. aureus infection progression (Weidenmaier et al. 2005). Although not as 
immunostimulatory as Gram-negative lipopolysaccharide (LPS), TAs have been shown to be 
involved in cytokine induction (Draing et al. 2008) and may play a role in sepsis (Wang et al. 
2003) and multi-organ failure as they have been shown to activate multiple components 
which amplify cell damage of the host (reviewed in (Ginsburg 2002)). LTA in particular has 
been shown to be a major immunostimulatory component of S. aureus (Morath et al. 2001).  
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1.3.1.3 S-layers and other surface structures in Gram positive bacteria 
Beyond the cell wall, many Gram positive bacteria contain additional surface structures. The 
most prominent of these are S-layers, which are paracrystalline layers on the surface of 
bacteria (Reviewed in (Sleytr and Messner 1983; Sleytr and Sara 1997). They contain pores, 
suggesting they may have a role as a molecular sieve (Sara and Sleytr 1987) as well as a 
protective function. S-layers have been observed in Clostridia (Sleytr and Glauert 1976), 
Bacillus (Pollmann et al. 2005), Lactobacillus (Masuda and Kawata 1979) and 
Thermoanaerobacteria (Schaffer et al. 2000). 
S-layers are believed to be non-covalently attached to the surface of bacteria as they are 
easily extracted with gentle techniques such as low pH buffers (Koval and Murray 1984), as 
this disrupts charge interactions which are believed to facilitate the association of S-layer 
proteins with secondary cell wall polymers such as a teichoic acids or pyruvylated 
carbohydrate (Masuda and Kawata 1980; Mesnage et al. 2000; Kern et al. 2010). Where 
studied in detail this interaction has been found to be facilitated through SLH (S-layer 
homology) domains which have been found in numerous S-layer proteins (Lupas et al. 
1994). S-layers are often modified, such as S-layer glycoproteins found in Bacilli (Schaffer 
and Messner 2001). S-layer proteins are often related within a genus, and are hypothesised 
to have occurred through gene duplications, horizontal gene transfers and rearrangements 
(Pollmann et al. 2005).  
While S-layers are protein structures, Gram positive bacteria can also utilise 
polysaccharides. Capsules are made up of carbohydrates and could be important for binding 
to host cells (Freimer et al. 1978), virulence (Avery and Dubos 1931), an anti-phagocytic role 
(Fouet and Mesnage 2002) and protective immunity of the host (Macleod et al. 1945). They 
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can be very diverse, with S. pneumoniae having nearly 100 different serotypes which are 
structurally diverse (Bentley et al. 2006). 
1.3.2 Gram positive sortase mediated cell wall attachment 
 
As mentioned, Gram positive bacteria contain a peptidoglycan layer external to the 
cytoplasmic membrane. Proteins can be covalently attached to this cell wall and this is 
commonly performed by a group of enzymes called sortases (Figure 1.3). Many Gram 
positive bacteria have been found to contain sortase genes, including Staphylococcus, 
Streptococcus, Listeria, Bacillus and Clostridia (Schneewind and Missiakas 2012). 
Sortase action has been linked to virulence, with sortase (srtA) knockouts in S. aureus 
showing reduced substrate localisation to the surface of the bacterium and significantly 
reduced virulence compared with wild type (Mazmanian et al. 2000). This is also evident in 
other organisms such as Listeria monocytogenes (Bierne et al. 2002), Streptococcus suis 
(Wang et al. 2009), and Bacillus anthracis (Zink and Burns 2005). 
Sortase substrates have also been shown individually to be important in virulence, such as 
the SrtB substrate SvpA in Listeria monocytogenes which appears to be necessary for 
intracellular proliferation of the bacterium (Bierne et al. 2004). 
1.3.2.1 Sortase structure 
Sortase is a membrane bound enzyme, with its N-terminal signal peptide acting as a 
membrane anchor (Mazmanian et al. 1999). Sortase has been found to co-localise with Sec 
translocase in the cytoplasmic membrane in some Gram positives (Hu et al. 2008; Kline et al. 
2009), suggesting a relationship between protein export and protein sorting in Gram 
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positive bacteria. SrtA has also been shown to be localised to the division septum in 
Streptococcus pyogenes which would explain the incorporation of its substrates onto 
peptidoglycan precursors (Raz and Fischetti 2008).  
 
 
The crystal structure of sortase suggests that the enzyme and its substrates form a lock and 
key interaction, with the substrate entering a pocket of the sortase enzyme, with conserved 
proline and threonine residues of the substrates being held in place by hydrophobic 
residues within the sortase enzyme, allowing the threonine and glycine substrate residues 
to be positioned near the active site of the enzyme (Zong et al. 2004). 
A conserved catalytic cysteine is found in all sortases to date, at position 184 in S. aureus 
SrtA, with mutation of this residue rendering the enzyme inactive and incapable of 
anchoring substrates to the cell wall (Ton-That et al. 1999). However there are also 
Figure 1.3 Sortase mechanism of cell wall protein attachment 
1 – Sortase substrate is secreted from the cell and its signal peptide cleaved. 2 – The hydrophobic 
helix and charged tail of the substrate retain the protein within the cell membrane. 3 – Membrane 
bound sortase recognises and cleaves the LPXTG motif of the substrate and forms a covalent 
intermediate. 4 – Sortase performs a Transpeptidation reaction whereby the substrate is attached 
to a lipid II cell wall precursor cross-bridge. 5 – The cell wall precursor is incorporated into the cell 
wall of the organism including the surface protein. Adapted with permission from (Ton-That et al. 
1999) 
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additional residues of importance, with a possible catalytic diad of cysteine and a proximal 
histidine (Kang et al. 2011), which are highly conserved in sortase proteins, and a possible 
catalytic triad which also incorporates an aspartic acid residue, which is conserved between 
S. aureus and B. anthracis SrtB proteins (Zhang et al. 2004). However, other studies 
suggesting that a conserved arginine, not aspartic acid residue, is essential for catalysis 
(Marraffini et al. 2004), although this second study was in SrtA, while the former was in SrtB, 
so there may be differences in activity between classes of sortase.  
1.3.2.2 Multiple classes of sortase 
Since sortase was first observed in S. aureus (Mazmanian et al. 1999), sortases have been 
found in numerous other Gram positive bacteria. Four classes of sortase have been found 
thus far, which vary in their substrate recognition and their transpeptidation action. 
Bacteria, therefore, seem to utilise different sortases for different functions.  
SrtA is generally the most dominant, “housekeeping” sortase with the largest body of 
substrates and broadest specificity of action, being involved not only in sorting its own 
substrates, but often involved in sorting other sortases’ substrates, such as during the 
assembly of pili with SrtD (Budzik et al. 2008b). Typically its substrates contain an LPXTG like 
motif at their C-terminus (Schneewind et al. 1992) and the accepting nucleophile is 
peptidoglycan precursor lipid II which incorporates the substrate into the cross-bridge of the 
cell wall (Figure 1.3) (Perry et al. 2002).  
SrtB is typically involved in sorting proteins involved in iron acquisition, recognising an 
NXZTN motif in its substrates in S. aureus and L. monocytogenes and NPKTG in B. anthracis 
(Mazmanian et al. 2002; Bierne et al. 2004). Substrates are often “buried” further into the 
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cell wall than SrtA substrates and are therefore less susceptible to external protease action. 
They  are again attached to the pentaglycine crossbridge but in regions where there is little 
cross-linking of peptidoglycan, and they are linked to shorter glycan chains than SrtA 
substrates (Marraffini and Schneewind 2005). SrtB mutants are rarely defective in 
pathogenesis, but have been predicted to be important in adaption to different 
environmental conditions (Bierne et al. 2004) or propagation within host cells (Marraffini 
and Schneewind 2005). 
SrtC and SrtD. The literature is contradictory as to the definition of sortases C and D. SrtC in 
Bacillus is the spore specific sortase, cleaving the LPNTA motif of BasH and BasI in B. 
anthracis and targeting them onto a diaminopimelic acid crosslink on the cell wall of 
sporulating bacteria (Marraffini and Schneewind 2006; Marraffini and Schneewind 2007). 
Deletion of SrtC does not cause a defect in infection in guinea pigs, but cells less readily 
form spores. This sortase is in an operon with basI. However, in Enterococcus SrtC is known 
as a pilin specific sortase (Kline et al. 2009), while in Bacillus and Corneybacteria the pilin 
specific sortase is often annotated as SrtD (Ton-That et al. 2004; Budzik et al. 2008a; Budzik 
et al. 2008b) present in a pilin gene operon (Budzik et al. 2007). Pilin specific sortases 
recognise and cleave an LPXTG motif of one major pilin subunit and covalently link this to an 
ε-amino group of a lysine of another subunit, typically within a YPKN motif. Without this 
lysine residue pilin extension is impossible (Ton-That and Schneewind 2003; Budzik et al. 
2008a). The extension of the pilus is relieved by SrtA which cleaves the major pilin subunit at 
its LPXTG motif and covalently attaches the pilin polymer to peptidoglycan cross bridges 
(Budzik et al. 2007). As with other sortase substrates, this LPXTG motif is essential for 
sorting of the protein, with pili unable to form without this motif (Ton-That and Schneewind 
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2003). However, only SrtD in Bacillus was shown to be capable of the polymerisation step of 
pilin assembly (Budzik et al. 2008a). Meanwhile, in Actinomyces naeslundii the sortase 
annotated SrtC2 is a fimbriae specific sortase, required for type 2 fimbriae assembly (Mishra 
et al. 2007).  
A problem with these annotations is that many sortases are annotated chronologically 
within their genome (Dramsi et al. 2005), with C. diphtheriae containing sortases A-F; with 
SrtF in fact a homologue of SrtA in other bacteria (Swaminathan et al. 2007).  
1.3.2.3 Sortase substrate structure  
Sortase substrates have several conserved characteristics. They must have an N-terminal 
Sec signal sequence to target the proteins for export from the cell, and a C-terminal cell wall 
sorting signal. This sorting signal consists of an “LPXTG” like motif which is recognised by the 
sortase enzyme, followed by a hydrophobic helix and a charged tail both of which retain the 
protein in the membrane for recognition and cleavage by sortase (Figure 1.4) (Schneewind 
et al. 1992; Schneewind et al. 1993). These seminal studies by Schneewind showed that the 
C-terminal sorting signal is capable of targeting proteins to the cell wall, such that non-
sortase substrates can be attached to the cell wall with the addition of these sorting signals. 
Removal of the LPXTG motif prevents the protein from being properly sorted into the cell 
wall, while removal of the helix and charged tail or all three domains causes the protein to 
no longer be associated with the cell, but secreted into the culture medium (Schneewind et 
al. 1992; Schneewind et al. 1993). 
The sorting signal varies between species and the class of sortase enzyme which recognises 
the substrate. Thus, LPXTG is commonly seen in SrtA substrates and NPQTN in Srt B 
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substrates in S. aureus, but predicted substrates in Actinomycetes contain LAXTG, LSXTG or 
LGXTG motifs and predicted substrates in C. difficile contain SPXTG and PPXTG motifs (Pallen 
et al. 2001). 
 
 
1.3.2.4 Cleavage and transpeptidation – the dual role of sortase 
Sortase substrates are covalently attached to the peptidoglycan by sortase dependent 
transpeptidation activity. This has been studied in most detail in S. aureus and takes place in 
a number of steps. Maturation of the protein can be seen in Figure 1.4, with P1 the 
translated protein which is targeted for secretion, P2 the protein following signal peptide 
cleavage, and the mature M protein following sortase cleavage. Figure 1.3 shows the 
process of covalent attachment of proteins to the cell wall by sortase. First P1 is secreted via 
the Sec secretion system and its signal peptide is cleaved (1) to form the P2 precursor 
Figure 1.4 Maturation of sortase substrates 
Translated protein (P1) contains a signal peptide (red), and a C-terminal cell wall sorting signal 
with an LPXTG like motif, a hydrophobic helix (black) and a charged tail (+). P1 is cleaved by a 
signal peptidase to form P2. Cleavage by sortase removes the hydrophobic helix and charged tail 
leaving the mature, M, protein for attachment to the cell wall.  
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protein. There is accumulation of this precursor in sortase knockouts or mutants or with 
inhibition of sortase (Ton-That et al. 2000). The hydrophobic and charged residues of the 
cell wall sorting signal retain the C-terminus of the protein in the cell membrane (2) 
(Schneewind et al. 1993) allowing the membrane bound sortase to interact with the protein. 
The sortase enzyme recognises the LPxTG-like motif in the cell wall sorting signal and 
cleaves the protein between the threonine and glycine residues, forming a sortase-protein 
intermediate of the final mature protein (M) and the catalytic cysteine of sortase (3), 
observed in all classes of sortases (Mazmanian et al. 2002; Ton-That et al. 2002; Guttilla et 
al. 2009). Transpeptidation then occurs whereby the protein is transferred onto its final 
anchor, in the case of SrtA a Lipid II molecule at the NH2-Gly3 crossbridge position (3) (Perry 
et al. 2002). Lipid II is a peptidoglycan precursor molecule containing UDP – GlcNAc-
MurNAc- [L-Ala – D-Gln – L-Lys{NH2-Gly3} – D-Ala – D-Ala], whereby NH2-Gly3 is the 
precursor to the pentaglycine crossbridge that joins L-Lys3 to D-Ala4 in another peptide 
chain. In S. aureus, SrtA always attaches the substrate to the amino group of glycine, with 
the number of residues varying at an optimum of 5 glycines (Ton-That et al. 1998). This 
peptidoglycan precursor with covalently attached sortase substrate is then incorporated 
into the cell wall (5). As mentioned in 1.3.2.3 the nucleophilic attack of this enzyme-
substrate complex is performed by various molecules depending on the class of sortase and 
bacterial species. These can be pilin subunits, cell wall precursors, mature peptidoglycan, 
and different crossbridges, such as diaminopimelic acid in B. anthracis (Perkins 1969). 
1.3.3 The peptidoglycan cell wall of Clostridium difficile 
 
A recent study by Peltier et al found 93% of GlcNAc in the C. difficile peptidoglycan cell wall 
is deacetylated, accounting for its resistance to lysozyme (Peltier et al. 2011). Additionally, 
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this study found that the peptide polymers primarily follow a pattern of L-Ala – L-Gln – A2pm 
– D-Ala, where A2pm is diaminopimelic acid, with an occasional addition of D-Ala as a 5
th 
residue, or a substitution of D-Ala4 with a glycine residue. This study found that 73% of C. 
difficile crosslinks involve L-D transpeptidation between A2pm
3A2pm
3 of adjacent peptide 
polymers, with 27% of crosslinks involving D-Ala4A2pm
3. As there is no pentaglycine 
crossbridge C. difficile is therefore not susceptible to the action of lysostaphin, and it is likely 
that any sortase substrates present will be covalently attached to the diaminopimelic acid 
crossbridge as in B. anthracis (Perkins 1969).  
1.3.4 The S-layer of Clostridium difficile 
 
External to the peptidoglycan is a 2D proteinaceous array of proteins called the “S-layer” 
(Figure 1.5) (Masuda et al. 1989; Cerquetti et al. 2000). The S-layer is composed of S-layer 
proteins (SLPs) and cell wall proteins (CWPs) which are exported by the Sec-mediated 
pathway and contain three copies of the PF04122 cell_wall_binding_2 domain for non-
covalent attachment to the cell wall (Figure 1.6). Most of these genes are found in a cluster 
in the genome, with 11 CWP genes and the slpA gene located here (Karjalainen et al. 2001) 
along with secA2 which has been shown to be important for S-layer protein export (Fagan 
and Fairweather 2011). 
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1.3.4.1 SLPs of C. difficile 
The S-layer consists predominantly of two SLP proteins formed from the precursor protein 
SlpA (Calabi et al. 2001). Following export and signal peptide cleavage, this precursor is 
cleaved into two fragments by Cwp84 (Kirby et al. 2009; de la Riva et al. 2011). These two 
proteins, the high-molecular-weight (HMW) and low-molecular-weight (LMW) SLP proteins 
interact non-covalently with each other (Fagan et al. 2009) and these discrete proteins form 
a regular array (Kawata et al. 1984; Masuda et al. 1989). This interaction and the interaction 
of proteins within the S-layer are believed to be facilitated by Ca2+ or Zn2+ ions (Takumi et al. 
1992). There is high sequence diversity of these SLPs between strains, especially for the 
LMW SLP (Calabi and Fairweather 2002) with no cross reaction of antibodies between 
strains that produce different S-layer patterns by SDS PAGE analysis (McCoubrey and Poxton 
2001).  
Figure 1.5 The S-layer of C. difficile 
The surface of C. difficile containing an external S-layer composed of SlpA (red) and minor cell 
wall proteins (green, white, yellow, blue). Cell wall binding domains are shown in grey. Beneath is 
the peptidoglycan cell wall and secondary cell wall polymers (Fagan et al. 2009) 
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1.3.4.2 CWPs of C. difficile 
In addition to the SLPs there are other minor Cell Wall Proteins (CWPs) within the S-layer. 
These include a family of CWPs which show homology to SlpA (Calabi et al. 2001) containing 
the same PFAM domain for non-covalent interaction with the cell wall. The CWPs include 
Cwp84 which is the cysteine protease responsible for SlpA precursor protein cleavage (Kirby 
et al. 2009; Dang et al. 2010), Cwp13 which is involved in Cwp84 processing (de la Riva et al. 
2011), Cwp66 a putative adhesin (Waligora et al. 2001), and CwpV, a phase variable protein 
(Emerson et al. 2009) thought to bind fibronectin and be involved in aggregation of C. 
difficile (Reynolds et al. 2011) and which undergoes autoprocessing (Dembek et al. 2012). 
Figure 1.6 S-layer proteins of C. difficile 
All known S-layer proteins of C. difficile containing a signal peptide (black square), and 3 cell wall 
binding PFAM domains (grey boxes). Other putative functional domains are shown. Reproduced 
with permission by SGM from (Fagan et al. 2011). 
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The most abundant surface protein after the HMW and LMW proteins is Cwp2 (Figure 5.2) 
but little is known of this protein. Many of these proteins have varied sequences between 
strains (Pechine et al. 2005; Reynolds et al. 2011). 
1.3.5 Other surface components 
 
Other than the S-layer, C. difficile contains sortase and sortase substrate genes, as well as 
genes for flagella and pili.  
Flagella have been observed on the surface of C. difficile by electron microscopy (Delmee et 
al. 1990) but not all strains appear to be flagellated despite expression of the fliC gene 
(Tasteyre et al. 2000b). FliC is the flagellin protein (Tasteyre et al. 2000a), while FliD is the 
flagellar cap protein (Tasteyre et al. 2001b). The sequence of fliC is highly conserved 
between strains (Tasteyre et al. 2000a; Pechine et al. 2005) with antibodies against flagellin 
cross reacting between strains of C. difficile (Delmee et al. 1990). However, there is a high 
variation in the sequence of the central domain of fliC (Tasteyre et al. 2000b). FliD also 
contains a highly conserved sequence and is again transcribed in flagellated and non-
flagellated strains, but antibodies raised do not detect FliD in non-flagellated strains 
(Tasteyre et al. 2001b), suggesting a control of expression.  Flagellated C. difficile appear to 
bind to mouse caecal cells more effectively than non-flagellated strains, suggesting a role in 
colonisation (Tasteyre et al. 2001a), with glycosylation believed to be essential for flagella 
production (Twine et al. 2009). Flagella have also been shown to have a possible role in 
biofilm formation (Ethapa et al. 2013). However, despite both FliC and FliD being shown to 
be important for C. difficile motility, strains with deletions in these genes have been found 
to be more virulent than wild type C. difficile in the hamster model of C. difficile infection 
(Dingle et al. 2011b). The role of flagella remains to be determined. 
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C. difficile 630 contains two putative type IV pili loci (Sebaihia et al. 2006) and strains have 
been found to possess fimbriae (Borriello et al. 1988), with pilus like structures observed by 
electron microscopy (Goulding et al. 2009). However, most strains in the literature do not 
appear to possess pili, and there has been no research to date as to whether these are true 
pilus structures and what the role is of pili in C. difficile infection.  
 
1.4 Tools for studying C. difficile 
 
Studying the basis of C. difficile pathogenesis can be divided into two broad categories; 
genetic manipulation of phenotypes and experimental observation of phenotype. Genetic 
manipulations ascertain the importance of gene expression and protein production by 
removing or increasing expression, while experimental observations allow for observations 
of phenotype in a variety of biologically relevant scenarios to analyse genetic manipulations 
or to compare “natural” strains of C. difficile. Genetic manipulation of C. difficile is still in its 
infancy, with only 10 years of research, but important advances have been made to shed 
light on C. difficile pathogenesis.   
1.4.1 Plasmid vectors for expression studies  
 
The first advance in genetic manipulation of C. difficile was the expression of genes from 
plasmids. These can be used for exogenous or C. difficile genes for over-expression, 
complementation of mutants and manipulation of genome expression. The majority of 
plasmids used are based on an E. coli – C. difficile shuttle vector developed by Purdy et al 
which utilised the replicon from C. difficile native plasmid pCD6 (Purdy et al. 2002). A catP 
gene from C. perfringens is included as a selectable marker and the ColE1 E. coli origin of 
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replication and the conjugative transfer origin oriT from the conjugative plasmid RK2 for 
maintenance and conjugation of the plasmid. pCD6 can be effectively conjugated from the 
E. coli donor strain CA434, which carries R702, into C. difficile.  
 
 
From this original construction, more elegant systems have been developed. Plasmids have 
been used to successfully express C. difficile genes using indigenous promoters as standard 
expression systems. This has been shown successfully with the cwp2 promoter for CwpV 
expression (Reynolds et al. 2011) and dominant negative expression of a mutated form of 
Figure 1.7 ClosTron system of gene mutagenesis 
A: Plasmid pMTL007 encoding a group II intron with an erythromycin selection cassette  (ermR) 
containing a group I intron between the promoter and ermB preventing expression of this 
marker (red cross). 
B: mRNA transcript of group II intron with inactivated ermB. 
C: Group II intron is retrotargeted to a specific location within the genome 
D: Insertion of the group II intron within the genome causes splicing of the group I intron, 
allowing activation and expression of ermB as a resistance marker for intron insertion.  
Adapted with permission from (Heap et al. 2007) 
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Cwp84 (de la Riva et al. 2011). An inducible promoter system has also been developed 
incorporating the tetracycline inducible promoter from Staphylococcus aureus into a 
pMTL960 backbone (Fagan and Fairweather 2011) where expression of genes can be 
increased in a dose dependent manner. This has been used successfully for knockdown of 
gene expression using antisense RNA expressed from a plasmid (Fagan and Fairweather 
2011). A modular approach to plasmid design has been suggested, such that resistance 
cassettes and replicons can easily be swapped depending on the plasmid role (Heap et al. 
2009). This is necessary when unstable plasmids are required such that they will be lost 
from the cell quickly, as required during mutation of the genome.  
1.4.2 Genomic mutation of C. difficile 
 
Early attempts at mutation of the C. difficile genome involved single crossover events which 
are largely unstable but has been used successfully in a few experiments (O'Connor et al. 
2006; Lyras et al. 2009). In 2007 the ClosTron mechanism of gene mutation was developed 
(Heap et al. 2007) and further refined (Heap et al. 2010). The ClosTron system works on the 
basis of insertion of a group II intron from Lactococcus lactis (Mohr et al. 2000) containing a 
retrotransposition-associated marker (RAM) (Zhong et al. 2003) into specific sites within the 
genome. Unstable plasmids are conjugated into C. difficile and the group II intron allows for 
site specific insertion. Chromosomal integration leads to excision of a self-splicing group I 
intron within the RAM which had prevented functional expression, allowing for positive 
selection for gene disruption (FIGURE 1.7). This system has been effectively exploited in 
numerous laboratories (Kirby et al. 2009; de la Riva et al. 2011; Reynolds et al. 2011; 
Dawson et al. 2012; Deakin et al. 2012). A double mutant has been created with this system 
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by changing the erythromycin resistance marker to thiamphenicol resistance in the second 
insertion event (Kuehne et al. 2010).  
This system can be manipulated for the creation of a library of random mutations. The 
mariner-transposon mutagenesis has been used successfully in C. difficile to insert randomly 
into the genome, as it targets TA sites which are rich in the C. difficile genome (Cartman and 
Minton 2010).The transposon and its transposase are encoded on an unstable plasmid such 
that following insertion of the transposon into the genome the plasmid is lost from the cell, 
removing the transposase gene from the cell. This allows for immobilisation of the 
transposon within its genome site. This again makes use of insertion mutations within the 
genome with a marker for insertion, and 98% of mutants show a single insertion event has 
occurred.  
More recently, silent mutations of the C. difficile genome have been developed. This is a 
valuable tool as it allows for multiple gene deletions within the genome without the need 
for additional selection markers, can remove the ambiguity of insertion deletions truly 
removing expression, allows for more relevant complementation of mutants by inserting 
genes into the chromosome and allows for direct mutation of proteins, such as point 
mutations and truncations. These systems again use the shuttle vectors described in 1.4.1 
and so far two systems have been designed for allele exchange (Cartman et al. 2012; Heap 
et al. 2012). The first system utilises the cytosine deaminase (codA) gene from E. coli as a 
heterologous counter-selection marker for a double crossover event. CodA converts the 
innocuous 5-fluorocytosine (FC) into toxic 5-fluorouracil (FU), a compound to which C. 
difficile is naturally sensitive. C. difficile does not contain a homologue of the codA gene. 500 
bases of homology flanking the sequence to be altered both up- and down-stream are 
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designed and incorporated separately from the codA gene into an unstable plasmid 
conferring thiamphenicol resistance. Single crossover events are identified with 
thiamphenicol selection and PCR analysis such that the new allele and entire plasmid 
(including codA) are present within the sequence to be altered. Double crossover events are 
selected for with plating of C. difficile single crossover mutants onto agar supplemented 
with FC, with excision of the plasmid backbone and replacement of the original allele with 
the new one. FC resistant clones were tested for thiamphenicol sensitivity to show loss of 
plasmid and PCR analysis undertaken to distinguish double crossover events from reversion 
events. Thus, single crossover events contain plasmid markers of thiamphenicol resistance 
and FU sensitivity, while double crossover events without the plasmid show thiamphenicol 
sensitivity and a return to FU resistance as FC would no longer be converted to FU by CodA. 
Revertants occur at a much high frequency than mutations as the plasmid and new allele 
are excised rather than the original allele. This system has been used to correct point 
mutations in tcdC in R20291 to study the role of these mutations in toxin production 
differences (Cartman et al. 2012). The second system can be used to insert large DNA 
sequences, such as for complementation of genes, and exploits pyrE which is involved in the 
uracil biosynthesis pathway (Heap et al. 2012). PyrE aids cell growth on agar lacking uracil 
and cells are sensitive to 5-fluoroorotic acid (FOA). Regions of homology which differ in 
length target the DNA insert to pyrE on the chromosome such that a single crossover event, 
which does not interrupt the gene, occurs first. This results in thiamphenicol resistance from 
the plasmid catP gene and FOA sensitivity from intact pyrE. A double crossover event with 
plasmid excision disrupts pyrE and renders a cell sensitive to thiamphenicol and resistant to 
FOA. DNA is stably inserted into the chromosome in pyrE and FOA selection prevents 
revertants forming. For further mutations, this truncated and inactive pyrE gene can be 
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returned to a full length functional gene by homologous recombination to reinsert its 5’ 
region, selected for by growth in the absence of uracil. This results in the DNA insertion 
alongside a functional pyrE gene. In a pyrE mutant, DNA can be inserted anywhere in the 
genome by integrating both the gene of interest and a functional pyrE lacking a promoter. 
Recombination linking the pyrE gene to a chromosomal promoter would allow for pyrE 
expression as a selectable marker for DNA insertion. This system can also be utilised for 
other markers such as ermB for insertions of large regions of DNA in a multi-step technique 
(Heap et al. 2012). 
1.4.3 In vitro models of colonisation and disease  
 
In vitro models of colonisation are usually employed prior to studying infection in vivo 
models. In C. difficile these include the cell rounding assay for measuring toxin titres. These 
involve various cell lines, typically HT29 cells and Vero cells which are sensitive to toxin A 
and toxin B respectively (Torres et al. 1992; Xie et al. 2013). These are often used to quantify 
the toxin titre following C. difficile infection in animal models, and can be used to assess the 
level of neutralising antibody against toxins following vaccination or infection (Xie et al. 
2013).  
Cell binding assays are used to assess proteins hypothesised to be involved in colonisation. 
Cell lines commonly used include caco2-BBE1 (Drudy et al. 2001; Cerquetti et al. 2002; 
Schwan et al. 2009; Dingle et al. 2010), HT29 (Eveillard et al. 1993) and IMR-90 (Tulli et al. 
2013). The caco2-BBE1 cell line is derived from human epithelial colorectal adenocarcinoma 
cells which spontaneously differentiate into a polarised monolayer (Hidalgo et al. 1989) 
mimicking the in vivo morphology of intestinal epithelial cells. These have been used with 
mixed results for binding of C. difficile cells, but spores of C. difficile seem to bind well to 
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these cells (Paredes-Sabja and Sarker 2012). HT29-MTX cells are a mucus producing colon 
carcinoma cell line and viewed as a more biologically accurate model of the gut despite 
difficulty in assays from the sticky mucus produced. IMR-90 cells are human fibroblasts that 
produce high levels of extracellular matrix proteins. These have not been used to a high 
degree to investigate C. difficile colonisation as they are a fibroblast cell line, but their 
production of ECM proteins make them an interesting model for studying protein binding to 
the ECM following disruption of tight junctions by the toxins. These are the most biologically 
relevant cell lines as Vero cells, to which C. difficile binds to a high degree (Waligora et al. 
1999) is a non-human kidney epithelial cell line and therefore not as relevant for 
understanding colonisation of the human intestine. C. difficile has been found to bind with 
higher affinity to primary colonic epithelial cells than to immortalised intestinal cell lines 
(Drudy et al. 2001) which are more clinically relevant than these cell lines but are more 
difficult to obtain as they must be cultured from patient biopsies.  
Models of C. difficile colonisation and infection have been taken further than tissue culture 
with development of an in vitro model of the human gut. This uses a continuous flow system 
which mimics the environment within the human gut (Macfarlane et al. 1998) and has been 
further developed to study C. difficile colonisation (Freeman et al. 2003). This model is 
useful for studying the effects of the microbiota on C. difficile colonisation and infection as it 
involves growing C. difficile in fresh emulsified faecal extracts from healthy volunteers under 
a controlled environment. It has been used to study the effects of antibiotics on the 
microflora leading to C. difficile growth and production of toxin (Freeman et al. 2003; Baines 
et al. 2005; Freeman et al. 2007; Chilton et al. 2012) as well as the effects of antibiotic 
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treatment on C. difficile itself (Baines et al. 2009). This model also has its limits as interaction 
of C. difficile with host cells and immune defences are absent.  
1.4.4 Animal models of colonisation and disease 
 
In vitro models lack the complexity of in vivo models as they are not multifaceted. 
Interaction with cells, or effect on the immune system, or interactions with the microbiota 
are observed, but not all at once. In vivo models are therefore of most interest for studying 
C. difficile colonisation and infection and there are two predominant models for this, the 
hamster and murine models.  
1.4.4.1 The hamster model of C. difficile infection 
Hamster model of C. difficile infection has been used for over 30 years, since the 
observation that they show acute symptoms from infection similar to the disease phenotype 
in humans, such as diarrhoea and histological damage (Bartlett et al. 1977; Fekety et al. 
1979; Douce and Goulding 2010). Golden Syrian hamsters are typically treated with 
clindamycin to reduce the diversity of the normal protective microbiota of the gut and then 
challenged with C. difficile. Infection is lethal, with time to death commonly within 24-72 
hours (Razaq et al. 2007). The model has been further refined to meet government 
guidelines and uses telemetry chips to monitor the body temperature of hamsters, giving a 
drop in temperature below 35°C as a humane endpoint to the experiments at which point 
the hamsters are culled before their infection becomes severe (Douce and Goulding 2010). 
This model is primarily used as a model for the acute phase of C. difficile infection and is 
frequently used to demonstrate protective effects of therapies and vaccinations (Fernie et 
al. 1983; Torres et al. 1995; Giannasca et al. 1999; Tian et al. 2012). It is difficult to observe 
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long term changes in colonisation in the hamster model as collection of faeces during these 
acute infections is problematic due to the severe diarrhoea observed. Colonisation is usually 
determined from tissue samples at the end point of experiments by quantification of spores.   
1.4.4.2 Mouse models of C. difficile infection 
The murine model is useful for studying long term changes in colonisation, as well as 
asymptomatic carriage and transmission of infection. C. difficile infection of mice can show 
severe histological changes under certain conditions, such as when treated with a high 
number of antibiotics before challenge with C. difficile spores which also shows 
development of diarrhoea and proved lethal (Chen et al. 2008), following treatment with a 
single antibiotic such as third generation cephalosporin cefaperazone which also shows 
elevation of neutrophils (Theriot et al. 2011) and in gnotobiotic (germ free) mice (Pawlowski 
et al. 2010) although some studies show no clinical symptoms of CDI in gnotobiotic mice 
(Reeves et al. 2012). Gnotobiotic mice have limited use for studying C. difficile infection 
unless studying the direct link of certain bacterial species to prevent C. difficile infection as 
the microbiota have been shown to be important for modulating host immune responses 
and prevention C. difficile infection (Lopez-Boado et al. 2000; Stappenbeck et al. 2002; 
Lawley et al. 2012). Unlike hamsters, mice generally do not succumb to infection and survive 
for long term analyses. Mice can be asymptomatically colonised by C. difficile and induced to 
a super-shedder state by treatment with clindamycin whereby they shed high numbers of 
spores in their faeces and show slight inflammation of the gut (Lawley et al. 2009a). 
Shedding tapers off and can be induced again with further antibiotic treatment, allowing for 
study of long term colonisation and recurrence. Another model for studying recurrence of 
disease has recently been established using an initial cocktail of antibiotics along with 
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clindamycin treatment and further antibiotic treatments or re-exposure to C. difficile (Sun et 
al. 2011). Knockout mice can also be used to study C. difficile infection, such as Myd88(-/-) 
mice which have impaired innate immune function leading to fatal infection by C. difficile 
challenge (Lawley et al. 2009a). Libraries of knockout mice are already widely available and 
so can be useful in studying the host factors which determine responses to C. difficile 
infection.  
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1.5 Project Aims 
 
In addition to its external S-layer, C. difficile has a thick peptidoglycan cell wall to which 
surface proteins are potentially bound. In other Gram positive bacteria the sortase 
mechanism of cell wall attachment is well understood, but this system and the protein 
substrates are yet to be studied in C. difficile.   
The role of toxins in C. difficile pathogenesis has been extensively studied, and vaccination 
studies against C. difficile have largely focused on targeting the toxicity of disease. However 
little is known of surface protein involvement in colonisation or the major S-layer protein 
after SlpA, Cwp2. It is therefore of interest to determine whether surface proteins such as 
Cwp2 could be utilised to enhance a toxin based vaccine and additionally prevent 
colonisation.  
The major aims of this project were therefore: 
1) To identify potential sortase substrates in C. difficile based on characteristics found 
in other Gram-positive bacteria and analyse their expression 
2) To develop a method for extracting proteins from the peptidoglycan cell wall 
3) To characterise the function of sortase substrates in C. difficile  
4) To understand the mechanism of sortase mediated cell wall attachment 
5) To characterise the S-layer protein Cwp2 
6) To determine the suitability of Cwp2 in a multi-component vaccine 
7) To investigate the effect of Cwp2 and S-layer proteins as antigens in hamster and 
mouse immunisations with toxin fragments 
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2Chapter 2 Materials and Methods 
2.1 Bacterial strains and culture 
 
2.1.1 C. difficile strains 
Table 2.1 Strains externally supplied to this study 
Strain Ribotype Isolated Source Detail 
630 012 Switzerland Peter Mullany 
Fully sequenced 
Toxin A+/B+ 
630Δerm 012 UK Peter Mullany 
Erythromycin sensistive 
derivative of 630 
R20291 027 UK Brendan Wren Fully sequenced 
R13537 001 Ireland Deirdre Ni Eidhin  
M9 017 Ireland Denise Drudy Tcd A-/B+ 
NF2029 106 UK Mark Wilcox  
AY1 ? USA Dale Gerding Non-toxic 
M120 078 UK Trevor Lawley  
R20352 027 Canada Brendan Wren  
cwp66::erm 012 
ClosTron mutant of 
630Δerm 
Zoe Seager No cwp66 expression 
630Δerm 
pZLS002 
012 
Plasmid conjugated 
into 630Δerm 
Zoe Seager cwp66 overexpression 
Strains detailed which were not produced from this study, detailing the strain name, ribotype, 
country of isolation, kindly provided by and relevant details.  
 
2.1.2 C. difficile culture conditions 
Plated cultures of C. difficile were grown on brain heart infusion (BHI) agar plates (Oxoid), TY 
agar plates (3% Tryptose, 2% Yeast Extract, 1.5% Agar (Bacto)) or BHIS agar plates (for 1 
litre: 37 g BHI (Oxoid), 5 g Yeast Extract (BD Bacto), 1 g L-Cysteine (Sigma), 15 g Agar (BD 
Bacto)). Liquid cultures of C. difficile were grown in BHI broth (Oxoid), TY broth (Bacto) or 
BHIS broth. Agar plates and liquid cultures were supplemented with antibiotics as 
appropriate: 5 µg/ml erythromycin, 15 µg/ml thiamphenicol. Anhydrotetracycline was used 
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at 500 ng/ml for induction of the Ptet promoter in C. difficile expression vectors based on 
pRPF185 (Fagan and Fairweather 2011). 
2.1.3 E. coli strains  
Commercially produced chemically competent Escherichia coli NovaBlueTM (Merck) and NEB 
5-α (NEB) were used for initial transformation following cloning. E. coli strain CA434 
competent cells produced in the lab were used for E. coli – C. difficile conjugation. RosettaTM 
(Novagen) E. coli were used to carry out protein expression. These are BL21 (DE3) E. coli 
containing the pRARE plasmid encoding tRNAs for E. coli rare codons, which enhance 
expression of T-A rich C. difficile genes.  
2.1.4 E. coli culture conditions 
Plated cultures E. coli were grown on LB-agar (VWR) and liquid cultures for cloning grown in 
LB broth (VWR). For inducible protein expression for purification, E. coli were grown in 
OverNight ExpressTM TB media (Merck) + 10 ml/L glycerol. All cultures were grown with 
appropriate antibiotics for plasmid selection (15 µg/ml chloramphenicol, 50 µg/ml 
kanamycin, 50 µg/ml carbenicillin) at 37°C.   
2.1.5 Production of chemically competent E. coli 
An overnight culture of E. coli in LB media was sub-cultured with shaking at 37°C in a baffled 
flask. Its optical density at 600nm was monitored until cultures were in exponential growth 
phase (OD600 0.4 – 0.6). Cultures were harvested by centrifugation at 3,400 g for 10 minutes 
at 4°C and pellets resuspended in 5 ml ice-cold 100 mM CaCl2 and incubated on ice for 15 
minutes. Samples were then harvested at 3,400 g for 10 minutes at 4°C and resuspended in 
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1 ml ice-cold 100 mM CaCl2 with 15% (v/v) glycerol. Cells were incubated on ice for 2 hours 
before being aliquotted and frozen at -80°C. All steps except centrifugation were performed 
in a 4°C cold room.  
2.1.6 Chemical transformation of E. coli 
25 µl competent cells were thawed on ice and 2 µl purified plasmid DNA or ligation reaction 
was added. Cells were incubated on ice for 15 minutes and then transferred to a 42°C water 
bath for 30 seconds before being returned to ice. Cells were further incubated on ice for 2 
minutes before addition of 250 µl SOC medium (Invitrogen). Cells were shaken at 37°C for 1 
hour before plating on LB agar containing appropriate antibiotic selection.  
2.1.7 E. coli-C. difficile conjugation 
2 ml overnight LB cultures + 15 µg/ml chloramphenicol selection of E. coli CA434 containing 
a pMTL960 derived vector were harvested at 4,000 g for 2 minutes. Cells were washed 
gently in 1 ml PBS and harvested again and supernatant discarded before transfer to an 
anaerobic cabinet. E. coli cells were resuspended in 200 µl C. difficile overnight culture and 
20 µl spots were plated onto BHI agar plates. Plates were incubated at 37°C in the anaerobic 
cabinet for 8 hours while conjugation proceeded. 1 ml PBS was used to scrape up bacteria 
from the agar plate. 1:5 dilutions were plated onto BHI agar containing 15 µg/ml 
thiamphenicol for plasmid selection and 250 µg/ml cycloserine to inhibit E. coli growth. 
Plates were grown overnight at 37°C in the anaerobic cabinet. Transconjugated were picked 
and streaked onto fresh selective plates twice to purify C. difficile containing pMTL960 
based plasmids and to thoroughly remove E. coli from the conjugation.  
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2.2 Bioinformatics and computer programmes 
 
2.2.1 Genome visualisations 
Genome sequences were obtained from The Wellcome Sanger Institute website 
(www.sanger.ac.uk). The Geneious software (Biomatters) was used to visualise the genome 
sequences and annotations (Sebaihia et al. 2006).  
2.2.2 DNA sequencing, alignments and homology 
The Geneious software (Biomatters) was used to view sequencing chromatograms obtained 
from GATC (http://www.gatc.com), construct contigs from multiple sequencing reactions, 
create plasmid maps for cloning and align sequences for analysis after cloning.  
2.2.3 Gene and protein property predictions 
Molecular weight of proteins, prediction of hydrophobic helices, subcellular localisation and 
other basic properties were calculated using tools from the ExPASy website 
(http://www.expasy.ch/tools). The Augur algorithm (http://bioinfo.mikrobio.med.uni-
giessen.de/augur/) and LocateP (http://www.cmbi.ru.nl/locatep-db/cgi-bin/locatepdb.py) 
were used to predict sortase substrates in C. difficile. SignalP 
(http://www.cbs.dtu.dk/services/SignalP/) was used to predict N-terminal signal sequences 
and signal cleavage sites. Softberry PROM (prediction of bacterial promoters) 
(http://www.softberry.com) was used to predict promoter sites. 
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2.3 DNA manipulation 
 
2.3.1 Extraction of genomic DNA from C. difficile 
25 ml cultures of C. difficile were grown overnight in TY broth and harvested. Pellets were 
frozen at -80°C. Thawed pellets were resuspended in 2 ml TE buffer (200mM NaCl, 50mM 
EDTA, 20mM Tris-HCl pH 8.0) and incubated at 37°C for 1 hour in a water bath. 50 µl 
pronase (20 mg/ml) was added and incubated at 55°C for 1 hour. 500 µl 10% N-
lauroylsarcosine solution was added and incubated at 37°C for 1 hour. 2.5 ml nuclease-free 
water with 250 µg/ml RNaseA was added and incubated at 37°C for 1 hour. Suspension was 
added to a 15 ml Phase lock gel (PLG) tube (VWR) with an equal volume of 
Phenol:Chloroform:Isoamyl alcohol (25:24:1) and spun at 4,000 rpm for 10 min at RT. 
Supernatant was transferred to a new PLG tube with equal volume of 
Phenol:Chloroform:Isoamyl alcohol (25:24:1) and spun again. Supernatant was transferred 
to a new PLG tube with an equal volume Chloroform:Isoamyl alcohol and spun again. 
Supernatant was transferred to a fresh PLG tube with equal volume of Chloroform:Isoamyl 
alcohol and spun again. Supernatant was transferred to a 15 ml Falcon tube. 2.5 volumes of 
ice-cold 100% EtOH was added to sample and incubated overnight at -20°C. Sample was 
spun at 4,000 rpm for 15 minutes at 4°C. EtOH removed and pellet washed with 500 µl 70% 
EtOH and spun at 4,000 rpm for 10 minutes at 4°C. EtOH was removed and pellet air dried 
for a maximum of 10 minutes. The pellet was resuspended with care in 50 µl nuclease-free 
water. Quantity and quality of DNA samples was checked by NanoDrop and agarose gel.  
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2.3.2 Chelex preparations 
Rough DNA preparations could be extracted from colonies using Chelex 100 resin (Bio-Rad) 
at 0.05 g/ml in DNase-free water. A single colony was suspended in 100 µl 5% Chelex, boiled 
for 10 minutes at 100°C and cell debris pelleted at 14,000 g for 10 minutes. Supernatants 
containing DNA were transferred to a fresh tube for analysis.  
2.3.3 Polymerase chain reaction (PCR) primers 
All primers used in this study were synthesised by Eurofins MWG Biotech. All primers were 
used at a final concentration of 10 pmol/µl. Primer annealing temperatures were generally 
5°C below the predicted melting temperature (Tm) of the primers, or were optimised with a 
gradient of annealing temperatures in PCR reactions.  
2.3.4 Diagnostic PCR 
For screening PCR where polymerase fidelity was not of importance, such as for screening 
cDNA, a Taq polymerase (Sigma) was used. Taq was used in a final 20 µl reaction mix in H2O 
of 2 µl 10 X PCR buffer, 0.2 mM dNTPs, 1 mM MgCl2, 1 µl forward primer, 1 µl reverse 
primer, 0.05 U/µl Taq Polymerase. Thermal cycler parameters were typically 94°C 3 mins; 
thirty cycles of 94°C denaturing 30 s, primer appropriate annealing temperature for 30 s, 
72°C extension for 1 min per kb; a final extension at 72°C for 10 mins.  
2.3.5 High fidelity PCR 
High fidelity PCR for cloning purposes was conducted with a proofreading polymerase, KOD 
Hot-start DNA polymerase (Novagen), in a final 50 µl reaction mix in H2O of 5 µl 10 X PCR 
buffer, 0.2 mM dNTPs, 3 µl DMSO, 1.25 mM MgSO4, 1 µl forward primer, 1 µl reverse 
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primer, 0.02 U/µl KOD Hot Start DNA Polymerase. Thermal cycler parameters were: 94°C 2 
mins; thirty cycles of 94°C denaturing 15 s, primer appropriate annealing temperature for 30 
s, 68°C extension at 10 – 25 s/kb according to KOD polymerase manufacturer’s instructions 
for product size.  
2.3.6 PCR product purification 
If a single PCR product was visualised on an agarose gel then this product was purified from 
the PCR reaction using a QIAquick PCR purification spin kit (Qiagen). If multiple bands was 
present, the desired band was purified from the gel. The band was excised using a scalpel 
and purification was undertaken using QIAquick Gel Extraction Kit (Qiagen) according to the 
manufacturer’s instructions.  
2.3.7 Agarose gel electrophoresis 
PCR reactions and DNA samples were run on 1 – 2% TAE-agarose gels (TAE: 40 mM Tris, 20 
mM acetic acid, 1 mM EDTA) containing SYBR Safe DNA gel stain (Invitrogen). DNA was 
visualised using a Gel Doc system (Bio-Rad).  
2.3.8 Restriction enzyme digestion 
For subcloning or cloning of PCR products into specific vector DNA sites, or for digestion of 
genomic DNA, restriction endonucleases were used. All restriction enzymes were obtained 
from NEB and reaction conditions followed as the manufacturer’s instructions. Generally 
digestions of PCR products and vector DNA were conducted at 37°C for 2 hours, while 
genomic DNA was digested at 37°C overnight.  
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2.3.9 Purification and Quantification of digested DNA 
Digested PCR products were purified for ligation using the QIAquick PCR purification spin kit 
(Qiagen). Digested vectors would often have two or more products so the desired fragment 
was purified from agarose gel by excision using a scalpel and the QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer’s instructions.  
2.3.10 DNA ligation 
DNA concentrations were quantified using a NanoDrop Spectrophotometer (Thermo 
Scientific). 50 ng digested and purified DNA vector was mixed with purified insert in a molar 
ratio 1:3. Freshly thawed and aspirated DNA ligase buffer containing ATP was mixed with 
DNA samples and Quick Stick ligase (Bioline). The reaction was incubated at room 
temperature for 15 minutes before transformation into chemically competent NovaBlue E. 
coli (Merck).  
2.3.11 Colony PCR 
For screening PCR where polymerase fidelity was not of importance, such as for screening 
for insertion events following ligations and transformations, a Taq polymerase was used. 
RedTaq polymerase kit (Sigma) contains a master mix which includes MgCl2, dNTPs,  Taq 
polymerase and loading buffer. Colonies were resuspended in 10 µl RedTaq, 8 µl DNase-free 
H2O, 1 µl forward primer, 1 µl reverse primer to make a final volume of 20 µl. Following an 
initial 10 min boil step to promote lysis of bacterial cells, thermal cycler programme was as 
follows: 94°C 3 mins; thirty cycles of 94°C denaturing 30 s, primer appropriate annealing 
temperature for 30 s, 72°C extension for 1 min per kb; a final extension at 72°C for 10 mins. 
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Primers annealed to either side of the insertion site to allow for distinction between empty 
vector and vectors containing an insert.  
2.3.12 Plasmid purification 
Plasmids were purified from overnight E. coli cultures grown in LB broth with the 
appropriate antibiotic for plasmid maintenance. Plasmids were purified using a QIAprep 
Spin Miniprep Kit (Qiagen) according to the manufacturer’s instructions.  
2.3.13 DNA Sequencing 
GATC Biotech (Konstanz, Germany) was used for sequencing of 100 ng/µl purified plasmid 
DNA. Sequencing primers were provided at 10 pmol/µl or synthesis by GATC. 
2.3.14 Construction of C. difficile ClosTron insertion mutants 
Mutants was generated in C. difficile 630 Δerm by insertion of a bacterial group II intron 
containing a retrotransposition-activated marker (RAM) conferring erythromycin resistance 
using the ClosTron clostridial gene knockout system (Heap et al. 2007).  
www.clostron.com/clostron1.php was used to design ClosTron targeted sequences, and 
plasmids were produced with pMTL007C-E5 vector backbone. CA434 E. coli containing these 
ClosTron plasmids were grown in LB with 15 μg/ml chloramphenicol. 1 ml CA434 was 
harvested at room temperature and conjugated with 200μl C. difficile ∆erm grown in TY 
media overnight. Conjugation was incubated overnight at 37°C under anaerobic conditions 
on non-selective Brazier’s agar. pMTL007C-E5 positive C. difficile were selected for with 
thiamphenicol (15 μg/ml), with cefoxitin and cycloserine (Bioconnections) counter-selection 
against E. coli. Transconjugates were tested for intron insertion by selection on Brazier’s 
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agar with erythromycin selection (5 μg/ml) and for thiamphenicol sensitivity. DNA was 
extracted with chelex and Taq PCRs performed to determine the presence and orientation 
of the intron.  
 
2.4 RNA analysis 
 
All surfaces were wiped down with RNase Zap (Ambion), and RNase free tubes and tips 
used. 
2.4.1 C. difficile RNA extraction 
2 volumes of pre-reduced RNA protect (Qiagen) was added to 5 ml of C. difficile culture of 
required growth phase and incubated for 5 min in the cabinet. Samples were centrifuged at 
4,000 rpm for 10 min at 4°C and pelleted cells frozen at -80°C. Pellets were resuspended in 1 
ml RNA pro solution (MP Biomedicals) and transferred to a matrix tube (FastRNA Pro Blue 
Kit MP Biomedicals). Matrix tubes were processed in a FastPrep instrument for 40 s at 6 
m/s. Tubes were centrifuged at 13,000 rpm for 10 min at 4°C. Liquid supernatant (~700 µl) 
was transferred into a fresh eppendorf and incubated for 5 min at room temperature. 300 
µl chloroform was added and vortexed for 10 s. Samples were centrifuged at 13,000 rpm for 
15 min at 4°C and 500 µl upper phase transferred to a fresh tube containing 500 µl 100 % 
EtOH. Following overnight precipitation at -20°C samples were centrifuged at 13,000 rpm 
for 15 min at 4°C. Supernatant was removed and discarded before washing the pellet in 500 
µl 70 % EtOH (made with nuclease-free H2O. Samples were centrifuged at 13,000 rpm for 5 
min at 4°C. Supernatants were removed and the pellet air dried for up to 10 min. Pellets 
were resuspended in 45 µl nuclease-free H2O and DNases treated with Turbo DNase Kit 
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(Ambion) according to the manufacturer’s instructions. Briefly, 5 µl 10X reaction buffer was 
added to RNA sample with 1 µl DNase and incubated for 37°C for 30 min. 5 µl inactivation 
reagent was added, mixed and incubated for 5 min at room temperature. Samples were 
centrifuged at 10,000 x g for 2 min at 4°C and supernatants transferred to fresh tubes. RNA 
yield and quality was checked by NanoDrop Spectrophotometer (Thermo Scientific) and 
agarose gels. RNA was stored at -80°C.  
2.4.2 Reverse transcription (RT)-PCR 
cDNA was reverse transcribed from purified RNA using RETROscript® First Strand Synthesis 
Kit (Ambion) as follows: 2 μl (50 μM stock) Random Decamers were added to 1 μg RNA to a 
total volume of 12 μl. The reaction was heated to 85°C for 3 minutes and returned to ice. 2 
μl 10x RT buffer, 4 μl (dNTP mix containing 2.5 mM each dNTP) dNTPs, 1 μl (10 units/μl) 
RNase inhibitor and 1 μl (100 units/μl) MMLV-RT (Moloney murine leukaemia virus reverse 
transcriptase) were added to the sample, mixed thoroughly by pipetting up and down, and 
incubated at 44°C for 1 hour. The enzyme was heat-inactivated at 92°C for 10minutes. 2 µl 
of generated cDNA was used as a template in a standard 20 μl Taq PCR reaction 
2.4.3 5’ RACE 
Rapid Amplification of cDNA Ends (RACE) was conducted according to the manufacturer’s 
instructions (Invitrogen): 3 µg purified RNA and 2.5 pmoles GSP1 (gene specific primer 1) 
were incubated in a total volume of 15.5 µl in RNase free water at 70°C for 10 minutes and 
chilled on ice for 1 minute. To this reaction was added 2.5 µl 10X PCR buffer, 2.5 µl 25 mM 
MgCl2, 1 µl 10 mM dNTP mix, 2.5 µl 0.1 M DTT, mixed gently and incubated at 42°C for 1 
minute. 1 µl SuperScriptTM II RT was added, mixed gently and incubated at 42°C for 50 
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minutes. Reaction was terminated at 70°C for 15 minutes and reaction placed at 37°C. 1 µl 
RNase mix was added and incubated at 37°C for 30 minutes following which the reaction 
was placed on ice. cDNA was purified by addition of 120 µl binding solution (6 M NaI) and 
transferred to a S.N.A.P. column, centrifuged at 13,000 g for 20 seconds and flow-through 
transferred to a microcentrifuge tube. The spin cartridge was washed four times with 400 µl 
4°C 1X wash buffer, 13,000 g for 20 seconds and flow-through discarded. The spin cartridge 
was washed twice more with 400 µl 4°C 70% ethanol, 13,000 g for 20 seconds. The spin 
cartridge was spun empty at 13,000 g for 1 minute and then transferred to a fresh sample 
recovery tube. 50 µl sterilised, distilled water preheated to 85°C was added to the spin 
cartridge and centrifuged at 13,000 g for 20 seconds to elute cDNA. cDNA was TdT tailed by 
adding 6.5 µl DEPC-treated water, 5 µl 5X tailing buffer, 2.5 µl 2 mM dCTP to 10 µl S.N.A.P. 
purified cDNA sample and incubated at 94°C for 3 minutes. Contents were placed on ice, 1 
µl TdT was added and the reaction incubated at 37°C for 10 minutes. A standard Taq 
reaction was conducted with 2 µl 10 µM Abridged Anchor Primer and 2 µl 20 µM nested 
GSP2 primer for 35 cycles and 5’ RACE products analysed by agarose gel electrophoresis.  
 
2.5 Protein manipulation 
 
2.5.1 C. difficile protein expression 
pMTL960 vectors under control of the cwp2 promoter or the tetracycline inducible 
promoter (Fagan and Fairweather 2011) were used for expression of genes of interest in C. 
difficile. Overnight TY cultures were sub-cultured to OD 0.05 and grown to mid-log with 15 
µg/ml thiamphenicol. Cultures containing the derivative of pRPF185 were induced with 500 
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ng/ml anhydrotetracycline at OD 0.1 and grown to mid-log. Cells were harvested at 4,000 
rpm for 15 minutes and frozen at -20°C. For His-tag purification cells were thawed and 
resuspended in 7 ml Lysis buffer (50 mM HEPES, 300 mM NaCl, 10 mM Immidazole) with 40 
μg/ml DNase1 (Sigma). For Strep-tag purification cells were thawed and resuspended in 5 ml 
binding buffer (100 mM Tris-HCl pH8, 150 mM NaCl, 1 mM EDTA) with 40 μg/ml DNase1 
(Sigma). Suspensions were incubated at 37°C for 45 minutes in a water bath. Following lysis 
the suspension was centrifuged at 14,000 rpm for 10 minutes at 4°C. Supernatants were 
collected containing soluble protein and filtered with 0.2 μM filter for protein purification.  
2.5.2 E. coli recombinant protein expression 
pET28a containing genes of interest under control of the lactose inducible promoter was 
used for recombinant protein expression in E. coli. 5 ml cultures were grown for 6 h in 
Overnight Express Autoinduction medium (Novagen) with kanamycin for maintenance of 
pET28a.  These cultures were then used to inoculate 300 ml Overnight Express 
Autoinduction medium which was grown overnight to saturation of the medium at 37°C 
with shaking. Cells were harvested at 4,000 rpm and frozen at -20°C. Thawed pellets were 
resuspended in lysis buffer (50 mM HEPES, 300 mM NaCl, 10 mM Immidazole) with 1/100 
DNase1 (4 mg/ml stock), 1/100 lysozyme (50 mg/ml stock) and 1/10 BugBuster Protein 
Extraction Reagent (Novagen). Lysis proceeded for 45 minutes at room temperature with 
gentle agitation. Following lysis the suspension was centrifuged at 14,000 rpm for 10 
minutes at 4°C. Supernatants were collected containing soluble protein for protein 
purification. 
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2.5.3 Purification of soluble His-tagged proteins 
ÄKTA FPLC (GE Healthcare) is an automated liquid chromatography system for purifying 
proteins. A Nickle His-Trap HP column (GE Healthcare) was used to purify His-tagged 
proteins. Soluble protein was loaded into the system and purified using the HisTrap 
automated programme with a final elution concentration of 250 mM immidazole in 50 mM 
HEPES, 300 mM NaCl. Fractions within the peak at A280 were run by SDS-PAGE and 
Coomassie stained.  
2.5.4 Purification of insoluble His-tagged proteins 
Pellets equivalent to 300 ml saturated Overnight Express Autoinduction medium (Novagen) 
cultures were resuspended in 7 ml lysis buffer (PBS, 40 μg/ml DNase, 0.5 mg/ml lysozyme) 
and subjected to 1,000-1,500 PSI 4 times in a French Press. Lysates were centrifuged at 
25,000 g 5 minutes 4°C. The supernatant was spun again for 30 minutes at 25,000 g 4°C and 
the pellet from this spin combined with the pellet from the previous harvest. These were 
resuspended in 5 ml lysis buffer with 500 μl BugBuster Protein Extraction Reagent 
(Novagen) and incubated at 50 minutes at room temperature with rotation. Membranes 
were harvested at 25,000 g for 1 minute at 4°C, the pellet resuspended as before in lysis 
buffer with BugBuster and incubated at room temperature with rotation for 5 minutes. 
Suspensions were spun at 25,000 g 15 minutes 4°C and resuspension and incubation of the 
pellet repeated for 5 minutes at room temperature. This was repeated until the supernatant 
following spins was clear. The pellet was washed in 5 ml PBS and resuspended in A1 
denaturing buffer (20 mM Tris-HCl pH7.7, 500 mM NaCl, 8 M Urea) and rotated for 1 hour at 
room temperature until a yellow solubilised solution was obtained. Suspension was spun at 
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25,000 g for 10 minutes at 4°C to remove any cell debris. The supernatant was injected into 
the loop of an ÄKTA FPLC. Following loading of the sample onto the His-Trap column (GE 
Healthcare), the column was washed with 20 ml A2 buffer (20 mM Tris-HCl pH 7.7, 500 mM 
NaCl, 0.1% Triton X-100), 20 ml A3 buffer (20 mM Tris-HCl pH 7.7, 150 mM NaCl, 5 mM β-
cyclodextrin) and finally 20 ml A4 buffer (20 mM Tris-HCl pH 7.7, 150 mM NaCl, 20 mM 
immidazole). Protein was eluted with elution buffer (20 mM Tris-HCl pH7.7, 150 mM NaCl, 
250 mM immidazole).  
2.5.5 Purification of Strep-tagged proteins 
ÄKTA FPLC is an automated liquid chromatography system for purifying proteins. A Strep-
Trap HP column (GE Healthcare) was used to purify Strep-tagged proteins. Soluble protein 
was loaded into the system and purified using the StrepTrap automated programme with a 
final elution concentration of 100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 2.5 mM 
desthiobiotin, pH 8.0. Fractions within the peak at A280 were run by SDS-PAGE and 
Coomassie stained.  
2.5.6 Dialysis of Purified Protein 
To store purified proteins long-term dialysis was performed into a more suitable buffer. 
Purification fractions containing the desired protein with few minor bands if any were 
transferred to a Slide-A-Lyzer Dialysis Cassette (Thermo Scientific) of a relevant size. 
Cassettes were floated in 2 litres pre-cooled HBS (10 mM HEPES, 150 mM NaCl) for 2 hours 
with stirring at 4°C. The buffer was changed and left overnight at 4°C with stirring. The 
following morning the buffer was changed once more for a further 4 hours. Protein was 
retrieved from the cassette and run on a gel to check purity and stability. 
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2.5.7 BCA Determination of protein concentration 
A BCA assay (Pierce) was used to accurately determine protein concentration according to 
the manufacturer’s instructions. Briefly, BSA standards of known concentrations and 
purified protein samples were diluted in HBS. Reagents A and B were mixed in a 50:1 ratio, 
with 180 µl reagent added to 20 µl sample in a 96 well plate. The reaction was incubated at 
37°C for 30 minutes and the absorbance read at 595 nm using a Benchmark microplate 
reader (Bio-Rad).  
2.5.8 C. difficile surface layer preparation 
C. difficile cells were grown to the desired growth phase in TY or BHIS broth. Cells were 
harvested at 4,000 g for 10 minutes at room temperature, washed in PBS and harvested 
again. Cells were then resuspended to required OD in 0.2M glycine-HCl pH 2.2 and 
incubated with rotation at room temperature for 30 minutes. Suspensions were centrifuged 
at 25,000 g for 10 minutes at 4°C. Supernatants containing the S-layer proteins were 
transferred to a fresh tube for analysis and pH adjusted to pH6-8 with 2M Tris and pH strips 
(Whatman).  
2.5.9 C. difficile cell wall protein extraction 
Cells were grown in TY broth to mid-exponential growth phase and harvested at 4,000 g for 
2 minutes. Cells were resuspended to required OD in PS buffer (0.05 M sodium phosphate, 
0.5 M sucrose, pH 7.0) with 30 μg/ml amidase (see Chapter 3) and incubated anaerobically 
for 1 hour at 37°C. Suspensions were then centrifuged at 6,000 g for 20 minutes to harvest 
the protoplasts. Supernatant containing the cell wall extracts were transferred to a fresh 
tube for analysis. Protoplasts could be further lysed by resuspending in 0.05 M sodium 
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phosphate pH 7.0 and incubated at 37°C for 1 hour. Soluble and membrane fractions were 
separated at 25,000 g for 10 minutes at 4°C.  
2.5.10 Concentration of culture supernatant proteins 
Cultures were grown to required OD and harvested at 4,000 g for 10 minutes. Supernatant 
was carefully separated from the pellet and placed in a fresh tube. TCA was added to a final 
concentration of 10% and incubated on ice for 30 minutes. Samples were spun at 25,000 g 
for 10 minutes at 4°C and supernatant removed. The pellet was resuspended in 1 ml 90% 
pre-chilled acetone and vortexed for 15 minutes. Harvest and acetone wash steps were 
repeated. The final pellet was dried for 3 minutes at room temperature and resuspended to 
required OD in PBS.  
2.5.11 Tetracycline induction of protein expression in C. difficile 
Overnight cultures were sub-cultured to OD 0.05 in TY broth with 15 μg/ml thiamphenicol. 
Cultures were grown to OD 0.2 and induced with 500 ng/ml anhydrotetracycline (ATc). Cells 
were grown for at least one generation before being harvested.  
2.5.12 SDS-PAGE and Coomassie staining 
SDS-PAGE gels with 12 % acrylamide were prepared using mini-protean kits (Bio-Rad). The 
resolving gel (12% 39:1 acrylamide:bisacrylamide, 375 mM Tris pH 8.8m 0.1% SDS, 0.5% 
APS, 0.07% TEMED) was poured and allowed to set with a layer of isopropanol above. Once 
set, the isopropanol was discarded and replaced with stacking gel (5% 39:1 
acrylamid:bisacrylamide, 62.5 mM Tris pH 6.8, 0.1% SDS, 0.1% APS, 0.24% TEMED) and a 
comb (10 or 15 wells) placed to form the wells. One set, the gel was immersed in 
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electrophoresis running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) and the comb 
removed. Protein samples were loaded with sample buffer (final concentration 45 mM Tris 
pH 6.8, 0.7% SDS, 0.7 mg/ml sucrose, 3.5% β-mercaptoethanol, trace bromophenol blue). 
Samples were loaded into the wells of the gel, along with 10 µl Broad Range Protein Marker 
(NEB). Gels were run at a constant voltage of 200 V over 45 minutes. Gels were either 
Coomassie Blue stained or prepared for immunoblotting (2.6.3).  
2.5.13 Coomassie Blue staining 
Gels were stained with Coomassie blue (45% methanol, 10% acetic acid, 1 mg/ml Coomassie 
blue stain) for 2 hours for visualisation of proteins. Gels were destained using 45% 
methanol, 10% acetic acid. To rehydrate and complete destaining the gel was incubated in 
10% acetic acid.  
 
2.6 Immunodetection 
 
2.6.1 Raising mouse antibodies 
30 kDa N-terminal fragments of target proteins were purified in E. coli and dialysed into 10 
mM HEPES, 150 mM NaCl. Proteins were sent to collaborators at Royal Holloway and 5 mice 
were immunised for each antigen. 
2.6.2 Western immunoblotting 
A semi-dry protocol was used to transfer SDS-polyacrylamide gels to PVDF Immobilon-P 
Transfer Membrane (Millipore). SDS-PAGE gels and 3 pieces of filter paper were pre-soaked 
in cathode buffer (25 mM Tris-HCl, 40 mM glycine, 10% (v/v) methanol, pH 9.4). Immobilon-
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P membrane was prepared for transfer by sequential incubation in methanol for 10 seconds, 
H2O for 2 minutes and anode II buffer (25 mM Tris-Hcl, 10% (v/v) methanol, pH 10.4) for 5 
minutes. Two pieces of filter paper were pre-soaked in anode I buffer (0.3 M Tris-HCl, 10% 
(v/v) methanol, pH 10.4) and one piece pre-soaked in anode II buffer). The filter paper, 
membrane and gel were stacked in a Trans-blot SD semi-dry transfer cell (Bio-Rad) as 
follows from the base up: anode I filter paper, anode II filter paper, Immobilon-P membrane, 
SDS-PAGE gel, cathode filter paper. Transfer was run at 15 V for 15 minutes for one gel. 
Transferred proteins were visualised with Ponceau S solution (Sigma) staining for 1-2 
minutes with H2O destaining. Molecular weight marker bands were marked onto the 
membrane with a pencil. The gel was transferred to methanol for one minute and allowed 
to dry completely. Primary antibody for detection was appropriately diluted in 10 ml 3% 
milk PBS and incubated with the membrane for one hour. For His-tag detection anti-His 
antibody HRP Conjugate (Abcam) was used. For Strep-tag detection mouse anti-Strep-tag II 
(Novagen) was used. Secondary HRP-conjugated antibodies were required for non-
conjugated primary antibodies. Goat anti-rabbit HRP (Dako) or goat anti-mouse HRP (Dako) 
were used. Between antibody incubation steps the membrane was washed four times in 
PBS for 10 seconds. Secondary antibodies were incubated with the membrane for 30 
minutes in 10 ml 3% milk PBS. Following the final antibody incubation the membrane was 
again washed four times in PBS for 10 seconds and excess PBS removed. 1 ml freshly 
prepared SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) was added 
to the membrane and chemiluminescence detected using a LAS-3000 Image Reader 
(Fujifilm). A white image was also taken for visualisation of the molecular weight marker.  
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Primary Antibody Raised Dilution Source 
Anti-Cwp2 mouse 1:50,000 Simon Cutting 
Anti-Cwp66 C-term mouse 1:20,000 Simon Cutting 
Anti-Cwp84 mouse 1:4,000 Simon Cutting 
Anti-LMW rabbit 1:200,000 Ema 
Anti-HMW rabbit 1:100,000 Ema 
Anti-his-tag-HRP conjugate N/A 1:2,000 Sigma 
Anti-Toxin A (PCG4) mouse 1:10,000 Borriello/TechLab 
Anti-Toxin B repeats 16-24 mouse 1:10,000 Simon cutting 
Anti-Strep-Tag II mouse 1:1,000 Novagen 
Anti-LMW 027 mouse 1:25,000 Simon Cutting 
Anti-CD0183 mouse 1:1,000 This study 
Anti-CD2831 mouse 1:1,000/1:100 Novartis/This study 
Anti -CD3392 mouse 1:1,000 Novartis 
Anti-CD3145 mouse 1:1,000 Novartis 
Anti-CwpV type II repeats rabbit 1:5,000 Cate Reynolds, Covalab 
Anti-C. difficile 630 rabbit n/a Novartis 
Table 2.2 Antibodies used and raised in this study 
Details of antibodies used in this study, their animal origin, working dilution for western blotting and 
source. Secondary antibodies used were HRP-conjugated from DAKO.  
2.6.3 Immunofluorescence microscopy 
1 ml C. difficile culture at required growth phase was harvested at 6,000 g for 1 minute and 
washed twice with 1 ml PBS. The pellet was resuspended in 1 ml fresh 8% formaldehyde in 
PBS and incubated for 15 minutes at room temperature. Pellets were washed twice with 
500 µl PBS and resuspended in 500 µl 20 mM NH4Cl for 15 minutes at room temperature. 
Pellets were washed twice with 500 µl H2O and resuspended in 500 µl H2O. Suspensions 
were serially diluted 1/3, and 10 µl neat, 1/3 and 1/9 were spotted onto frosted microscope 
slides (Thermo Scientific) and allowed to dry. 20 µl primary antibody at 1:20 dilution in PBS 
with 10% donkey serum (Sigma) was added to each spot and incubated for 45 minutes. 
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Slides were gently washed in PBS and 20 µl secondary antibody (rhodamine red conjugated 
anti-mouse) at 1:200 dilution in PBS with 10% donkey serum (Sigma) was added to each 
spot and incubated for 45 minutes in the dark. Slides were gently washed in PBS and then 
washed in H2O and allowed to dry. Coverslips were mounted with prolong gold anti-fade 
reagent (Invitrogen) and left to dry overnight in darkness. Slides were imaged using a Nikon 
DMX1200 camera fitted to a Nikon Eclipse E600 microscope.  
 
2.7 Reporter assays 
 
2.7.1 GusA reporter assay 
400 µl supernatant samples were mixed with 400 µl fresh Z buffer (60 mM NaH2PO4, 10 mM 
KCl, 1 mM MgSO4, 50 mM 2-mercaptoethanol, pH7) and incubated at 37°C for 5 minutes. 
160 µl 6 mM p-nitrophenyl-β-D-glucuronide (Sigma) was then added to each tube and 
incubated at 37°C for a defined length of time. The reaction was stopped by addition of 400 
µl 1 M Na2CO3. Samples were centrifuged at 16,000 g for 10 minutes to remove cell debris. 
The A405nm of each supernatant was measured. GusA activity was calculated using the 
formula: (A405nm x 1000)/(OD600 x reaction time (min) x 1.25 x vol. of culture (ml)) 
 
2.8 Phenotypic assays 
 
2.8.1 Colony morphology 
C. difficile cultures were diluted such that isolated single colonies would grow on agar 
plates. Cultures were plated onto BHI agar (Oxoid) and grown for 5 days anaerobically. 
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Plates were then scanned using a transmissive flat-bed scanner (Epson) from below, or 
photographed from above with a Canon Camera to record images of the colonies.  
2.8.2 C. difficile collagen ELISA 
96-well MaxiSorp PS Immuno F96 plates (Nunc) were coated overnight at 4°C with 50 µl 
cellular collagen III (Sigma) at 10 µg/ml. Plates were washed three times with PBS + 0.1% 
Tween-20 (PBS-T) and blocked with 100 µl PBS-T + 3% dried skimmed milk (milk) per well for 
2 hours at 37°C. Plates were washed three times with PBS-T. Meanwhile, C. difficile 
overnight cultures were harvested and resuspended to an OD600 of 10. A two-fold dilution 
series of this bacterial suspension was carried out in PBS. 50 µl of OD600 10 to 0.3125 C. 
difficile cultures were then added to the collagen-coated wells and incubated for 1 hour at 
37°C. Following incubation the wells were washed gently three times with PBS-T. Anti-HMW 
SLP (1:15,000 dilution) and anti-LMW SLP (1:30,000 dilution) antibodies in 3% milk were 
added to each well and incubated for 1 hour at 37°C. Wells were washed three times with 
PBS-T before anti-rabbit HRP (1:2,000 dilution) in 3% milk was added to each well, and 
incubated for 1 hour at 37°C.  Wells were washed three times in PBS-T and 50 µl OPD 
substrate (5ml 0.1 M citric acid, 5 ml 0.2 M Na2HPO4, 10 ml H2O, 1 OPD tablet (Sigma), 8 µl 
H2O2) was added to each well. Plates were incubated at room temperature for up to 1 hour. 
The reaction was stopped with 20 µl 3M H2SO4 per well. The optical density at 450nm was 
determined using a microplate reader.  
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2.9 Mammalian cell binding assays 
 
2.9.1 IMR-90 culture conditions  
IMR-90 cells (human fibroblasts, ATCC) were propagated in Eagle’s Minimum Essential 
Medium (EMEM, ATCC) supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Gibco) in flasks with antibiotics at 37°C with 5% CO2. Cells were subcultured by detaching 
with trypsin. Collagen Type I Cellware 8-well culture slides (BD BioCoat) were used to induce 
ECM protein production in fibroblasts. Cells were seeded onto 8-well chamber slides or 96 
well plates and cultured for 3 days. One day before infection with bacteria cells were 
incubated in antibiotic-free medium.  
2.9.2 IMR-90 ECM protein staining 
Cells were washed and fixed with 3.7% PFA for 20 minutes. Cells were washed three times, 
blocked with 2% BSA for 30 minutes and washed three more times.  Cells were incubated 
with the following rabbit anti-ECM components antibodies for 1 hour at room temperature: 
anti-fibronectin (SIGMA) 1:200, anti-collagen I (Abcam) 1:50, anti-collagen V (Santa Cruz) 
1:50, anti-collagen VI (Santa Cruz) 1:50, anti-heparan sulfate (Millipore) 1:50. Chambers 
were washed three times with 2% BSA and then incubated with Alexa Fluor 568 goat anti-
rabbit IgG (1:500) and Alexa Fluor 647-conjugated phalloidin (1:200) (Molecular Probes). 
Glass coverslips were mounted with ProLong® Gold antifade reagent with DAPI and 
analysed with Zeiss LSM710 confocal microscope. 
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2.9.3 C. difficile IMR-90 cell binding Assay 
C. difficile cells were grown to exponential phase and normalised in DMEM without glucose 
to a multiplicity of infection (MOI) of 100:1. Growth media was aspirated from 96 well plates 
and plates were transferred to the anaerobic cabinet where 500 µl C. difficile cultures were 
added. Cells were incubated with bacteria for 2 hours in the anaerobic cabinet. Wells were 
washed three times with PBS and cells lysed with 1% saponin (Sigma). Bacterial suspensions 
were serially diluted and plated onto BHI agar for CFU enumeration.  
2.9.4 C. difficile IMR-90 cell infection immunofluorescence 
For immunofluorescence analysis of bacteria bound to IMR-90 cells, cells seeded onto 
chamber slides coated with collagen I were incubated with bacteria as described in 2.9.3. 
Following incubation, chambers were gently washed three times with PBS and fixed with 1 
ml 3.7% PFA for 20 minutes. Chambers were gently washed three times and then blocked 
with 250 µl PBS containing 2% BSA for 30 minutes at room temperature. Chambers were 
incubated with mouse polyclonal serum against PFA-fixed whole bacteria (1:1000) for 1 
hour at room temperature. Chambers were gently washed three times with PBS 2% BSA. 
Secondary antibodies were added and incubated for 30 minutes at room temperature: 
Alexa Fluor 488 goat anti-mouse IgG (1:500) and Alexa Fluor 568-conjugated phalloidin 
(1:200). Chambers were gently washed twice with PBS 2% BSA, once with PBS and once with 
H2O before mounting with ProLong® Gold antifade reagent with DAPI and analysed with 
Zeiss LSM710 confocal microscope. 
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2.10 Animal vaccination studies 
 
2.10.1 Production of pure C. difficile spores 
C. difficile cells were incubated overnight on BHIS agar anaerobically, before subculturing a 
single colony into 15 ml TGY medium (per litre: 30 g Tryptic Soy Broth (Bacto), 2% glucose, 
10 g Yeast Extract (Bacto), 1 g L-cysteine) and grown statically overnight anaerobically. The 
overnight culture was diluted 1:10 into 15 ml SMC medium (per litre: 90 g Bacto Peptone 
(Bacto), 5 g Proteose Peptone (Sigma), 1 g (NH4)2SO4, 1.5 g Tris-(hydroxymethyl) 
aminomethane) and incubated anaerobically until an OD600 of 0.4-0.6 was reached. 100 µl of 
this culture was plated onto SMC agar plates (as medium with 15 g Agar (Bacto) per litre) 
and incubated for 7 days anaerobically at 37°C. Sporulation was checked under phase-bright 
microscopy and when 50-60% sporulation had occurred, spores were harvested for 
purification. The plate was scraped in 3 ml H2O and spores washed five times with 500 µl ice 
cold H2O (5,000 g 1 minute). Spores were resuspended in 500 µl 20% (w/v) HistoDenz 
(Sigma) and 1 ml 50% (w/v) HistoDenz was layered on top. Samples were centrifuged for 15 
minutes at 15,000 g at room temperature and HistoDenz supernantant removed. Spores 
were washed a further five times in ice cold water.  
2.10.2 Immunisation of hamsters 
Detailed in Chapter 6, in brief; Female Golden Syrian hamsters were immunised 
intraperitoneally with 50 µg each protein per dose four times over two week intervals with 
MF59 adjuvant. Hamsters were challenged orally with C. difficile spores and disease 
symptoms followed as described in the literature (Douce and Goulding 2010). Faeces were 
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collected for colonisation counts and end point toxin titres for caecum and colon washes 
were analysed.  
2.10.3 Immunisation of mice 
Detailed in Chapter 6, in brief; Female C57BL/6 mice were immunised intraperitoneally with 
5 µg each protein per dose three times at two week intervals with Alum adjuvant. Mice 
were challenged by transfer of contaminated bedding and faeces collected for colonisation 
counts following clindamycin treatment as previously described (Lawley et al. 2009a).   
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Table 2.3 Primers used in this study 
Name Sequence 5'to 3' Description  
NF1350 GTT CAA AAC ATA GCT TAT TCT GGA GAT For RT-PCR CD0183 
NF1351 GGG TTT ACT TGT GGC TCT TCT ATT For RT-PCR CD0183 
NF1352 GAC TAA TGA AAA TGG AAA TAC AGA TGT T For RT-PCR CD0386 
NF1353 GTC TTT GTA ACC CAT GTA CGA GTA For RT-PCR CD0386 
NF1336 GGA TGA TTA CCA TAT ACA CAT TAA CAT AC For RT-PCR CD1380 
NF1337 GTG CTA CCA ATG CTT GAA CCT AAA A For RT-PCR CD1380 
NF1338 GGA CAG CTT GTT TAG TTC TAA AGG For RT-PCR CD2498 
NF1339 GCT TCT CTA GCT ATG AGA GCC ATA For RT-PCR CD2498 
NF1340 GTG CAA CAC CTT TAG CAT ATT CAA AA For RT-PCR CD2782 
NF1341 GGC ATT CCA CTT TTA GCG GCA TA For RT-PCR CD2782 
NF1342 GTT CCA GAT GCT AAA GGA ACA CTT For RT-PCR CD2831 
NF1343 GTT TTG CAT TTT TGT CAC TGA TTC TAG For RT-PCR CD2831 
NF1344 GGG TAA GAT AGC ACA GAA TTT ATC AAA For RT-PCR CD2833 
NF1345 GTT ACT AAT GCA TTT ATC TTT GCC ATC For RT-PCR CD2833 
NF1346 GAT GGT GGT GCA TAT GCA CAT G For RT-PCR CD3145 
NF1347 GCA CCA CCA TTA ATA ATA ATA TTT CCT C For RT-PCR CD3145 
NF1348 GAA ATA GAT GGT TCA GAT AGA CCT TA For RT-PCR CD3246 
NF1349 GTC ATC AAT TCA TTT TCT TCT CCA CC For RT-PCR CD3246 
NF1588 CAAGATTGACATGGAAACACAGAAA For RT-PCR CD3392  
NF1589 GCA AGG TCG CCG TCC TC For RT-PCR CD3392  
NF1427 GAGGATTTATCAAAGATTAACAGTGATTTT For RT-PCR srtB (CD2718) 
NF1428 CATAATCAGATTCTACAATATAAGCAGAA For RT-PCR srtB (CD2718) 
NF1425 GCAGGAGAAGATAGAATAGAAACTG For RT-PCR slpA 
NF1426 CAACTACAAATGCTTTATCATTATCAAG For RT-PCR slpA 
NF408 TCTTGAATATCAAAGGTGAGCCAGTACA For RT-PCR 16S rRNA 
NF409 TACAGCGTGGACTACCAGGGTATCTAAT For RT-PCR 16S rRNA 
NF1499 GGAGCTCAATATAATGTTGGGAGGAATTTAAGAAATG 
Amplification of SlpA secretion signal, cleavage site and spacer 
from 630 gDNA with a StrepTag for N-terminally tagging proteins  
NF1528 CAAATTGTGGATGACTCCATTGTGTTCCAGTAGTTGCAGC SlpA Sec signal sequence amplification - pair with NF1499 Step 1 
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NF1529 GGG ATC CTC CTC CTT ACT CGA GTT TTT CAA ATT GTG GAT GAC TCC ATT G SlpA Sec signal sequence amplification - pair with NF1499 Step 2 
NF1503 GCT CGA GGA TGA AGT AAA TGA TTC ATC TCA AAA TAA G Amplification of CD0183 from cleavage site for Strep Tagging 
NF1504 GGG ATC CTT ATA ATA TTC TTT TTG CTG TAA CAA ATC TTG Amplification of CD0183 from cleavage site for Strep Tagging 
NF1535 GGGGCTCGAGGAAAGTAAGCAATACTGGACGGAAAGTG Amplification of CD0386 from cleavage site for Strep Tagging 
NF1536 GGGGGGATCCTTATGATTTCTTCATTTTACGGCGTTTGTAGAAG Amplification of CD0386 from cleavage site for Strep Tagging 
NF1505 GCT CGA GAG AAC GAT TAT ACA AAA TAG CCT TG Amplification of CD1380 from cleavage site for Strep Tagging 
NF1506 GGG ATC CTT ATC TAG TTT TAT TTT CTT TAT AGA AC Amplification of CD1380 from cleavage site for Strep Tagging 
NF1507 GCT CGA GGA TAA TGA ACC AGC TAT AGT TGC Amplification of CD2498 from cleavage site for Strep Tagging 
NF1508 GGG ATC CTT ACT TTT TCA TAT TTT TTT TAC TTC TAG C Amplification of CD2498 from cleavage site for Strep Tagging 
NF1509 GCT CGA GGA TGC AAA TCC CAA AAG AGA G Amplification of CD2782 from cleavage site for Strep Tagging 
NF1510 GGG ATC CCT ATT TCG ACT CAT ATC TAA GTG C Amplification of CD2782 from cleavage site for Strep Tagging 
NF1537 GGGGCTCGAGTCAGAATTAGGAGAGAATAGTCAGATTCAAAG Amplification of CD2831 from cleavage site for Strep Tagging 
NF1538 GGGGATCCCTAATTTGTATTTTTATTTCTTCTTAATACGATAAGTCCTAC Amplification of CD2831 from cleavage site for Strep Tagging 
NF1656 GGGGCTCGAGGATACTATAGAAGAAAGTACTAATGCAG Amplification of CD3145 from cleavage site for Strep Tagging 
NF1657 GGGG ACTAGT TTA TTT ACG TCT TAA GTA TTT ATT TGT TAG ATT TTT AAT TA Amplification of CD3145 from cleavage site for Strep Tagging 
NF1595 GGGGCTC GAG GAAAGTAAGCAATACTGGACGGAAAG Amplification of CD3392 from cleavage site for Strep Tagging 
NF1596 GGGGGGATCCTTA TGA TTT CTT CAT TTT ACG GCG TTT ATA AAG Amplification of CD3392 from cleavage site for Strep Tagging 
NF1568 GGCGAAGGTTGGTTAGCTACTAG CD0183 ClosTron screening primer (549|550s) 
NF1569 GAT GTT CTT GGT ATA TTC TTT CCT ACT GC CD0183 ClosTron screening primer (549|550s) 
NF1570 CTT ATA CAT TAA AGG TAA TTA GTA TTG AAG ATA GC CD2831 ClosTron screening primer (1962|1963s) 
NF1571 CGT ATA GTC TCC CCA ACT TTT ACA TTT G CD2831 ClosTron screening primer (1962|1963s) 
NF1572 GCTAGAGAAAGTTAGCGCAATAATGC CD3145 ClosTron screening primer (-18|-17a) 
NF1573 CTA TAG TAT CTG CGA AAG TAT TTG ACG C CD3145 ClosTron screening primer (-18|-17a) 
NF1574 GAAATGCAAAACTGCAAAAAACCTCCAG CD3392 ClosTron screening primer (840|841s) 
NF1575 GAT TGT CTT TGT AAC CCA TGT ACG AG CD3392 ClosTron screening primer (840|841s) 
NF1612 GGGCCATGGATGATGAAGTAAATGATTCATCTCAAAATAAGG His-tag 30kDa of CD0183 between NcoI and XhoI sites of pET28a  
NF1613 GGGCTC GAG AGT TGT GAA GAA TAC TAA GTC TCC TG His-tag 30kDa of CD0183 between NcoI and XhoI sites of pET28a  
NF1614 GGGCCATGGATTCAGAATTAGGAGAGAATAGTCAGATTC His-tag 30kDa of CD2831 between NcoI and XhoI sites of pET28a  
NF1615 GGGCTC GAG TTC TAT TTT TCC AGT AGT TTC AAT ATG TAT TTT TG His-tag 30kDa of CD2831 between NcoI and XhoI sites of pET28a  
NF1616 GGGCCATGGATGAAAGTAAGCAATACTGGACGGAAAG His-tag 30kDa of CD3392 between NcoI and XhoI sites of pET28a  
NF1617 GGGCTC GAG ATC TGA TAC TTT CAA GGT CGC TGT TTC His-tag 30kDa of CD3392 between NcoI and XhoI sites of pET28a  
NF1785 GAGCTCGAAAATTTTAGGAGGTTTATCG Cloning total CD0183 with ribosome binding site. Pair with 1504 
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NF1786 AAAACAGTTAGTGTAACTAGTATAAATTCATC Inverse PCR to delete SPSTG of CD0183 
NF1787 ATG TAT CAT ATT ACC CCC ACC TAC Inverse PCR to delete SPSTG of CD0183 
NF1817 GG GGA TCC TCC TCC CTC GAG TAA TAT TCT TTT TGC TGT AAC AAA TCT TGC 
Deleting CD0183 stop codon and introducing XhoI site. Pair with 
NF1785 
NF1799 GGG GGA TCC TTA TAC TAC TTT TCC TGC TTC AAA TGT C 
For introducing 2 x CwpV Type II repeats between XhoI and 
BamHI sites after CD0183 
NF1818 GGG CTC GAG TCA TCA AAA GTA GAT AAA GTA GTT TTG AAA AA 
For introducing 2 x CwpV Type II repeats between XhoI and 
BamHI sites after CD0183 
NF1921 GGCTCGAGATGATACATAAAACAGTTAGTGTAACTAG Pair with 1504 to amplify CWSS of 0183 without SPSTG 
NF1922 GGCTCGAGCCTAGCGACAGTCCCAAAACGG  For amplifying C-terminus of CD0386. Pair with 
NF1536 NF1923 GGCTCGAGCCTAGCGACGATAACACCAACCTTTACGGACT For amplifying C-terminus of CD0386 without SPKTG 
NF1924 GGCTCGAGAGCAGTCTTCCATTTTTGACTGAAAA For amplifying C-terminus of CD2498 Pair with 
NF1508 NF1925 GGCTCGAGAGCAGTCTTCCATTTTTGACTGAAAA For amplifying C-terminus of CD2498 without PFLTE 
NF1926 GGCTCGAGCCACCAGTACCACCAAAAACAG For amplifying C-terminus of CD2831 Pair with 
NF1538 NF1927 GGCTCGAGCCACCAGTAGATAGTACTACAATTATTGGAGAAATAC For amplifying C-terminus of CD2831 without PPKTG 
NF1928 GGCTCGAGGTAGGTCAAAATGTACAAACAGGAGAT For amplifying C-terminus of CD3145 Pair with 
NF1946 NF1929 GGCTCGAGGTAGGTCAAGATCAAAGTAATATAATGCTAGATTTAGC For amplifying C-terminus of CD3145 without NVQTG 
NF1946 GGGGA TCC TTA TTT ACG TCT TAA GTA TTT ATT TGT TAG ATT For amplifying C-terminus of 3145 
NF1930 GGCTCGAGATAGTAAAATCACCAAAAACAGGTGATG For amplifying C-terminus of CD3246 Pair with 
NF1932 NF1931 GGCTCGAGATAGTAAAAGATGAAACTCAGCTAATGTCATATGTATT For amplifying C-terminus of CD3246 without SPKTG 
NF1932 GGGGA TCC TTA ATT TCT TTT TAT TTT ACA TTG ATA CGC TAA  For amplifying C-terminus of CD3246 
NF1933 GGCTCGAGCCTAGCGACAGTCCCAAAAC For amplifying C-terminus of CD3392 Pair with 
NF1596 NF1934 GGCTCGAGCCTAGCGACGACAGTACAAACCTTATGGCTTTTATC For amplifying C-terminus of CD3392 without SPKTG 
 
NF1658 GGGGGGATCCATAAACTACATTTAACTCGAGGTGATATATTG For amplification of Sortase antisense 
NF1659 GGGGGAGCTCTCT TTT TTA TAT TCT TTT TTT TGA AGT TCT GAG G For amplification of Sortase antisense 
NF1576 CAATCATGATACTAAAATATCCTCAGAACTTC Sortase ClosTron screening primer(354|355a) 
NF1577 GCT ATT TAC CTT AAT AGG AGA TTT ATA CAA TG Sortase ClosTron screening primer(354|355a) 
NF1839 GATTCTATTTCTGGTACACTGTTTATG Sortase Clostron screening primer (510|511s) 
NF1840 GTGGTCTAATTTATAAATTATAGGTATAAAAGA Sortase Clostron screening primer (510|511s) 
NF1935 CGT TCA AAA AAG ACT GTA GAT AAG TCT G CD3146 genome screening primer 
NF2012 GGGAGCTCTAATACTAAGGGGTAATTAATTGAAAAAC Amplification of CD3146 
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NF2013 GGGGATCCGTTCAAAAAAGACTGTAGATAAGTCTG Amplification of CD3146 
NF1936 GGGAGCTCTAAACTACATTTAACTCGAGGTGATATATTG To amplify srtB (CD2718) for complementation 
NF1937 GGGGA TCC TTA AAT CAA TCT ACC ATG AAT CAC CAT TC To amplify srtB (CD2718) for complementation 
NF1944 GTGGTGGTGAATCAATCTACCATGAATCACCATTC To add a C-terminal His-tag to srtB. Pair with 1936. Step 1 
NF1945 GGGGATCCTTAGTGGTGGTGGTGGTGGTGAATCAATCTACCAT To add a C-terminal His-tag to srtB. Pair with 1936. Step 2 
NF1938 GCCACCTATGAATTTGATGATGCCAGAATG For 208 cys-->ala mutation of srtB by inverse PCR 
NF1939 TGT AGA AAG TGT AAC TAT TTT ATC ATT GCT ATT For 208 cys-->ala mutation of srtB by inverse PCR 
 
NF1422 GCTTCATATGATAGTGCTAAAGATAAGTTAGTTA For screening ClosTron insertion in cwp2 (669|670s) 
NF1423 ATATTTTCCTGTTTCTGAATCTTTTGCTGAAATATCAC For screening ClosTron insertion in cwp2 (669|670s) 
NF1304 GGA ATT CTG AAT TTT TTA GGG GGA AAA TAC CAT GAA TAA AAA AAA TC To clone cwp2 from 630 into pUC19-Pcwp2 
NF1305 GGG ATC CTT ATT ACC AAC CTA GTA TTT TAG CTA TCT TTT GTA TTA CTG To clone cwp2 from 630 into pUC19-Pcwp2 
NF1591 GTT AGT TAT AAC TTT AAG AGA TAA AAC AGA AAC For RT-PCR cwp2  
NF1592 CCT GTT TCT GAA TCT TTT GCT GAA ATA T For RT-PCR cwp2  
NF1593 GTG AGT GTT GGA GCT ATA GCT G For RT-PCR cwp66 
NF1594 GTA TCA AGC TTA TTT CCT GCT AAT ACT ATT For RT-PCR cwp66 
NF1626 CACAGGTAAAAAAAGAAACAATAACTAAGAAAG For RT-PCR cwp2 pre-intron 
NF1627 CTT ATC TTT AGC ACT ATC ATA TGA AGC TT For RT-PCR cwp2 pre-intron 
NF1628 GCA TCT GGA AAA GCA ACA GAG C For RT-PCR cwp2 post-inton 
NF1629 CTT AGT TAC TGA TTC TAA TTG CTT TTT AGC For RT-PCR cwp2 post-inton 
NF1630 GGTAATGGAGTTGAATTGACAGTAATAC For RT-PCR between cwp2 and cwp66 (within cwp2)  
NF1631 GTA TTT CCA TAT AAT GTA ACA GTT AAA AAT GTC For RT-PCR between cwp2 and cwp66 (within cwp66)  
NF1788 CTC TAT CTT TTG AAA ATT CAC TTT CTG ATA AAG For RT-PCR intergenic region cwp2 - CD2790. Pair with 1630 
NF1789 GCATTAGGAGAAGCTGCATTAGAG For RT-PCR intergenic region CD2790 - cwp66.Pair with 1631 
NF1868 GCT TTT CAA TCT CTG AAC GSP1 for cwp66 5' RACE 
NF1869 CAT TTT TCA CAC CAA GTC TTT TTA ATT C GSP2 for cwp66 5' RACE 
 
NF1398 GGA GCT CTG AAT TTT TTA GGG GGA AAA TAC CAT  Cloning cwp2 with Sac1 site before gene 
NF1399 GTG GTG GTG CTC GAG CCA ACC TAG TAT TTT AGC TAT CTT C-terminally His-Tag cwp2. Pair with NF1398. Step 1 
NF1400 GGG ATC CTT AGT GGT GGT GGT GGT GGT GCT CGA GC C-terminally His-Tag cwp2, BamHI site. Pair with NF1398. Step 2 
NF1532 CCCCCCATGGATATGGTATCTGGATTAATATATATTAATGATTCATTATA 
To amplify TcdB repeats 1-24 from 630 gDNA for insertion into 
pET28a between NcoI and XhoI sites for C-terminal HisTag 
NF1534 CCCCCTCGAGTTCACTAATCACTAATTGAGCTGTATCAG Pair with NF1532.  
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Table 2.4 Plasmids used in this study 
Name Backbone Promoter Detail Source/reference 
pMTL960 pMTLl960 n/a Empty pMTL960 vector  
p5/6HIS pRSET-A T7 
C-terminal binding repeats 25-38 from C. difficile VPI 10463 N-
terminally His-tagged 
Dr Gill Douce 
 (Ward et al. 1999a) 
pCBR004 pUC19 Pcwp2 Gene cloning sites EcoRI and BamHI following Pcwp2 
Dr Cate Reynolds 
(Reynolds et al. 2011) 
pRPF144 pMTL960 Pcwp2 Gene cloning sites SacI and BamHI following Pcwp2 
Dr Robert Fagan  
(Fagan and Fairweather 2011) 
pRPF185 pMTL960 Ptet Gene cloning sites SacI and BamHI following Ptet 
Dr Robert Fagan  
(Fagan and Fairweather 2011) 
pHAS002 pMTL960 cwp2 
Entire cwp2 gene with RBS ligated between EcoRI and BamHI 
restriction sites of pCBR004 and subcloned into pMTL960 between 
KpnI and BamHI restriction sites 
This study 
pHAS003 pMTL007-E5  ClosTron plasmid targeting cwp2 at position 670 – SENSE orientation DNA 2.0 
pHAS005 pMTL960 Pcwp2 
cwp2 ligated between SacI and BamHI sites in pRPF144 with a C-
terminal 6xHis-Tag 
This study 
pHAS007 pMTL960 Pcwp2 
For N-terminally Strep-tagging genes: slpA RBS, sec secretion signal 
sequence and cleavage site followed by a spacer and Strep-Tag, XhoI 
site introduced before BamHI  
This study 
pHAS009 pMTL960 Pcwp2 Derivative of pHAS007 containing CD1380 This study 
pHAS010 pMTL960 Pcwp2 Derivative of pHAS007 containing CD2498 This study 
pHAS011 pMTL960 Pcwp2 Derivative of pHAS007 containing CD2782 This study 
pHAS012 pMTL960 Pcwp2 Derivative of pHAS007 containing CD0386 This study 
pHAS013 pMTL960 Pcwp2 Derivative of pHAS007 containing CD2831 This study 
pHAS014 pET28a T7 
C-terminal receptor binding domain of C. difficile 630 toxin B with C-
terminal 6xHisTag 
This study 
pHAS016 pMTL960 Ptet 
SacI-BamHI fragment from pHAS007 subcloned into pRPF185 to 
Strep-Tag gene inserts under control of Ptet 
This study 
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pHAS017 pMTL007C-E5  
ClosTron plasmid targeting 2831 at position 1962 – SENSE 
orientation 
DNA 2.0 
pHAS018 pMTL007C-E5  
ClosTron plasmid targeting 3145 at position 482 – ANTISENSE 
orientation 
DNA 2.0 
pHAS019 pMTL007C-E5  ClosTron plasmid targeting 3392 at position 840 – SENSE orientation DNA 2.0 
pHAS022 pMTL960 Ptet Derivative of pHAS016 containing CD0183 This study 
pHAS023 pMTL007C-E5  ClosTron plasmid targeting 0183 at position 549 – SENSE orientation DNA 2.0 
pHAS024 pMTL007  
ClosTron plasmid targeting srtB at position 354 – ANTISENSE 
orientation 
DNA 2.0 
pHAS025 pMTL960 Pcwp2 Derivative of pHAS007 containing CD3392 This study 
pHAS026 pET28a T7 30 kDa N-terminal fragment of CD0183 His-tagged This study 
pHAS027 pET28a T7 30 kDa N-terminal fragment of CD2831 His-tagged This study 
pHAS028 pET28a T7 30 kDa N-terminal fragment of CD3392 His-tagged This study 
pHAS033 pMTL960 Pcwp2 
Derivative of pHAS007 containing CD3145 between SacI and MluI 
sites 
This study 
pHAS034 pMTL960 Ptet sortase antisense  This study 
pHAS035 pMTL960 Ptet CD0183 entire gene This study 
pHAS036 pMTL960 Ptet CD0183 with SPSTG motif deleted by inverse PCR This study 
pHAS039 pMTL960 Ptet 
CD0183 without its stop codon followed by two CwpV Type II 
repeats 
This study 
pHAS040 pMTL960 Ptet pHAS039 with SPSTG motif deleted by inverse PCR This study 
pHAS041 pMTL007C-E5  ClosTron plasmid targeting srtB at position 510 – SENSE orientation DNA 2.0 
pHAS042 pET28a T7 Catalytic residues 1-179 of amidase His-tagged This study and (MAYER) 
pHAS045 pMTL960 Ptet R20291 LMW without interaction domain This study 
pHAS047 pMTL960 Ptet 
Derivative of pHAS045 containing CD0183 cell wall sorting signal 
(CWSS) 
This study 
pHAS049 pMTL960 Ptet pHAS049 without SPSTG motif This study 
pHAS050 pMTL960 Ptet Derivative of pHAS045 containing CD0386 CWSS This study 
pHAS051 pMTL960 Ptet Derivative of pHAS045 containing CD2498 CWSS This study 
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pHAS052 pMTL960 Ptet Derivative of pHAS045 containing CD2831 CWSS This study 
pHAS053 pMTL960 Ptet Derivative of pHAS045 containing CD3145 CWSS This study 
pHAS054 pMTL960 Ptet Derivative of pHAS045 containing CD3246 CWSS This study 
pHAS055 pMTL960 Ptet Derivative of pHAS045 containing CD3392 CWSS This study 
pHAS057 pMTL960 Ptet SrtB (CD2718) cloned in its entirety This study 
pHAS059 pMTL960 Ptet pHAS057 with the addition of a C-terminal 6 x HisTag This study 
pHAS061 pMTL960 Ptet pHAS057 C208A mutation by inverse PCR This study 
pHAS063 pMTL960 Ptet pHAS059 C208A mutation by inverse PCR with C-terminal 6 x HisTag This study 
pHAS064 pMTL960 Ptet pHAS050 without SPKTG motif This study 
pHAS065 pMTL960 Ptet pHAS051 without PFLTE motif This study 
pHAS066 pMTL960 Ptet pHAS052 without PPKTG motif This study 
pHAS067 pMTL960 Ptet pHAS053 without NVQTG motif This study 
pHAS068 pMTL960 Ptet pHAS054 without SPKTG motif This study 
pHAS069 pMTL960 Ptet pHAS055 without SPKTG motif This study 
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Figure 2.1 pRPF144 plasmid map 
Plasmid map showing key properties of pRPF144 including gene insertion sites (SacI, BamHI), cwp2 
promoter (Pcwp2) and thiamphenicol resistance (catP) 
 
Figure 2.2 pRPF185 plasmid map 
Plasmid map showing key properties of pRPF185 including gene insertion sites (SacI, BamHI), tet 
promoter (Ptet) and thiamphenicol resistance (catP)  
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3Chapter 3 Potential sortase substrates in C. difficile  
3.1 Introduction 
Sortase substrates are recognised by an enzyme termed sortase and cleaved before 
incorporation into the peptidoglycan cell wall (summarised in Figure 3.1). Substrates must 
possess an N-terminal signal sequence for export form the cell (1) and a C-terminal cell wall 
sorting signal. This sorting signal is comprised of an “LPXTG”-like motif, a hydrophobic helix 
(black) and a charged tail (red) (Schneewind et al. 1992; Schneewind et al. 1993).  The 
hydrophobic helix and charged tail prevent complete secretion from the cell, acting as a 
membrane anchor (2). This allows the membrane bound sortase to approach the substrate 
and recognise its “LPXTG”-like motif. Sortase then cleaves the substrate between threonine 
and glycine residues, forming a covalent intermediate between its catalytic cysteine and the 
threonine of the substrate (3). Cell wall precursors or mature proteins then act as 
nucleophiles and release the substrate from sortase, forming a covalent bond between the 
substrate and the cell wall (4, 5). In this way sortase substrates are covalently bound to the 
peptidoglycan cell wall and often exposed on the surface of the organism. 
In S. aureus, sortase substrates are key players in virulence of the organism, such that 
removal of the SrtA system renders the bacterium incapable of infection (Mazmanian et al. 
2000). This phenotype is less distinct in other organisms such as B. anthracis. Sortase 
substrates are often extracellular matrix binding proteins or pili components and therefore 
would be predicted to be involved in colonisation and virulence (Ni Eidhin et al. 1998; 
Arrecubieta et al. 2007). Some substrates have also been suggested to play a role in biofilm 
formation (Corrigan et al. 2007). Sortase substrates in C. difficile have not yet been 
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identified and as such there have been no studies to date on the sortase substrates of C. 
difficile and their role in colonisation and infection.  
 
In this chapter bioinformatic analysis was undertaken to identify potential sortase 
substrates in C. difficile 630, the lab reference strain, and in the clinically relevant strain 
R20291. Potential sortase substrates were identified and cloned in C. difficile to investigate 
their localisation and phenotypes. Insertional mutants were created for some of the 
potential sortase substrates and their phenotypes were further investigated.  
 
 
 
Figure 3.1 Sortase action in Gram positive bacteria 
Sortase substrate is shown in blue with an LPXTG like motif, a hydrophobic domain (black) and a 
charged tail (red +). (1) The protein is secreted from the cell where a signal peptidase cleaves the 
signal sequence. (2) the hydrophobic domain and charged tail retain the protein in the 
membrane. (3) Membrane bound sortase recognises the LPXTG motif and cleaves between 
threonine and glycine residues, forming a covalent intermediate. (4) Cell wall precursors act as 
nucleophiles and release the substrate from sortase, forming covalent bonds between threonine 
and and cell wall crossbridges. (5) Cell wall precursors are incorporated into the cell wall with 
sortase substrate attached. Adapted with permission from (Ton-That et al. 1999). 
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3.2 Results 
 
3.2.1 C. difficile contains multiple potential sortase substrates 
 
Previous work by Dr Anne Wright had identified 7 potential sortase substrates in C. difficile 
630; CD1380, CD2498, CD2782, CD2831, CD2833, CD3145 and CD3246 (Anne Wright, PhD 
thesis, University of London). Using the Augur algorithm (Billion et al. 2006) and LocateP 
(Zhou et al. 2008) to search for putative LPXTG proteins, 3 more proteins were identified; 
CD0183, CD0386 and CD3392. Of these 10 genes, 7 were found in the genome of C. difficile 
R20291 (Table 3.1).  
The translated protein sequence of these 10 genes in C. difficile 630 were analysed by 
SignalP (Bendtsen et al. 2004) for an N-terminal signal sequence, PSORT (Yu et al. 2010) for 
sub-cellular localisation, TMHMM (Krogh et al. 2001) for hydrophobic helices, DNA 
microarray data for presence in C. difficile genomes (Stabler et al. 2006), and BLAST for 
putative functions. Table 3.1 summarises these results. CD2833 was not predicted to have a 
signal peptide, and CD1380 had a low probability of a signal peptide (0.2), so these proteins 
are unlikely to be true sortase substrates. Both proteins additionally were found to have 
multiple hydrophobic helices making them unlikely sortase substrates even if secreted; 
instead they would be membrane proteins, as predicted by PSORT. The remaining proteins 
were predicted to be exported from the cell, to be cell wall associated and to contain a 
single hydrophobic domain at the C-terminus followed by a charged tail. CD0183 did not 
have a strong prediction for a hydrophobic helix, but analysis of the amino acids shows a 
high proportion of hydrophobic residues. These results suggest that these proteins may be 
true sortase substrates. Genome analysis reveals CD2782 to be annotated as Cwp7. It 
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contains 3 PFAM domains homologous to those found in the SLPs and CWPs of C. difficile 
(Fagan et al. 2011) so is likely to be a membrane bound S-layer protein. It is therefore also 
unlikely to be a sortase substrate, especially as analysis of its C-terminal does not reveal an 
“LPxTG”-like motif. Of the remaining 7 potential sortase substrates, 6 have a definite 
“LPxTG” like motif, and one, CD2498, shows weak homology to this motif with the sequence 
“LPFLTE” (Table 3.2).  
The first 3 residues of the “LPXTG” motif vary between the other proteins; SPS, SPK, PPK and 
NVQ. The final variation is the most markedly different and is found on CD3145 which is 
situated upstream of a copy of the sortase gene (CD3146) which is a pseudogene containing 
an inframe stop codon upstream of the potential catalytic cysteine. These two genes are 
both not found in all genomes of C. difficile by DNA microarray analysis and therefore 
CD3145 could possibly have originally been a substrate of this sortase. All substrate motifs 
end with a threonine and glycine which is typical of substrates of a class A sortase, rather 
than a class B sortase as labelled in the C. difficile genome. The variation in amino acids may 
affect substrate recognition and cleavage, as substitution of proline with asparagine in the 
LPETG motif of protein A in S. aureus resulted in mis-sorting of the protein (Schneewind et 
al. 1992), thus the valine in CD3145 may affect sorting of this protein. However, in Listeria 
monocytogenes some substitutions at position 2 are tolerated by sortases (Mariscotti et al. 
2009). The residues before the TG cleavage site vary between substrates; serine contains a 
short side chain, while glutamine has a slightly longer and more bulky side chain and lysine a 
long and charged side chain. These too may contribute to differences in protein sorting.  
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 Table 3.1 Analysis of potential sortase substrates 
Gene identifier (ID) for strains C. difficile 630 and R20291 are shown, and results from bioinformatic analysis.  indicates a positive result, while  indicates 
a negative result. DNA microarray analysis covered 75 strains (Stabler et al. 2006). 
  
Gene ID 
Signal 
peptide 
PSORT 
location 
Membrane 
helix 
LPxTG-
like 
domain 
Charged 
tail 
Predicted 
MW 
(kDa) 
DNA Microarray data 
Putative functions 
630 R20291 Present Unclear Absent 
CD0183 CD0184 
extra-
cellular 
weak SPSTG  34.4 74 1 0 putative cell wall hydrolase/p60 protein 
CD0386 X  cell wall  SPKTG  108.6 13 13 49 
Collagen-binding protein, Cna protein 
B-type domain protein 
CD1380 CD1226 weak membrane multiple   86.8 74 1 0 
putative transport-related membrane 
protein. Putative sugar transporter 
CD2498 CD2390  non- cytoplasmic  PFLTE  45.3 72 3 0 
D-alanyl-D-alanine carboxypeptidase. 
Putative sporulation-specific penicillin-
binding protein 
CD2782 CD2670  cell wall    36.7 72 3 0 cwp7 -  cell wall protein 
CD2831 CD2722  cell wall  PPKTG  104.4 49 26 0 putative collagen-binding protein 
CD2833 CD2724  membrane multiple   101.8 75 0 0 putative transport-related ATPase 
CD3145 X  cell wall  NVQTG  122.6 28 28 19 
putative serine-aspartate-rich surface 
anchored fibrinogen-binding protein 
CD3246 X  cell wall  SPKTG  76.5 23 23 29 
putative surface protein, cell surface 
glycoprotein 1 precursor 
CD3392 CD3453  cell wall  SPSTG  108.6 14 14 47 
Collagen-binding surface protein CNa-
like, B region 
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Table 3.2 C-terminal analysis of 7 potential sortase substrates 
 
 
BLAST analysis in Table 3.1 shows that four of the predicted substrates are possibly 
extracellular matrix binding proteins; CD0386, CD2831, CD3145, CD3392. CD0183 is 
predicted to be a cell wall hydrolase, while CD3246 is purely annotated as a putative surface 
protein. Phyre (cite) analysis predicts homology to cell surface glycoprotein 1 precursor. 
Expression of CD3246 has been shown to be controlled by a riboswitch which senses c-di-
GMP (Lee et al. 2010). It should be noted that CD0386 and CD3392 show almost identical 
translated protein sequences (94% translated protein sequence identity) and are likely to 
have arisen from a gene duplication event. The presence of both genes is not consistent 
between strains, with many strains containing neither gene or only a single gene, typically in 
a location similar to CD3392 within the genome where genome analysis has been possible. 
CD3145 and CD3246 were absent in approximately 30% of strains analysed by DNA 
microarray, while CD0183 and CD2831 were present in almost all strains analysed.   
 
   “LPxTG”         Hydrophobic domain          Charged tail             
CD0183  ...SPSTG...KT.....VSVTSINSSYYTARFVTA..........KRIL 
CD2498  ...PFLTE...NNVL...MTFVKIIAGILVLLVLFIIASNI.....KKKKRKKARSKKNMKK 
CD2831  ...PPKTG...DSTT...IIGEILLVIGAIVGLIVL..........RRNKNTN 
CD3145  ...NVQTG...DQSN...IMLDLALMFISLFFLIKNLTN.......KYLRRK 
CD3246  ...SPKTG...DETQ...LMSYVFISVIAICGLAYQC.........KIKRN 
CD0386 ...SPKTG...DNTN...LYGLLALLLTSGAGLAGIFFY.......KRRKMKKS 
CD3392 ...SPKTG...DSTN...LMAFIVMLLVSGGGLAGTYLY.......KRRKMKKS 
 
SPA ...LPETG...EEN....PFIGTTVFGGLSLALGAALLAG......RRREL 
BcpA ...LPVTG...GIGT...TLFTVIGLTLMLTAAFVFF.........RKKFARN 
Translated protein sequence alignment of the C-terminal amino acids of 7 potential sortase 
substrates. Genome number indicated of C. difficile potential sortase substrates and C-termini 
compared with those of known sortase substrates from S. aureus (SPA) and B. anthracis (BcpA). 
Highlighted in blue are “LPXTG” like motifs, in black are hydrophobic residues, and in red are 
charged residues in the “charged tail” as indicated in the table labels above.  
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Figure 3.2 Transcription analysis of potential sortase substrates 
RNA was extracted from C. difficile strains 630 and R20291 grown in TY broth at both exponential 
and stationary phase. cDNA was synthesised along with RT negative controls (no reverse 
transcriptase). 30 cycle PCRs were performed on cDNA and RT negative samples for each growth 
phase, with gDNA positive controls for both strains. 300-400 bp of each potential sortase 
substrate and sortaseB (CD2718) was amplified, with slpA and 16S rRNA for positive controls of 
cDNA synthesis.  
Strain 630 shows presence of all genes of interest in genomic DNA, with all genes transcribed 
during both growth phases. Strain R20291 shows presence of 5 of the sortase substrate genes of 
interest in genomic DNA, with 4 of these being well transcribed in both growth phases, while 
CD3392 shows a low level of transcription during exponential phase and is absent in stationary 
phase. The sortaseB gene is transcribed in both strains in both growth phases.   
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3.2.2 C. difficile sortase substrates are expressed in strains 630 and R20291 
 
RT PCR was conducted to determine whether these genes are transcribed in C. difficile 
strains 630 and R20291. Primers were designed to amplify 300-400 bp products from each 
potential sortase substrate and the sortase gene CD2718, predicted to be a SrtB enzyme. 
RNA was extracted from exponential and stationary phase cultures grown in TY broth and 
cDNA was synthesised. gDNA was used as a positive control, and RT negative samples (no 
cDNA produced due to absence of reverse transcriptase) as negative controls. 16S rRNA and 
slpA were amplified as controls for cDNA synthesis.  
All 7 potential sortase substrates (and CD2782) are found in the 630 genome, and 5 of these 
are found within the R20291 genome, as shown by PCR with genomic DNA (Figure 3.2). RT 
PCR data shows that all sortase substrates are transcribed well in both growth phases in 
strain 630. However, only 4 genes are transcribed well in R20291, with CD3392 weakly 
transcribed compared with other genes in exponential phase, and almost absent in 
stationary phase. The srtB gene is also transcribed in both growth phases, suggestive that 
this system of covalent cell wall attachment is active in all growth phases in C. difficile.  
3.2.3 Developing a system for N-terminally Strep-tagging proteins 
 
It was not possible to raise antibodies against all the potential sortase substrates, so a 
system was devised to easily Strep-tag these proteins for further study. As the N-terminal 
signal peptide is cleaved, and the C-terminal “LPxTG”-like motif is also cleaved, tagging 
these proteins is complicated. A universal system for N-terminally Strep-tagging proteins 
was therefore created. DNA encoding the ribosome binding site, secretion signal sequence 
and cleavage site of SlpA (the major S-layer protein) was amplified from slpA in C. difficile 
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630 as this protein is known to be secreted from the cell. To the 3’ terminus of this 
sequence was added a spacer and Strep-tag sequence, followed by an XhoI site, with the 
entire sequence between a 5’ SacI site and a 3’ BamHI site (Figure 3.3a). The sequence was 
ligated between SacI and BamHI sites in pRPF144 (under the constitutive cwp2 promoter) 
and pRPF185 (under the tetracycline inducible promoter), creating pHAS007 and pHAS016 
respectively. The latter was necessary for expression of CD0183 as E. coli mutated the gene 
sequence when under control of the cwp2 promoter during cloning.  
 
 
Figure 3.3 Cloning a system for N-terminally Strep tagging secreted proteins 
A: The RBS binding site, sec signal sequence, signal cleavage site and a spacer from the N-
terminus of slpA was cloned upstream of a sequence encoding a Strep-Tag, between SacI and 
XhoI restriction sites. XhoI and BamHI sites allow for insertion of genes of interest. 
B: Sortase substrates can be cloned from their predicted signal cleavage site to their C-terminus, 
between XhoI and BamHI sites within pHAS007/pHAS016 to allow N-terminal Strep-tagging.  
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3.2.4 Strep-tagged sortase substrates are expressed in C. difficile and show 
distinct colony phenotypes  
 
Potential sortase substrates were amplified from their predicted signal peptide cleavage site 
(SignalP (Zhou et al. 2008)) to their 5’ stop codon from 630 genomic DNA, and ligated 
between XhoI and BamHI sites of pHAS007 or pHAS016 (Figure 3.3b). CD3246 was not 
successfully cloned. Plasmids were conjugated from E. coli into 630Δerm and whole cell 
lysates analysed for expression. For clear visualisation of all samples, all strains were loaded 
to OD/ml of 50 except CD0183 and CD2831 which were diluted to an OD/ml of 20. As can be 
seen in Figure 3.4a, CD0183, CD0386, CD2782, CD2831, CD3145 and CD3392 were all 
expressed in C. difficile. 
 Expression of CD2498 could not be observed, possibly due either to weak expression or an 
incorrectly predicted signal cleavage site. Predicted sizes of these proteins are shown in 
Table 3.1, showing that all proteins migrated approximately at their predicted size, with the 
StrepTag adding approximately 2 kDa to the molecular weight. CD0386 and CD3392 show an 
additional high MW band (consistently seen in other analyses) at the very edge of the gel, 
suggesting that some of the protein did not enter the gel. CD0183 shows a banding pattern 
in whole cell lysates. This is suggestive of incomplete cell wall hydrolysis during lysis of the 
cell, resulting in the attachment of the protein to varying sizes of cell wall fragments.  
Cultures of C. difficile 630Δerm expressing each plasmid were diluted and plated onto BHI 
agar such that single isolated colonies could be observed. BHI agar was supplemented with 
thiamphenicol (15 µg/ml) for plasmid propagation, and plates for CD0183 additionally 
contained 500 ng/ml ATc for induction of the Ptet promoter. Plates were grown for 96 hours 
and the colony morphology imaged from above (A) and underneath (U). As can be seen in  
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Figure 3.4 Expression of N-terminally Strep-Tagged proteins 
A: C. difficile 630Δerm carrying pMTL960 (vector) or tagged potential sortase substrates were 
grown to mid-log (CD0183 induced with ATc (500 ng/ml)) and whole cell lysates were prepared. 
Proteins were detected using antibodies raised against the Strep-tag ligand.   
Concentrations loaded: CD0183 and CD2831 OD 20; Vector control, CD0386, CD2498, CD2782, 
CD3145 and CD3392 OD 50 
B: Cultures were diluted at plated on BHI agar such that single isolated colonies could be 
observed, with thiamphenicol selection (15µg/ml) and for CD0183 Atc (500 ng/ml). Plates were 
incubated for 96 hours and imaged with a flatbed scanner from underneath (U) and with a Canon 
camera from above (A). Additional colony morphology for CD0183 is shown beneath.  
114 
 
Figure 3.4b there are a variety of colony morphologies. Wild type 630Δerm shows a slight 
spreading out of growth, with a pale white colour. CD0183 showed much greater spreading 
of growth, with all colonies observed markedly larger than wild type. There was also more 
frequent irregular shaped spreading of colony growth, shown below. CD2498 shows very 
similar colony morphology to wild type, as does CD2831, though the colonies appear to be 
denser, with a darker colour for CD2831. CD2782 shows irregular colony morphology. 
CD0386, CD3392 and CD3145 all show tighter colony morphology than wild type, with 
colonies appearing denser and shinier. This is most striking for CD3145. These three proteins 
are predicted to be extracellular matrix (ECM) binding proteins, but they may also be 
involved in C. difficile – C. difficile interactions like the potentially fibronectin binding S-layer 
protein CwpV (Reynolds et al. 2011).  
3.2.5 Creation of sortase substrate insertional mutants 
 
To try to determine the function of some of these substrates, insertion mutants were 
produced using ClosTron technology (Heap et al. 2007). Plasmids were designed to target 
CD0183 at position 549 in the sense orientation (pHAS023), CD2831 at position 1962 in the 
sense orientation (pHAS017) and CD3392 at position 840 in the sense orientation 
(pHAS019). There were no predicted insertion sites within CD3145, so the sequence 
between the predicted transcriptional start site and translational start site was analysed 
(BPROM Softberry). CD3145 was targeted 18 bp upstream of its translational start site in the 
antisense orientation (pHAS018).  
DNA was extracted from wild type 630Δerm and each mutant for PCR analysis. Primers were 
designed to bind within the gene of interest and amplify across the intron insertion site, 
giving approximately a 400 bp product in wild type DNA and approximately 2.5 kb following 
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insertion of the group II intron. Each of these primers could be paired with an EBS primer 
within the intron to confirm orientation of the intron, and primers specific for the 
retrotransposition activity marker (RAM) confirm presence of the erythromycin cassette and 
that the group I intron had been excised for expression of ermB. Figure 3.5 shows that 
mutants were produced for all four genes. Compared with wild type gDNA, all mutated 
genes contained an intron in the required orientation and were positive for the RAM.  
 
 
 
Figure 3.5 Creation of potential sortase substrate ClosTron insertion mutants 
PCRs were conducted on genomic DNA extracted from each mutant (KO) and wild type 630Δerm 
(wt). Primers amplifying from within the genes of interest coupled with the EBS primer within the 
intron confirmed orientation of the intron in either the sense or antisense orientation. PCR for 
RAM confirms the presence of the erythromycin cassette (following group I intron excision) in 
these mutants and absent in wild type gDNA. Primers spanning each intron insertion site show 
the presence of an intron in each mutant which is absent in wild type gDNA, where a smaller PCR 
product is observed.   
116 
 
To detect changes in protein expression, antibodies were raised against those proteins of 
interest. 30 kDa N-terminal fragments of CD0183, CD2831 and CD3392 were cloned and 
expressed in E. coli for purification. Expressed in E. coli, the 30 kDa domain of CD2831 was 
an insoluble protein and had to be denatured and refolded during purification. 
Antibodies were raised in mice against these recombinant proteins. However, only 
antibodies against CD0183 proved to be effective at detecting the wild type protein, 
possibly due to low levels of expression of CD2831 and CD3392 in C. difficile or mis-folding 
in E. coli or during purification. When antibodies against CD2831 were used at a 1:100 
dilution, a band of the correct size could faintly be detected, however there was a great deal 
of cross-reaction with other proteins which did not make this antibody ideal to work with.  
Cultures of the insertional mutants were analysed for loss of expression of their respective 
sortase substrate (Figure 3.6).  CD0183 could not be detected in the insertion mutation 
(Δ0183). Antibody against CD2831 at a 1:100 dilution detected a band of approximately 100 
kDa in wild type and absent in the mutant, indicating abbrogation of CD2831 expression. 
There is a great deal of cross reaction with this antibody however, so results are 
inconclusive. Mouse antibodies against CD3145 and CD3392 were obtained from our 
collaborators at Novartis, and Figure 3.6 shows that CD3145 expression was absent in the 
insertion mutant (Δ3145). CD3392 could not be detected at its predicted size, a cross 
reaction occurs around 66 kDa, but a high molecular weight band can be observed, similar 
to the band seen for strep-tagged CD3392 (Figure 3.4). This band is fainter in the mutant, 
potentially suggesting absence of CD3392 expression. However, this antibody will cross 
react with CD0386 due to their high protein identity, which would explain why a band is still 
detected in the mutant. RT PCR could be undertaken to determine whether transcription 
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was prevented following mutation of these genes but would not be conclusive for changes 
in translation.  
 
 
3.2.6 Changes in potential sortase substrate expression can alter colony 
morphology of C. difficile but doesn’t change cell interaction in liquid culture 
 
Manipulation of the potential fibronectin binding protein CwpV showed changes in colony 
morphology and cell interactions (Reynolds et al. 2011). It was therefore of interest to see if 
the same could be observed for some of the potential sortase substrates. Colony 
Figure 3.6 Loss of sortase substrate protein expression in insertion mutants 
C. difficile strain 630Δerm and mutants of CD0183, CD2831, CD3145 and CD3392 were grown 
overnight and cultures were lysed. Proteins in whole cell lysates of wild type (wt) and each 
knockout (KO) were detected with their corresponding antibodies. Bands of the correct size are 
indicated with a black arrow.   
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morphologies were examined of 630Δerm, 630Δerm over expressing either CD2831 
(pHAS013) or CD3392 (pHAS025), the insertional mutants of these genes and their 
respective complemented mutants. Cultures were plated on BHI agar with thiamphenicol 
selection (15 µg/ml) to obtain single isolated colonies and grown for 72 hours under 
anaerobic conditions. As can be seen in Figure 3.7 a denser colony morphology is observed 
when over-expressing CD2831, with smooth rather than snowflake edges. The Δ2831 
mutant appears as wild type 630Δerm, and complementation shows intermediate colony 
morphology. Meanwhile, mutant Δ3392 still shows a slightly smoother edge than wild type, 
similar to the morphology observed in wild type over expressing the protein (pHAS025). 
Further, the complemented mutant shows the tightest colony morphology of all.  
It was possible that these large proteins, predicted to be adhesins, could be involved in C. 
difficile – C. difficile interactions. The same strains were therefore investigated for changes 
in cellular aggregation when concentrated to an OD/ml of 5. However, there was no change 
in aggregation between these strains, suggesting they are not involved in interactions 
between C. difficile cells (data not shown).  
I would like to extend thanks to Emily Shaw for conducting this colony morphology and cell 
aggregation work.  
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3.2.7 CD2831 and CD3392 do not appear to enhance binding of C. difficile to 
collagen III 
 
Surface proteins are likely to be involved in binding to the cells of the intestine, but 
additionally many surface proteins have been found to bind to extracellular matrix proteins, 
such as collagens and fibronectin. Collagen III is the most abundant collagen found in the 
intestinal tract. CD2831 and CD3392 were shown to not be involved in C. difficile 
aggregation but they are predicted to be collagen binding proteins (Table 3.1) due to 
homologous regions within their sequence to CbpA, a collagen binding protein in S. aureus 
(Tulli et al. 2013). C. difficile strains were analysed for collagen binding using an ELISA plate 
assay. 50 µl of overnight cultures of C. difficile were serially diluted, from 10 OD/ml down to 
0.3125 OD/ml, and incubated in 96 well plates pre-coated with 0.5 µg Collagen III. Plates 
were washed and detected for bound C. difficile. Wild type 630Δerm was compared with 
Figure 3.7 Colony morphology following CD2831 and CD3392 manipulation 
Cultures were diluted and plated on BHI agar such that single isolated colonies could be observed, 
with thiamphenicol selection (15 µg/ml). Plates were incubated for 72 hours and imaged from 
underneath with a flatbed scanner.   
C. difficile wild type 630Δerm with empty vector (wild type) or over expressing CD2831 (pHAS013) 
or CD3392 (pHAS025); CD2831 deletion mutant with empty vector (Δ2831) or complemented for 
CD2831 (Δ2831 + pHAS013); CD3392 deletion mutant with empty vector (Δ3392) or 
complemented for CD3392 (Δ3392 + pHAS025). 
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wild type over expressing either CD2831 (pHAS013) or CD3392 (pHAS025), each insertional 
mutant, and their respective complemented mutants.  
As can be seen in Figure 3.8, there is poor binding of whole cells to collagen III with data 
showing large error bars. It is difficult to conclude anything from this data due to the low 
level of binding, suggesting that the assay has not worked either due to an inability of C. 
difficile to bind collagen in this setting or due to flaws in the assay. However, it appears that 
both loss and overexpression of CD2831 results in almost complete loss of binding.s.  
I would like to extend thanks to Emily Shaw for conducting this work.  
121 
 
 
Figure 3.8 Collagen III binding of C. difficile following potential sortase substrate manipulation 
C. difficile strains were grown overnight and incubated on ELISA plates pre-coated with Collagen 
III before washing and detecting for bound C. difficile. Initial C. difficile cultures were added at 
total ODs of 0.5, 0.25, 0.125, 0.0625, 0.03125 and 0.01563 in 50 ml.  
A: C. difficile strains wild type 630Δerm and CD2831 deletion mutant (Δ2831) with empty vector 
(pMTL960) or expressing CD2831 (pHAS013). 
B: C. difficile strains wild type 630Δerm and CD3392 deletion mutant (Δ3392) with empty vector 
(pMTL960) or expressing CD3392 (pHAS025). 
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3.2.8 Sortase substrates may have a role in binding C. difficile to extracellular 
matrix proteins produced by human fibroblast cells 
 
To determine whether putative sortase substrates could be involved in binding to cells, cells 
which produce large quantities of extracellular matrix (ECM) proteins were employed. IMR-
90 is a line of human fibroblast cells which produce ECM proteins when grown on a scaffold 
(Sigma) or collagen I. As Figure 3.9a shows, these cells produce fibronectin, heparan 
sulphate, collagen I and collagen V. They do not produce collagen VI. IMR-90 cells in 
chamber slides were incubated with 500 µl OD 0.1 of C. difficile strains for 2 hours under 
anaerobic conditions. Chamber slides were washed with PBS, and bound C. difficile fixed 
with 3% PFA before staining with antibodies raised against C. difficile 630.  
Surface exposure of CD3392 could not be confirmed with antibodies, so CD2831 and 
CD3145 were analysed for binding properties. Compared with 630Δerm, Δ2831 and Δ3145 
did not appear to show reduced binding to IMR-90 by microscopy analysis (Figure 3.9b). 
Binding of Δ2831 was compared with its complemented mutant to determine whether there 
was a difference in binding, as 630Δerm possibly showed weaker binding to IMR-90 than 
630 (the parental strain from which Δerm had been derived). Therefore it was felt that the 
role of CD2831 could be determined more clearly when comparing the mutant, with or 
without plasmid expression of CD2831. Initial microscopy shown in Figure 3.9c suggested 
that plasmid expression of CD2831 enhanced binding of Δ2831. However, when compared 
with wild type 630Δerm expressing empty vector and 630Δerm overexpressing CD2831 
(Figure 3.9d) there appeared to possibly be a reduction in binding in Δ2831 which was not 
resolved by complementation. Microscopy has its drawbacks as it is subjective and not 
quantitative. Therefore it was important to determine the percentage adhesion of each 
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strain to IMR-90 by CFU counting. Only preliminary experiments could be conducted with 
calculating colony forming units bound to IMR-90 cells. As can be seen in Figure 3.9e, there 
was low binding to IMR-90 by C. difficile and there was not a significant difference between 
wild type 630Δerm and the mutants Δ2831 and Δ3145.  
Further experiments are shown in Appendix 1, showing that removal of CD3145 (CbpA) does 
not alter C. difficile binding to IMR-90 cells. However, recombinantly expressed and purified 
CbpA does bind to immobilised collagen I, and when expressed on the surface of L. lactis it 
increases the binding of this bacterium to IMR-90 cells.   
This work was conducted at Novartis, Siena, and thanks are extended to Lorenza Tulli and 
Rosanna Leuzzi for their assistance. A manuscript for the role of CD3145 in collagen binding 
can be found in Appendix 1.  
3.2.9 Developing a cell wall extraction protocol  
 
An effective process for digesting the peptidoglycan and extracting cell wall proteins in C. 
difficile was unavailable at the commencement of this project. Attempts to utilise published 
methods with Tris-sucrose buffer proved to be largely ineffective (data not shown). 
Additionally, enzymes known to digest peptidoglycan in other Gram positive bacteria are 
not able to digest the cell wall of C. difficile (summarised in Figure 3.10). Due to a large 
degree of glucosamine deacetylation in the C. difficile cell wall (Peltier et al. 2011), lysozyme 
is ineffective, and mutanolysin has poor activity. The cross bridge in C. difficile is a direct 
diaminopimelic acid (DAP) – DAP linkage, rather than pentaglycine as observed in S. aureus, 
therefore lysostaphin will be ineffective.  
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Figure 3.9 Binding of C. difficile to IMR-90 cells 
IMR-90 cells were grown for 3 days on a scaffold in chamber slides. Nuclei were DAPI stained 
(blue/teal), actin were phalloidin stained (red). Images shown are representative of those seen in 
every field of view for each experiment.  
A: ECM proteins were stained with specific antibodies as labelled and are shown in green.  
B-D 500 ml OD 0.1 C. difficile were incubated on IMR-90 cells in chamber slides for 2 hours under 
anaerobic conditions. Bound bacteria detected with antibodies against C. difficile 630 (green). 
B: Δerm, Δ2831 and Δ3145 were compared for binding to IMR-90 cells.   
C: Δ2831 and Δ2831+2831 (plasmid complemented mutant) compared for binding to IMR-90 cells 
D: Δerm, Δerm+2831, Δ2831 and Δ2831+2831 were compared for binding to IMR-90 cells. 
E: Δerm, Δ2831 and Δ3145 adhesion to IMR-90 cells was quantified by dilution plating.  
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Figure 3.10 Peptidoglycan structures and hydrolytic enzymes 
Site of action of various hydrolytic enzymes are shown together with known (S. aureus) and 
predicted (C. difficile) sites of attachment of sortase substrates. Black arrows indicate site of 
enzyme action. Red crosses depict loss of activity, red strikes indicate reduced activity.  
A: Cell wall structure of Staphylococcus aureus, B: Cell wall structure of Clostridium difficile  
MN - N-acetylmuramic acid, GN - N-acetylglutamic acid, G - deacetylated glucosamine, DAP - 
diaminopimelic acid, CB ? - unknown crossbridge 
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The task therefore was to find an enzyme which could effectively digest the peptidoglycan 
cell wall of C. difficile. An N-acetylglucosaminidase has been identified in C. difficile which 
cleaved between GlcNAc and MurNAc in the glycan chain of C. difficile (Dhalluin et al. 2005) 
and additionally Mayer et al (Mayer et al. 2008; Mayer et al. 2011) have characterised a C. 
difficile phage protein capable of mediating lysis of many strains C. difficile. This phage 
endolysin is predicted to have N-acetylmuramoyl-L-amidase activity (hereafter termed 
“amidase”) and therefore is predicted to hydrolyse the cell wall of C. difficile between the 
glycan backbone and peptide strands (Figure 3.10). DNA encoding residues 1-179 were 
commercially synthesised with an N-terminal His-tag and a 3’ stop codon. This was ligated 
between NdeI and XhoI sites in pET28a to produce pHAS042 (Figure 3.11a), and this 
truncated amidase containing the catalytic domain only was expressed and purified from E. 
coli Rosetta. Figure 3.11b shows there was a good level of expression of the amidase and 
that this was a very clean purification. The amidase was retained in wash buffer (see 
methods) for all experiments. The lysis experiments performed by Mayer et al were 
repeated, with 0.5 – 50 µg amidase in 500 ml C. difficile (final concentrations 1 – 100 µg/ml), 
and show the same pattern of concentration dependent lysis of C. difficile (Figure 3.11c). 
Following this confirmation of amidase activity under our laboratory conditions, the 
amidase was tested for effective release of cell wall proteins.  
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Figure 3.11 Purification of a potential amidase which lyses C. difficile 
A: Plasmid map showing pET28a containing residues 1-179 of a phage endolysin (amidase) with 
an N-terminal His-Tag 
B: 1 µg amidase purified from E. coli stained by Coomassie blue and detected with antibodies 
against His x 6 
C: Lysis curve of C. difficile 630Δerm with amidase (0.5, 2.5, 5, 10, 25, 50 µg in 500 µl) measured 
by drop in OD600 over 90 minutes from an initial OD ~ 1.0.   
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Phosphate sucrose buffer has been described to create C. difficile protoplasts over 4 hours 
but no protoplast images were shown (Purdy et al. 2002). This buffer (0.5 M sucrose, 0.05 M 
sodium phosphate, pH 7.0, hereafter referred to as PS buffer) was investigated for 
protoplast formation. C. difficile 630Δerm cultures were grown to mid-log (OD 0.4) in 20 ml 
TY broth and harvested at 4,000 g for 2 minutes. Cells were then resuspended in 950 μl 
reduced PS buffer + either 50 μl amidase or a buffer control. Amidase was used at 25 μg/ml 
as this efficiently lysed C. difficile cells after an hour, thus would be at an excess under these 
conditions. Suspensions were incubated for 2 hours at 37°C anaerobically. Protoplasts were 
spotted onto slides and viewed under the microscope. As Figure 3.12 shows, after 2 hours 
incubation in PS buffer alone, ~80% of the cells had rounded to form protoplasts, while with 
the addition of the amidase, 100% of the cells had rounded.  
To determine the optimal concentration for protoplast formation and cell wall protein 
release, an amidase concentration gradient was investigated. Mid-log cultures were 
resuspended in PS buffer to OD 20 and incubated for 1 hour 37°C anaerobically. Amidase 
was added at the following concentrations, 0 μg/ml, 5 μg/ml, 10 μg/ml, 20 μg/ml and 30 
μg/ml, in the presence or absence of 10 mM MgCl2. 10 μl was spotted onto slides and the 
remainder harvested at 6,000 g for 20 minutes. The supernatant containing the cell wall 
fraction was removed. As Figure 3.13a shows, the presence of amidase released more cell 
wall proteins than PS buffer alone. Compared with an S-layer extract, obtained by 
incubation of cells in low pH glycine, more protein bands can be observed by coomassie 
staining in the amidase treated cultures, suggesting release of covalently bound proteins.  
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However there does not appear to be an amidase concentration dependent release of 
proteins. Despite this, microscopically there does appear to be a concentration dependent 
formation of protoplasts (Figure 3.13b). Additionally the presence of magnesium ions did 
not enhance the release of proteins from the cell wall. This suggests that the higher 
concentrations of amidase would be optimal as there may be cell wall proteins that cannot 
Figure 3.12 Formation of protoplasts in phosphate-sucrose buffer 
C. difficile strain 630Δerm were grown to mid-log in TY broth and resuspended in phosphate 
sucrose (PS) buffer with (+) and without (-) 25 µg/ml amidase. Cells were incubated anaerobically 
for 2 hours at 37°C and spotted on to slides. Views show presence and absence of rod shaped 
cells dependent on amidase incubation.   
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be seen by Coomassie which would still be retained on the cell at lower concentrations of 
amidase digestion and that magnesium is not required for efficient release of cell wall 
proteins.  
Having efficiently determined a method by which cell wall proteins could be removed from 
cells it was necessary to clarify that cell lysis had not occurred during this process. 630Δerm 
was grown in triplicate to mid-log phase with constitutive expression of the cytoplasmic 
protein β-glucuronidase (GusA) from pRPF144 (Fagan and Fairweather 2011). Cells were 
harvested and resuspended in PS buffer to OD20, with or without 30 μg/ml amidase and 
incubated for one hour. A higher concentration of 60 μg/ml was also included to determine 
whether higher concentrations incurred lysis. Lysis controls with phosphate buffer (no 
sucrose) on intact cells (IN) and cells which had been freeze-thawed (FT) at -20°C were 
included, with or without amidase (30 μg/ml). Resulting supernatants were used to measure 
GusA activity with a colormetric GusA substrate as previously described (Mani and Dupuy 
2001). As can be seen in Figure 3.14, there is almost no detectable GusA activity for any of 
the conditions producing protoplasts compared with lysis controls, with no significant 
increase in signal between PS alone and PS + amidase. Interestingly, without amidase and 
sucrose the phosphate buffer alone does not cause lysis of intact cells, potentially due to the 
lack of hydrolases and a thick peptidoglycan cell wall which could protect the cell structure. 
Lysis has been observed previously with -20°C freeze thaw cycles, predicted to be in part 
due to action of internal hydrolases.  
3.2.10 Potential sortase substrates are located in cell wall extracts 
 
The strep-tagged potential sortase substrates (section 3.2.4) were analysed for release into 
the cell wall fraction following amidase digestion of protoplasts. Cutures were grown to OD  
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Figure 3.13 Optimisation of cell wall protein extraction 
Cells were grown to mid-log and resuspended in PS buffer with or without amidase in the 
presence or absence of 10 mM MgCl2. Incubation proceeded for 1 hour. 
A: Coomassie Blue staining of cell wall fractions of protoplast incubations and an S-layer extract.  
B: Microscopic view of protoplast formation with varying concentrations of amidase, with (+) or 
without (-) 10 mM MgCl2.   
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0.4 in TY broth and the protoplast protocol detailed above was followed with 30 µg/ml 
amidase. Again, samples were loaded at OD20 for CD0183 and CD2831 and at OD50 for all 
other samples due to differences in expression levels. CD2498 was not included due to lack 
of observable expression in whole cell lysates (see 3.2.4), and membrane bound CD2782 
was included as a control as a non-cell wall associated protein. Cell wall extracts were 
probed with anti-Strep II antibody. As shown in Figure 3.15, all proteins predicted to be 
sortase substrates were found localised in the cell wall except CD0386 and CD2782. The lack 
of CD0386 may be due to a low level of expression as a bands representing CD3392 and 
CD3145 are weakly observed. Interestingly there is reduced banding observed for CD0183 
Figure 3.14 GusA assay to determine lysis of C. difficile during protoplast formation 
C. difficile strain 630Δerm carrying pRPF144 were grown to mid-log and either frozen at -20°C for 
freeze-thaw lysis (FT), resuspended for lysis in 0.05 M sodium phosphate (IN), or in PS buffer (30, 
60). Cells were incubated for 1 hour with (+) or without (-) amidase (30 µg/ml for all except 60+ 
with 60 µg/ml amidase). Suspensions were all centrifuged at 6,000 g for 20 minutes and β-
glucuronidase activity measured from supernatants. Error bars represent standard deviations of 
independent incubations (n = 3). 
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compared with freeze-thawed whole cell lysates in Figure 3.4. This reduction in banding may 
indicate removal of cell wall fragments due to amidase action in cell wall extract 
preparations.  
 
3.2.11 Purification of Strep-tagged CD0183 
 
As cell wall extraction showed CD0183 to be localised to the cell wall, and there was a 
reduction in its banding pattern following amidase action, it suggests that this protein is 
covalently attached to the peptidoglycan cell wall of C. difficile. As this protein was N-
terminally Strep-tagged it could be purified for analysis of C-terminal binding to 
peptidoglycan fragments. C. difficile (pHAS022), which over-expresses Strep-tagged CD0183 
Figure 3.15 Cell wall localisation of N-terminally Strep-Tagged proteins 
C. difficile strain 630Δerm carrying pMTL960 (vector) or tagged potential sortase substrates were 
grown to mid-log (CD0183 induced with ATc (500 ng/ml)) and cell wall extracts prepared. Proteins 
were detected using antibodies raised against the Strep-tag ligand. Black arrows indicate faint 
specific bands.  
Concentrations loaded: CD0183 and CD2831 OD 20; Vector control, CD0386, CD2782, CD3145 and 
CD3392 OD 50  
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(CD0183-ST), was grown in TY broth to maximise cell density, cells were harvested and 
frozen at -20°C. The pellets were lysed by freeze-thawing, a procedure shown in our lab to 
effectively lyse C. difficile. After two cycles of freeze-thawing the samples were incubated at 
37°C for 45 minutes with DNase. The lysed suspension was centrifuged and soluble proteins 
filtered and purified using the ÄKTA-FPLC Strep-tag purification programme. CD0183-ST was 
successfully purified. It did not show signs of degradation and, as shown in Figure 3.16a, 
showed a clear double banding pattern in coomassie staining, confirmed by α-Strep-tag 
antibodies to be purified CD0183-ST. The double band is particularly clear in sample 36. The 
laddered banding pattern of whole cell lysates was only evident in the whole cell lysate 
soluble proteins sample and not the elution fractions from purification. However, the 
double band could possible indicate CD0183 and CD0183 attached to a small cell wall 
fragment.  
Flow through fractions were therefore analysed in case a semi-pure sample of laddering 
CD0183-ST could be obtained. However, as Figure 3.16b shows even early flow through 
fractions show loss of laddering and just double banding of CD0183 by Strep-tag detection. 
An antibody against the cell wall component N-acetyl glucosamine (GlcNAc) was available so 
these flow through fractions were probed with this antibody to determine whether cell wall 
components could be detected associated with CD0183 as a possible indication of cell wall 
binding. However this analysis proved to be negative.  
3.2.12 CD0183 is potentially a true sortase substrate  
 
Strep-tagged CD0183 showed a distinct banding pattern in whole cell lysates (Figure 3.4). 
Antibodies raised against CD0183 cleanly detect this protein (Figure 3.6) and cell wall 
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extractions release this protein from the cell (Figure 3.15). Thus this protein was taken 
forward for further investigation of the sortase system in C. difficile.  
 
 
Figure 3.16 Strep-tag purification of CD0183-ST 
C. difficile strain 630Δerm carrying pHAS022 was grown to mid-log with induction with ATc (500 
ng/ml) and CD0183-ST purified from whole cell lysates by affinity to StrepTactin resin. Flow 
through and elution fractions were analysed by coomassie staining, Strep II antibody and an 
antibody against peptidoglycan component GlcNAc where indicated.  
A: Whole cell lysate soluble fraction (Sol) and elution fractions 30-36.. 32* is a combined sample 
of 32, 33 and 34 elution fractions. 
B: Flow through fractions as indicated (5/6 and 7/8 show combined fractions)   
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The sorting motif in CD0183 is SPSTG. CD0183 was cloned in its entirety into pRPF185 (Fagan 
and Fairweather 2011) under the control of the inducible tetracycline promoter to create 
pHAS035 and then by inverse PCR its sorting motif 'SPSTG' was deleted to create pHAS036. 
These plasmids were conjugated into C. difficile Δ0183 and expression induced with 500 
ng/ml ATc. Cells were lysed by freeze-thaw lysis at -20°C and additionally separated into 
soluble and membrane fractions. As can be seen in Figure 3.17a, wild type CD0183 is found 
in the soluble fraction and shows a degree of banding. However, upon removal of the SPSTG 
motif the protein is largely localised to the membrane and no banding is evident. This 
suggests that, without its sorting motif, the protein is trapped in the membrane. Cell wall 
extractions from these cultures further show that without its SPSTG motif CD0183 is no 
longer sorted into the peptidoglycan cell wall (Figure 3.17b).  
3.2.13 Development of a sortase substrate cleavage assay  
 
Experiments in 3.2.11 indicated that CD0183 may be a sortase substrate, with its SPSTG 
motif necessary for sorting onto the cell wall. It would be expected that cleavage of CD0183 
would occur during the sorting process. For analysis of a cleavage event an asymmetrical 
cleavage assay was developed with a hybrid protein of CD0183 and CwpV repeats.   
CwpV is a cell wall protein which contains C-terminal repeat domains. There are 5 known 
“types” of CwpV repeats and these are antigenically distinct (Reynolds et al. 2011). C. 
difficile 630 expresses CwpV with Type I repeats, while strain R20352 expresses CwpV with 
antigenically distinct Type II repeats. Two Type II CwpV repeats were cloned at the C-
terminus CD0183, such that if a cleavage event occurs two fragments would be produced 
which could be clearly identified (Figure 3.18).  
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Figure 3.17 Localisation of CD0183 
C. difficile strain Δ0183 carrying pHAS035 (p0183) or pHAS036 (p0183ΔSPSTG) were grown to 
mid-log with (+) or without (-) Atc (500 ng/ml) 
A: Whole cell lysates were prepared and separated into whole cells (WC), soluble (S) and 
membrane (M) fractions. CD0183 was detected with antibody raised against the entire protein. 
Antibodies against ATP-synthase were used to show presence of membranes. 
B: Cell wall fractions were prepared by protoplast formation and CD0183 detected as above. 
Lanes; 1 - Δ0183, 2 - Δ0183 p0183, 3 - Δ0183 p0183ΔSPSTG  
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CD0183 was cloned to remove its stop codon and introduce an XhoI site before the BamHI 
site in pHAS035 (0183) and pHAS036 (0183ΔSPSTG). Two Type II repeats of the cell wall 
protein CwpV were amplified from R20352 and ligated between XhoI and BamHI sites, 
producing pHAS039 (0183-CwpV) and pHAS040 (0183ΔSPSTG-CwpV). As shown in Figure 
3.18 shows, if no cleavage occurs, an ~ 55 kDa band would be observed when detected with 
either α-CD0183 or α-CwpV Type II antibodies. If a cleavage event does occur, an ~ 35 kDa 
fragment representing CD0183 up to its threonine residue at position 4 of the SPSTG motif 
would be detected with α-CD0183 antibodies, and a 20 kDa fragment representing the C-
terminal of CD0183 with CwpV repeats would be detected with α-CwpV Type II antibodies.  
These plasmids were conjugated into Δ0183 and expression induced with 500 ng/ml ATc. 
Whole cell lysates were separated into soluble and insoluble fractions. As Figure 3.19a 
shows, there was expression of both proteins in whole cell lysates. However, with both 
0183-CwpV and 0183ΔSPSTG-CwpV, the full length protein of 60 kDa is detected by both 
antibodies against CD0183 and CwpV Type II repeats. This indicates that cleavage has not 
Figure 3.18 Development of a protein cleavage assay 
Fusion protein containing CD0183 in its entirety with two CwpV Type II repeats cloned to its C-
terminus. Arrows indicate signal peptidase and sortase cleavage sites. Bars underneath the 
protein indicate the size of mature protein fragments when no sortase cleavage occurs (~ 55 kDa), 
and after sortase cleavage (N-terminal ~ 35 kDa fragment, C-terminal ~ 20 kDa fragment).  
140 
 
taken place. However, 0183-CwpV is soluble, while 0183ΔSPSTG-CwpV is still insoluble and 
in the membrane fraction. There is an ~40 kDa band detected by α-CD0183 in the 
0183ΔSPSTG-CwpV sample which possibly indicates degradation of the protein, or cleavage 
elsewhere in the protein may occur. 
Cell wall extracts were produced and probed for both CD0183 and CwpV. As shown in Figure 
3.19b, full length 0183-CwpV is found in the cell wall as is full length 0183ΔSPSTG-CwpV, but 
in much lower levels. This suggests either that CD0183 is not cleaved for incorporation into 
the cell wall, or that the presence of CwpV at its C-terminal acts to release it from the Sec 
machinery.  
3.2.14 Development of a novel assay for cell wall attachment of an 
exogenous protein 
 
There are multiple sorting motifs amongst the potential sortase substrates of C. difficile. An 
assay was developed to investigate whether all of these sorting motifs are capable of sorting 
a protein onto the peptidoglycan cell wall. For this to be investigated, a secreted protein 
was required. There is little information of secreted proteins of C. difficile other than the 
toxins, but these are not secreted through the Sec secretion system, but predicted to be 
released through a holin (Govind and Dupuy 2012). The surface proteins of C. difficile 
however, are exported via the Sec machinery (Fagan and Fairweather 2011). The LMW SLP 
protein from strain R20291 is antigenically distinct from the LMW SLP protein of strain 630 
(McCoubrey and Poxton 2001) and therefore expression could be distinguished from 630 
LMW SLP. As the C-terminus of the LMW SLP interacts with the N-terminus of the HMW SLP 
(Figure 3.20a), the LMW SLP protein including its secretion signal, but lacking the low 
interaction domain (LID) was cloned from R20291. This should render it a secreted protein  
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Figure 3.19 Expression, cleavage and localisation study of 0183-CwpV 
C. difficile strain Δ0183 carrying pHAS039 (p0183-CwpV) or pHAS040 (p0183ΔSPSTG-CwpV) were 
grown to mid-log with (+) or without (-) Atc (500 ng/ml). CD0183 was detected with antibody 
raised against the entire protein, and CwpV type II repeats detected with antibodies raised 
against two repeats cloned from R20352.  
A: Whole cell lysates were prepared and separated into whole cells (WC), soluble (S) and 
membrane (M) fractions.  
B: Cell wall fractions were prepared: Lane 1, p0183-CwpV; Lane 2, p0183ΔSPSTG-CwpV   
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(Figure 3.20b) (Fagan et al. 2009). The C-terminal cell wall sorting signal of potential sortase 
substrates could then be cloned at the C-terminus to create a fusion protein (Figure 3.20c). 
As shown in Figure 3.20d, the LMW protein was cloned between SacI and BamHI sites of 
pRPF185 (Fagan and Fairweather 2011) with the addition of an XhoI site such that the C-
terminus of each potential sortase substrate could be cloned between XhoI and BamHI sites, 
creating pHAS045. The C-terminus of each potential substrate was cloned to include the 
Figure 3.20 Development of an exogenous protein cell wall attachment assay 
A: Interaction between mature low molecular weight SLP (LMW) and mature high molecular 
weight SLP (HMW) 
B: LMW with its signal peptide and without its LID which should be a soluble protein 
C: The structure of sortase substrates, with the C-terminal sorting domain composed of an 
“LPXTG” motif, hydrohphobic domain (black), and a charged tail (red).  
D: Combination of the LMW SLP with the C-terminal sorting domain of potential sortase 
substrates  
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entire cell wall sorting signal to the 3’ stop codon, with or without the “LPXTG” like motif. 
Plasmids were conjugated into C. difficile 630Δerm and expression induced with 500 ng/ml 
ATc.  
 
 
As Figure 3.21 shows, the LMW SLP from R20291 expresses well in C. difficile 630 and 
antibodies raised against it do not react with the LMW SLP of 630 as no band is detected for 
vector control. Whole cell lysates of vector control, LMW, LMW-0183 and LMW-
0183ΔSPSTG were analysed. R20291 LMW SLP is still associated with the cell, possibly the 
cell wall, and is not truly a secreted protein, as it was only weakly detected in culture 
supernatants (data not shown). However, upon addition of the CD0183 C-terminus a distinct 
banding pattern is observed with high molecular weight species. Such species would be 
consistent with attachment to the peptidoglycan which may retard migration. However, a 
Figure 3.21 LMW expression with the C-terminus of CD0183 
C. difficile strain 630Δerm carrying pMTL960 (vector), pHAS045 (LMW), pHAS047 (LMW-0183), or 
pHAS049 (LMW-0183ΔSPSTG) were grown to mid-log with Atc (500 ng/ml). Whole cell lysates 
were prepared and LMW was detected with antibody raised against LMW from R20291.   
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similar banding pattern is seen with the LMW-0183ΔSPSTG protein where the predicted 
sorting motif is absent.  
When the C-terminus of other potential sortase substrates are expressed with the LMW 
protein a variety of banding patterns are observed in whole cell lysates (Figure 3.22). LMW-
3246 shows a similar banding patter to LMW-0183, and also with its LMW-3246ΔSPKTG 
counterpart. All protein fusions showed double banding, with or without the sorting motif. 
This is absent when LMW is expressed alone (Figure 3.21), suggesting a requirement of the 
C-terminal sorting signal for this phenomenon, but explanations remain elusive. Cell wall 
extractions were conducted to try to understand these phenotypes but were inconclusive 
and could not be followed up in the time constraints of the project.  
 
 
Figure 3.22 LMW expression with the C-termini of potential sortase substrates 
C. difficile strain 630Δerm carrying pHAS045 derivatives expressing the LMW SLP from R20291  
with the C-termini of potential sortase substrates (as annotated) were grown to mid-log with Atc 
(500 ng/ml). Whole cell lysates were prepared and LMW was detected with antibody raised 
against LMW from R20291. Plasmids either expressed the entire C-terminal region of potential 
sortases including the LPXTG like cell wall sorting signal (CWSS), or the C-terminal region without 
the CWSS (ΔCWSS).  
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3.3 Discussion  
 
Bioinformatic analysis found 7 potential sortase substrates in the C. difficile 630 genome, 
with 4 found in R20291. The proteins have predicted functions typical of sortase substrates 
in other Gram-positive pathogens such as ECM protein binding. All had typical sortase 
substrate features: a hydrophobic domain and a charged tail, and all but CD2498 showed 
strong “LPXTG” like motifs. CD0183 had a “weaker” hydrophobic domain. RT PCR analysis 
showed that in strain 630 all sortase substrates and the potential srtB gene were transcribed 
and, in R20291, 3 of the 4 potential sortase substrates and srtB were transcribed. This 
suggests, but does not prove, that a sortase system is active in C. difficile.  
To analyse expression and localisation of these sortase substrates, rather than raise 
antibodies against all 7 proteins a system for tagging these proteins was engineered, the 
difficulty being that sortase substrates are cleaved at both their N- and C-termini. A 
universal system was devised such that all potential substrates contained the SlpA Sec signal 
sequence, thus ensuring they were all successfully secreted from the cell, and an N-terminal 
Strep-Tag for detection. Substrates were either expressed constitutively from the cwp2 
promoter, or under control of the inducible tetracycline promoter. Interestingly there was 
variability in the level of expression for each gene. CD0183 under control of the tetracycline 
promoter showed the highest level of expression, mostly due to the strength of the tet 
promoter compared with Pcwp2. CD0386 and CD3392, which were relatively poorly 
expressed, often show high molecular weight bands in addition to their predicted ~110 kDa 
band. Using antibodies against CD3392 only this high molecular weight band was detected. 
This suggested that CD3392 forms complexes and this could be followed up by attempting 
to disrupt complexes, for example by boiling in SDS and denaturation with urea. An 
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alternative explanation could be association of the proteins with cell wall fragments 
resulting in complexes too large to enter the separating gel. Incubation with amidase could 
potentially remove the peptidoglycan allowing migration through the gel. CD2831 showed a 
faint high molecular weight banding pattern, which was even more pronounced with 
CD0183. This was probably due to incomplete cell wall hydrolysis and indicated possible 
migration of these proteins through the gel with attached fragments of the peptidoglycan 
cell wall.  
Colony morphologies of strains over-expressing potential sortase substrates from a plasmid 
showed considerable variation. For example, over expression of CD0183 showed a greater, 
often irregular, spreading of growth than wild type C. difficile 630Δerm, while over-
expression of CD0386, CD2831, CD3145 and CD3392 showed a “tight” colony morphology. 
These changes could reflect alterations in cell-cell contact, as seen with over-expression of 
the S-layer protein CwpV which has been shown to be involved in aggregation (Reynolds et 
al. 2011). Only CD2831 and CD3392 were tested for aggregation properties but there was no 
observable difference between wild type, mutants of these genes or with over-expression of 
these genes from a plasmid.  A higher culture OD may have shown a greater difference 
between strains, but would have been artificial. CD3145 showed tighter colony morphology 
when over-expressed than other potential sortase substrates so should be investigated for 
aggregation properties. Biofilm assays could also be conducted to determine whether these 
proteins are important for the formation of C. difficile biofilms (Dawson et al. 2012). 
The collagen binding properties of CD2831 and CD3392 were initially investigated, as these 
proteins have predicted collagen-binding domains. Unfortunately, binding of C. difficile to 
immobilised collagen III was almost completely absent, and no increase in binding was 
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observed for wild type 630Δerm over-expressing either CD2831 or CD3392.  This may be due 
to the assay not working as there was no positive control available to show positive binding 
and detection of bound bacteria. The assay could be optimised, for example to include fixing 
of bacteria prior to wash steps, and other types of collagen could have been tested. 
Collagen III had been chosen due to its localisation to the intestinal tract, but collagen I is 
the most abundant collagen in the body. Direct binding of purified sortase substrates to 
collagens and other ECM proteins could also be investigated, as conducted for CD3145 in 
Appendix 1. The results show that purified CD3145, now named CbpA (collagen binding 
protein A) binds collagens I and V in vitro (with a Kd of ~109) and that CbpA co-localises with 
collagens I and V on IMR-90 cells and murine intestinal tissue. IMR-90 cells are human 
fibroblasts which produce a large quantity of ECM proteins when grown on a scaffold 
(Sigma) or on collagen I. ECM proteins produced include collagen I, collagen V and 
fibronectin (Tulli et al. 2013). Therefore, despite not being a cell type to which C. difficile 
would naturally bind, they would mimic the conditions observed following disruption of the 
tight junctions in the gut, with exposure of ECM proteins. Initial results indicated that there 
is no significant difference in binding to IMR-90 cells between wild type 630Δerm and the 
mutants tested. This work was continued by collaborators at Novartis, including the use of 
my CD3145 knock-out strain and pHAS033 (pCbpA) expressing CD3145. However, as 
outlined earlier, although better binding was observed than for other cell types (Cerquetti et 
al. 2002; Dingle et al. 2010), there was no observable difference between wild type and 
strains altered for CD2831 or CD3145 expression. This may partly be due to redundancy 
within C. difficile. Many surface proteins are predicted to be ECM binding, so removal of one 
protein is unlikely to affect binding of C. difficile as many others are there to fulfil the role.  
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Sortase substrates should be covalently attached to the cell wall, but there is currently no 
reliable method for digesting the cell wall of C. difficile and low pH glycine only removes 
non-covalently bound proteins such as the S-layer proteins. A cell wall extraction protocol 
was developed which employed the phage endolysin reported to lyse C. difficile cells (Mayer 
et al. 2008; Mayer et al. 2011), likely through N-acetylmuramoyl-L-alanine amidase activity. 
By preparation of protoplasts in a sucrose buffer, this amidase was shown to efficiently 
remove cell wall proteins of C. difficile without causing cell lysis. When comparing cell wall 
extracts obtained via protoplast formation and amidase with those obtaining using low pH 
glycine, additional minor bands were observed in protoplast extracts, indicating that this 
method releases more than just S-layer proteins. It would be informative to compare the 
protein profile of these extracts with an S-layer extract by mass spectrometry to determine 
the additional proteins present in the protoplast generated extracts. Additionally, 
peptidolgycan sacculi of C. difficile could be purified and digested with the amidase and 
released proteins analysed by mass spectrometry. Localisation studies using Strep-tagged 
potential sortase substrates showed CD0183, CD2831, CD3145 and CD3392 to be present in 
the cell wall. Further study should be undertaken to determine whether they are covalently 
attached to the cell wall. Manipulation of each cell wall sorting motif and study of changes 
in protein localisation will also help to determine their role in cell wall sorting. An E. coli RNA 
pol β antibody has been used successfully in other studies as a marker for cell lysis and could 
be used for future western blot analyses as a cytoplasmic marker (Govind and Dupuy 2012).  
The most promising protein for study was CD0183. The gene was found in all strains studied 
by DNA microarray, antibodies against this protein could cleanly detect this protein, and it 
had been observed in cell wall fractions of cells. Additionally, there was a suggestion that it 
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could be observed on the surface of peptidoglycan sacculi (data not shown). Purification of 
Strep-tagged CD0183 showed a double band pattern in highly purified CD0183. Western 
blot analysis with an antibody against GlcNAc proved inconclusive for the presence of 
peptidoglycan fragments, but this is not surprising as 93% of glucosamine in the C. difficile 
cell wall is deacetylated (Peltier et al. 2011). Mass spectrometry analysis of this purified 
protein could be used to determine the presence of sugar residues, indicating the presence 
of cell wall glycan polymers. Additionally a methionine residue 3 positions before the SPSTG 
motif could be targeted for cleavage with cyanogen bromide and this short peptide 
sequenced by Edman degradation to determine the anchor on the cell wall of this potential 
sortase substrate (Ton-That et al. 1998). This analysis would also determine whether 
cleavage of the SPSTG motif had occurred.  
Removal of the SPSTG motif of CD0183 rendered the protein insoluble. This initially 
suggested that this protein was a true sortase substrate, such that removal of its sorting 
signal prevented sorting onto the cell wall, retaining the protein in the membrane. This 
should be studied further by optimising immunostaining of protoplasts, with membrane 
bound proteins such as ATP synthase and Cwp7 as positive controls. This could determine 
whether the protein is anchored in the membrane following SPSTG removal, or whether this 
manipulation renders the protein insoluble in the cell cytoplasm. Additionally culture 
supernatants should be analysed to determine whether CD0183ΔSPSTG is released from the 
cell more or less than the wild type protein. In Bacillus anthracis a cleavage assay involving 
expression of a fusion protein was used to show cleavage of pilin subunits by specific 
sortases (Budzik et al. 2008b). When a similar cleavage assay was developed to investigate 
cleavage of CD0183, full length protein was detected, rather than two cleavage products. 
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This throws doubt over whether CD0183 is indeed a true sortase substrate. Analysis of cell 
wall extracts showed full length 0183-CwpV in the cell wall, which suggests that this fusion 
protein did not affect folding and export of CD0183. The addition of a protein at the C-
terminal of CD0183 could therefore act to push the protein further through the export 
system as CD0183 has a weaker predicted hydrophobic region than other potential sortase 
substrates. To investigate this further a simple tag, such as a Strep-tag, could be added to 
the C-terminus, rather than a bulky protein. Then the loss or retention of the tag could 
determine whether cleavage has occurred. In Listeria monocytogenes, the absence of an 
active SrtA allows some substrates to be sorted onto the cell wall potentially through 
additional modes of cell wall attachment (Mariscotti et al. 2012). We may be seeing a similar 
situation with CD0183 in C. difficile. To investigate this further, the C-terminal region of 
CD0183 could be substituted with an equivalent domain from another potential sortase 
substrate. A FRET assay to determine cleavage of potential sortase substrate motifs is 
commonly used in other organisms (Marraffini and Schneewind 2006), so further 
experiments with this technique should be undertaken to determine the sortase specificity 
for its substrate motifs as these vary in C. difficile, though all contain the classic “TG” 
cleavage site.  
Attachment of exogenous proteins has been often used as a proof of principle for sortase 
action in other organisms (Marraffini and Schneewind 2006). Antigenically distinct LMW SLP 
from C. difficile strain R20291 was cloned without its LID in an attempt to create a secreted 
protein. However, despite removal of its predicted interaction domain, LMW was still 
associated with the cell rather than secreted into the culture supernatant. In whole cell 
lysates of C. difficile the addition of the CD0183 and CD3246 CWSS to the LMW protein 
151 
 
showed a distinct banding pattern. This suggested migration of the protein with 
peptidoglycan fragments attached. However, further confirmatory experiments proved 
inconclusive. Analysis of other CWSS of potential sortase substrates showed double bands 
compared with the single band observed for LMW alone. These banding patterns are 
reminiscent of those seen with sortase substrates in Streptococcus pyogenes which show 
either close double banding or banding seen for CD0183 and CD3246 CWSSs (Barnett et al. 
2004). Further analysis in C. difficile would be markedly improved with a completely 
secreted protein, as then localisation with the cell following addition of CWSSs would truly 
be conclusive. The LMW SLP could be further truncated, or analysis of the secretome of C. 
difficile may identify a suitable secreted protein. Finally, it remains to be investigated 
whether sortase substrates are secreted through SecA1 or SecA2. SlpA is processed through 
SecA2 (Fagan and Fairweather 2011) and if sortase substrates are normally processed 
through SecA1, this may have resulted in mis-targeting of substrates and aberrant 
processing by sortase.  
In conclusion, it does appear that the sortase mechanism of cell wall attachment is active in 
C. difficile but the role of these substrates in C. difficile is yet to be determined, and the 
mechanism for attachment remains elusive. It is possible that C. difficile utilises a yet 
uncharacterised variation of the sortase pathway which complicates analysis using the 
methods investigated in this thesis.  
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4Chapter 4 Understanding Sortase in C. difficile 
4.1 Introduction 
 
Sortases are membrane bound cysteine proteases that cleave their substrates and perform 
transpeptidation reactions. There are 4 known classes of sortase; A,B,C and D (Dramsi et al. 
2005). Class A sortases cleave an “LPXTG” like motif at the C-terminal of their substrates 
(Schneewind et al. 1992) and covalently attach these substrates onto peptidoglycan 
precursors (Perry et al. 2002). Class B sortases typically cleave an “NXZTN” motif 
(Mazmanian et al. 2002) and covalently attach their substrates onto mature peptidoglycan 
(Marraffini and Schneewind 2005) in S. aureus. Sortase C is expressed shortly before 
sporulation for attachment of mature proteins to the mother cell or the endospore in B. 
anthracis (Marraffini and Schneewind 2006). The sortase annotated as Sortase D is usually 
involved in pili assembly, covalently attaching the LPXTG motif of one pilin subunit to the ε-
amino group of a conserved lysine residue within an YPKN motif (Budzik et al. 2008b). 
Sortases are membrane bound cysteine protease (Mazmanian et al. 1999). Upon secretion 
from the cell the signal peptide is not cleaved, but instead acts as a membrane anchor for 
the enzyme. As sortases are localised to the membrane they can easily come into contact 
with their substrates, which are retained in the cell membrane. Despite extensive research 
into sortases in other Gram positive bacteria such as Staphylococcus aureus and Bacillus 
anthracis nothing is yet known of sortases in C. difficile.  
As shown in Chapter 3, there are at least 7 potential sortase substrates in the C. difficile 630 
genome all of which are transcribed in both exponential and stationary growth phases. 
CD0183 in particular appears to be a true sortase substrate and most of the potential 
sortase substrates are found in the cell wall of C. difficile. RT PCR additionally showed that 
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CD2718, annotated as sortase B (srtB) in the genome, is transcribed in both exponential and 
stationary growth phases. These together suggest that a sortase system is active in C. 
difficile.  
Genomic annotation of the C. difficile 630 genome highlights two potential sortase genes. In 
this chapter, bioinformatic analysis is undertaken to discern whether both are potentially 
functional sortases, and the presence and sequence identity of these genes between strains 
is analysed. Finally, their sequences are compared with known sortases from Staphylococcus 
aureus and Bacillus anthracis to determine which class of sortase they belong to and 
whether they contain the functional residues found to be essential for sortase activity in 
other Gram positive bacteria. 
The essentiality of sortase in C. difficile is discussed in this chapter as difficulties in knocking 
out the sortase gene are encountered. Recently a method for knocking down gene 
expression using an inducible antisense RNA has been developed by Dr Robert Fagan (Fagan 
and Fairweather 2011) which allows for study of genes thought to be essential. This method 
for knocking down expression using antisense and the method of insertionally disrupting the 
gene by ClosTron technology (Heap et al. 2007) are attempted here, facilitating investigation 
into whether sortase covalently attaches its potential substrates to the peptidoglycan cell 
wall in C. difficile.   
Localisation of SrtB in C. difficile is investigated and a dominant negative approach is used to 
supplement results from the sortase insertional mutant and further understand residues of 
importance for SrtB catalysis. The results presented show initial support for the observation 
in other Gram positive bacteria that sortase is a cysteine protease and further clarify that 
CD0183 is a true sortase substrate.  
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4.2 Results 
 
4.2.1 There is at least one sortase gene in C. difficile strains 
 
Analysis of the C. difficile 630 genome reveals two genes annotated as class B sortases; 
CD2718 and CD3146. The “functional” sortase, CD2718, is found in all C. difficile genomes 
sequenced thus far and in 69 of 75 strains analysed by DNA microarray, with its translated 
protein sequences highly conserved between strains (Figure 4.1). The translated protein 
sequence of the second sortase gene, CD3146, contains an inframe stop codon which 
predicts the sortase to be inactive as the catalytic cysteine is not translated (Figure 4.2). This 
pseudo gene is found in a maximum of 58 strains of 75 studied by DNA microarray (Stabler 
et al. 2006), and all sequenced strains which contain this “pseudo-gene” include the in 
frame stop codon (Figure 4.2). When compared with the translated protein sequence of 
Staphylococcus aureus SrtA and SrtB, CD2718 shows higher homology to SrtB and BLAST 
searches hit SrtB in numerous organisms rather than SrtA (data not shown). This suggests 
that CD2718 is a class B sortase. The translated protein sequence of CD2718 was therefore 
compared with the protein sequences of Staphylococcus aureus and Bacillus anthracis SrtB. 
Analysis confirms that CD2718, hereafter referred to as sortase (SrtB), retains the conserved 
catalytic histidine and cysteine of class B sortases (Figure 4.3). This suggests that sortase 
may be active in C. difficile.  
155 
 
 
Figure 4.1 Alignment of CD2718 translated protein sequence from 10 C. difficile strains. 
Ten C. difficile genomes have been sequenced; 630, R20291, 196, BI1, 855, QCD32g58, VPI10463, 
M68, CF5 and M120. The translated protein alignment of sortase (SrtB) in these ten strains shows 
over 93% sequence identity. Strain M68 has two copies of the sortase gene, and CF5 contains 3 
copies of the sortase gene. Green bar indicates 100% conserved residues between strains.  
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Figure 4.2 Alignment of CD3146 “sortase pseudo gene” protein sequence from 5 C. difficile 
strains 
CD3146 is found in 5 of the 10 sequenced strains of C. difficile. The translated protein alignment of 
the “pseudo”-sortase in these strains shows 85% sequence identity. This sortase gene contains an 
in-frame stop codon (marked as an X in strain 630). Strain M68 has two copies of the “pseudo”-
sortase gene, and CF5 contains 3 copies of the “pseudo”-sortase gene. Strain VPI10463 has a 
truncated N-terminal sequence and strain M120 has a truncated C-terminal sequence.  
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4.2.2 Knockdown of sortase expression using antisense technology 
 
As bioinformatic analysis suggested sortase may be active in C. difficile it was important to 
determine whether this was true in laboratory conditions and in vivo. Repeated attempts to 
create an insertional deletion of srtB were unsuccessful (but see later) leading us to believe 
that srtB in C. difficile is an essential gene. Therefore a system for knocking down expression 
was attempted, such as has been used for SecA2 (Fagan and Fairweather 2011). An 
anhydrotetracycline-inducible antisense RNA transcript was designed to cover 175 bp of the 
Figure 4.3 Alignment of CD2718 translated protein sequence with SrtB from S. aureus and B. 
anthracis 
The translated protein sequence of CD2718 shows high sequence identity with SrtB from S. aureus 
and B. anthracis. It contains the key catalytic cysteine and histidine residues typical of this class of 
sortase, in a similar location to these known sortases.  
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5’ end of the genomic srtB (CD2718) transcript. This included the ribosome binding site and 
transcriptional start site of CD2718 (Figure 4.4a) and the DNA encoding this was cloned into 
a plasmid producing pHAS034. Expression of this RNA would ideally knock down expression 
of the sortase gene by targeting and sequestering the 5’ end of the transcript in an RNA 
duplex, thus preventing translation by the ribosome. 
Induction of the srtB antisense with 500 ng/µl anhydrotetracycline (ATc) demonstrated no 
growth defect compared with uninduced and empty vector cultures (data not shown). RT-
PCR was performed on cDNA samples from uninduced and induced samples to analyse 
whether antisense RNA was knocking down transcription of srtB as no antibody against SrtB 
was available to probe protein production. Prior to first-strand cDNA synthesis RNA samples 
were either heated or not heated as the knockdown process performed by the antisense 
RNA is unknown. Without heat treatment the mRNA/antisense RNA duplex is retained, thus 
preventing production of cDNA and representing the mRNA available for translation within 
the cell. However, rather than preventing translation the duplex may instead destabilise the 
mRNA and target it for degradation, thus knockdown may possibly still be observed for 
samples heated prior to cDNA synthesis. However, Figure 4.4b shows that in both 
preparations there is no difference in srtB transcription upon induction of the antisense RNA 
compared with uninduced and vector control samples.  
This is further confirmed by observing the phenotypic effects on potential sortase substrate 
CD0183. If there was no SrtB expression, one would expect CD0183 to no longer be sorted 
into the cell wall, and therefore be trapped in the membrane. However, Figure 4.4c shows 
that upon induction, CD0183 is still found in the soluble fraction of whole cell lysates. Not 
only is it soluble, but distinct banding can be observed. This is suggestive of incomplete cell 
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Figure 4.4 Antisense knockdown of sortase expression 
A: Scheme of genomic location of CD2718 (sortase), mRNA transcript of sortase and the target 
site of antisense RNA. 
B: RNA was extracted from C. difficile 630Δerm carrying pMTL960 (vector) or pHAS034 (sortase 
antisense) with (+) and without (-) ATc (500 ng/ml). RT PCR with oligonucleotides specific for the 
mRNA transcript of sortase were used to analyse the level of sortase expression under antisense 
induction. RNA (RT neg) and cDNA was also subjected to PCR with 16S rRNA specific 
oligonucleotides to check for DNA contamination and confirm cDNA synthesis.  
C-D: C. difficile strain 630Δerm carrying pMTL960 (vector) or pHAS034 (sortase antisense) were 
grown to mid-log with (+) or without (-) Atc (500 ng/ml). Whole cell lysates (C) were prepared and 
separated into whole cell lysate (WC), soluble (S) and membrane (M) fractions. Cell wall 
extractions were prepared (D). CD0183 was detected using antibodies raised against the entire 
protein.   
160 
 
wall lysis where CD0183 is migrating with varying lengths of cell wall still covalently 
attached. Additionally, CD0183 is still observed in cell wall extracts at the same level as 
control samples after induction of antisense (Figure 4.4d). Due to time constraints, RNA 
antisense transcripts of varying lengths could not be designed and investigated. 
4.2.3 Creation of a srtB ClosTron insertion mutant 
 
Antisense knockdown of srtB expression was unsuccessful; therefore continued efforts were 
made to create a ClosTron insertion mutant of srtB in strain 630Δerm. Two ClosTron 
plasmids targeting CD2718 were designed, targeting the gene at position 354 in the 
antisense orientation (pHAS024) and position 510 in the sense orientation (pHAS041). 
Several attempts had been made to create a mutant for both ClosTron designs using 
selection of 5 μg/ml erythromycin with no success. Following the observation that the cwpV 
ClosTron mutant was more sensitive to erythromycin than other mutants in our lab (Zoe 
Seager, personal communication), both insertions were again attempted but with the lower 
selection of 2 μg/ml erythromycin. In this way two independent insertion mutants 
(srtB::erm hereafter called ΔsrtB) were created using pHAS024. Mutants needed to be 
screened not only for insertion of the intron, but also for insertion into the correct copy of 
the srtB; CD2718 not CD3146 the pseudogene (Figure 4.5a). Though only showing ~60% 
sequence identity, Figure 4.5b shows that the insertion site is highly conserved. Primers 
were designed within the genome downstream of both srtB genes (Figure 4.5c) to be 
coupled with the intron EBS primer. Figure 4.5b shows PCR on genomic DNA from these two 
potential mutants confirmed that an insertion event had occurred when compared with wild 
type DNA and that this insertion had occurred in the correction orientation. PCR primers 
binding beyond the srtB genes coupled with the intron EBS primer show that the intron had  
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Figure 4.5 Creation of a sortase ClosTron insertion mutant 
A: Scheme for screening intron insertion. Primers A and B amplify ~400 bp in wild type, and ~1.2 
kb after an insertion event. Primers 722 and 723 amplify within the erythromycin cassette (RAM) 
to confirm presence of the intron. EBS primer coupled with either Primer A or B determines 
orientation of the intron. Primer C is within the genome and can be coupled with EBS primer to 
confirm genomic localisation of the intron.  
B:  Nucleotide alignment of intron insertion site in CD2718 and CD3146, with intron insertion site 
identified with a black triangle.  
C: Scheme showing differing sortase locations within the genome. Screen with EBS primer from 
within intron insertion site (black triangle) and genome specific primer (purple and grey) 
D: Genomic DNA was extracted from both potential sortase mutants (ΔS1 and ΔS2) and wild type 
630Δerm (wt). DNA was screened with the primer pairs described in A, for intron insertion, RAM, 
antisense orientation and insertion into CD2718 rather than CD3146.  
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inserted into the correct copy of srtB. Antibodies are yet to be raised against SrtB so 
removal of expression cannot be confirmed by western blot analysis. The two srtB mutants 
and wild type 630Δerm were grown in TY broth over 8 hours and growth compared. There 
does not appear to be any growth defect in the mutant (Figure 4.6a) and colony morphology 
on BHIS agar is very similar to wild type with regards to texture and outward growth (Figure 
4.6b).  
In the literature, a C-terminal 6 x His-Tag has been shown to not hinder sortase activity, 
whereas a bulky Strep-Tag could potentially affect folding or activity (Ton-That et al. 1999). 
To complement the mutant, CD2718 was amplified from 630Δerm genomic DNA to include 
its ribosome binding site and a C-terminal 6 x His-Tag. This was ligated into both pRPF144 
(containing constitutive cwp2 promoter) and pRPF185 (containing tetracycline inducible 
promoter) (Fagan and Fairweather 2011) creating pHAS058 and pHAS059 respectively. 
These plasmids were conjugated into the mutant and expression could be detected using α-
His antibody (Figure 4.6c). Whole cell lysates of these strains show there was no detectable 
expression of SrtB under control of the cwp2 promoter whereas the inducible tetracycline 
promoter showed expression so this latter system was carried forward for further 
experiments.  
4.2.4 CD0183 localisation in ΔsrtB 
 
As CD0183 had been identified as a potential sortase substrate in Chapter 3 and antibodies 
against this protein are available, its localisation was investigated in the srtB mutant. 
Plasmid pHAS035 was conjugated into the ΔsrtB mutants to allow for a higher level of 
protein for detection. Cultures of wild type 630Δerm and ΔsrtB containing pHAS035 were 
grown in TY broth to mid-log, with and without anhydrotetracycline induction of CD0183  
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Figure 4.6 Phenotype of sortase ClosTron insertion mutant 
A-B: C. difficile strains wild type 630Δerm (wild type) and two ClosTron insertional mutants in 
CD2718 (ΔsrtB1 and ΔsrtB2) were compared for phenotypic differences. 
A: Growth in TY media monitored by measurement of OD600. Cultures were grown over 8 hours 
and error bars indicate standard deviation (n=3).  
B: Colony morphology on BHIS agar grown for 6 days. Images on the left from underneath to 
show spreading, images on the right from above to show texture of colonies.  
C: C. difficile 630 ΔsrtB1 strain containing pMTL960 (vector), Pcwp2-srtB-H6 (Pcwp2) and Ptet-
srtB-H6 (Ptet) were grown in TY media and whole cell lysates were prepared and separated into 
whole cell lysate (WC), soluble (S) and membranes (M). Expression of complementation sortase 
was confirmed by detection with His-tag antibody.   
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expression, and whole cell lysates produced for analysis of CD0183 localisation. Cell wall 
proteins were also extracted separately to investigate CD0183 sorting. 
In Figure 3.17, deletion of the “LPXTG” like domain of CD0183 resulted in a change in its 
localisation. It was expected that upon removal of SrtB expression, a similar phenotype 
would be observed because CD0183 should no longer be sorted onto the cell wall. However, 
Figure 4.7a shows that in whole cell lysates of ΔsrtB1, CD0183 is still observed in the soluble 
fraction. Additionally in Figure 4.7b CD0183 shows its familiar banding pattern in ΔsrtB1 and 
ΔsrtB2 whole cell lysates, indicative of CD0183 covalently attached to cell wall fragments. 
The observation that CD0183 is still sorted is further confirmed by analysing cell wall 
extractions where CD0183 is present in the cell wall of both mutants when overexpressed 
Figure 4.7 CD0183 localisation in ΔsrtB 
A: C. difficile 630 ΔsrtB1 containing pHAS035 was grown in TY with (+) or without (-) ATc (500 
ng/ml). Whole cell lysates were prepared and separated into whole cell lysate (WC), soluble (S) 
and membranes (M).  CD0183 localisation was detected with antibodies raised against the entire 
protein.  
B: C. difficile 630Δerm ΔsrtB1 and ΔsrtB2 containing pHAS035 were grown in TY with (+) or 
without (-) ATc (500 ng/ml). Whole cell lysates (WC) and cell wall extractions (CW) were prepared. 
CD0183 localisation was detected with antibodies against CD0183.   
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from a plasmid (Figure 4.7b). There is only a very faint band for ΔsrtB2 cell wall extract, but 
this may reflect the reduced expression seen in WCLs compared with ΔsrtB1 and the 
observation that the signal for CW is less than that for WCLs in ΔsrtB1.  
4.2.5 The sequence of CD3146 is not altered in ΔsrtB 
 
The phenotype of CD0183 in ΔsrtB was not as expected. Due to the difficulty in mutating 
srtB it had been hypothesised that this was an essential gene, therefore during the process 
of creating the mutant the other copy of srtB (CD3146) may have reverted to a functional 
gene. The CD3146 sequence was amplified by PCR from wild type 630 Δerm and both srtB 
mutants for sequence analysis. Figure 4.8 shows that when sequencing data is aligned the 
sequence of CD3146 is identical in all strains retaining its inframe stop codon.  
 
 
4.2.6 Cell wall proteins in R20291 
 
The genome of 630 contains two srtB genes, one of which is a probable pseudogene. 
Knocking out CD2718 does not appear to alter the localisation of CD0183, yet the sequence 
of CD3146 retains its inframe stop codon. It is unclear however, whether this sortase may in 
fact be functional. The R20291 genome contains a homologue only of CD2718, the 
“functional” sortase. If this not in fact a functional sortase then it would be presumed that 
Figure 4.8 CD3146 sequence in 630Δerm and ΔsrtB 
CD3146 was amplified by PCR from ΔsrtB1 and the DNA sequenced. Alignments of 2 sequencing 
reactions (i & ii) with the sequence from wild type 630Δerm show identical sequences, with the 
region surrounding the in frame stop codon (highlighted in green) shown.  
630Δerm 
ΔsrtB1 i 
ΔsrtB1 ii 
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CD0183 should not be sorted onto the cell wall in R20291. Cell wall extractions were 
performed on wild type R20291 and R20291 expressing CD0183 on a plasmid (pHAS035). As 
can be seen in Figure 4.9a upon extracting the cell wall proteins in R20291, CD0183 is still 
found in the cell wall, suggesting that CD2718 is a functional sortase. Fractionation of cells 
also showed CD0183 to be almost entirely in the soluble fraction of whole cell fractions, but 
following removal of its SPSTG motif it was found in the insoluble fraction as observed in 
other strains (Figure 4.9b). 
 
 
Figure 4.9 CD0183 localisation in R20291 
A: R20291 was grown in TY media and cell wall proteins extracted. CD0183 was detected with 
antibodies against CD0183 from 630Δerm.  
B: R20291 containing pHAS035 was grown in TY with ATc induction (500 ng/ml). Whole cell 
lysates were prepared and separated into whole cell lysate (WC), soluble (S) and membranes (M).  
CD0183 localisation was detected with antibodies against CD0183 from 630Δerm.   
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4.2.7 Knockdown of SrtB activity with a dominant negative sortase 
 
The phenotype of CD0183 localisation was the same in both wild type 630Δerm and ΔsrtB. 
One possible explanation was that during the ClosTron process another gene may have been 
activated to perform the function of sorting the substrates. Despite investigation showing 
that the main candidate, CD3146, was still in its wild-type inactive form, there could be 
another unknown system in place. However, overexpressing a dominant negative form of 
CD2718 may show the effects of a sortase mutant by masking any other sortase phenotypes 
without the time frame required for other genomic alterations. To investigate this, the 
catalytic cysteine 208 of srtB was mutated to an alanine by inverse PCR on pHAS059 
(SrtBWT), giving an inducible dominant negative form of his-tagged sortase (pHAS063), 
named SrtBC208A. This protein should override any action of a cysteine protease performing 
the sorting reaction. This plasmid was conjugated into 630Δerm, ΔsrtB and R20291.  
Expression of these two plasmids was induced with 500 ng/ml anhydrotetracycline (ATc). 
Figure 4.10a shows that there was expression of SrtBWT and SrtBC208A. Cell fractionation 
shows both wild type and mutated sortases to be localised to the membrane fraction. 
Localisation of CD0183 was investigated by cell wall extractions, and Figure 4.10b shows 
that upon induction of SrtBC208A there is a lower quantity of CD0183 on the cell wall 
compared with induction of SrtBWT and vector controls in both wild type 630Δerm and 
ΔsrtB. R20291 growth was severely impacted upon induction with ATc, even for vector 
controls, so analysis was not conclusive and is not shown.  
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Figure 4.10 Dominant negative sortase expression 
C. difficile strains 630Δerm (wild type) and Δsortase1 were grown with pMTL960 (vector), 
pHAS059 (srtB) or pHAS063 (C208A) to mid-log with (+) or without (-) ATc (500 ng/ml).  
A: Whole cell lysates were prepared and separated into whole cell lysates (WC), soluble and 
membrane (m) fractions. Whole cell lysates and membrane fractions were run on a gel and srtB 
and srtBC208A detected with an antibody against their His-Tag. 
B: Cell wall proteins were extracted and detected for CD0183 localisation.  
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4.3 Discussion 
 
Sortase is an important enzyme in many Gram positive bacteria and has been found to be 
often necessary for pathogenesis. There is always a richness of substrates and an 
“embarrassment of sortases” (Pallen et al. 2001), and in this Chapter and Chapter 3 it is 
shown that this is the case in C. difficile also, with more than half a dozen substrates for only 
one functional sortase. However, it is yet to be discovered whether sortase truly is the 
enzyme required to cleave these substrates and covalently attach them to the 
peptidoglycan cell wall. 
In Chapter 3 RT PCR showed that in all growth phases srtB is transcribed in both C. difficile 
630 and R20291, suggestive that the protein is expressed. However, despite indication that 
CD0183 was a sortase substrate which could be prevented from being sorted into the cell 
wall, it was still unknown whether sortase is in fact active in C. difficile and whether its 
substrates are true substrates. As srtB was believed to be an essential gene a knockdown of 
expression with antisense was attempted. However, initial experiments were ineffective. 
This is most likely to be due to the design of the antisense, and a different size of RNA 
transcript, or a transcript covering further up or downstream may have been effective. 
Unfortunately there was not sufficient time to cover all these options during the course of 
the project. However, I was able to eventually create a srtB insertional mutant (ΔsrtB) using 
the ClosTron system, so now a system was in place to investigate the sorting process in C. 
difficile 630. This suggested that srtB is not an essential gene, especially as the second non-
functional sortase gene (CD3146) retained its inframe stop codon upon deletion of the 
supposedly functional sortase CD2718. There are no other known sortase genes in the C. 
difficile 630 genome, however one cannot rule out the possibility of another protein 
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performing a sortase-like function, or another genomic alteration having occurred during 
the ClosTron mutation process. There was no growth defect in the mutant similar to that 
seen in other organisms (Mazmanian et al. 2000), and there was no significant change in the 
colony morphology compared with wild type. However, sortase substrates will be minor 
surface proteins compared with the main S-layer proteins, so it is probably not surprising 
that the mutant is healthy and looks normal under lab conditions. Instead, a number of the 
substrates are putative adhesins, so if they are no longer surface exposed this may affect C. 
difficile colonisation or growth in vivo. It would be interesting to analyse the sortase mutant 
in the mouse and hamster models of C. difficile infection. Despite redundancy within surface 
proteins of C. difficile, this may alter sufficiently the complement of surface proteins such 
that a difference could be seen.  
Investigation into cell wall attachment of potential sortase substrate CD0183 proved to 
open up more questions about the role of SrtB in C. difficile. With an inactivated sortase one 
would expect sortase substrates to no longer be sorted into the cell wall and to be either 
found trapped in the cell membrane, or potentially processed from the membrane and 
therefore reduced within the cell (Mazmanian et al. 1999). However, localisation studies in 
ΔsrtB mutants found CD0183 in the cell wall. There was reduced detection of CD0183 in the 
cell wall of ΔsrtB2 but this may reflect the lower level of expression. Localisation of CD0183 
in this mutant should be further analysed to determine whether this was an artefact of 
expression and loading or a true reduction of CD0183. In both mutants banding could be 
seen, indicative of CD0183 with cell wall fragments attached. When CD0183 was 
overexpressed in the ΔsrtB mutant, it was almost entirely in the soluble fraction of cells, 
suggesting it was not trapped in the sorting process, but being attached to the cell wall. In 
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Listeria monocytogenes it has been observed that with removal of SrtA, some sortase 
substrates are mis-sorted while others still are found in the cell wall, possibly due to 
alternative attachment processes (Mariscotti et al. 2012). This may be the case with sortase 
substrates in C. difficile or purely for CD0183 alone.  
This raised the question of whether CD2718 is the functional sortase. However, it was 
observed that in R20291, a strain which contains only a homologue of CD2718 and not 
CD3146, CD0183 is sorted onto the cell wall. Additionally, deletion of the SPSTG motif of 
CD0183 again renders it insoluble, suggesting that CD0183 is trapped within the membrane, 
incapable of being sorted onto the cell wall. This led to the conclusion that CD2718 must be 
the functional sortase, unless another unknown system was in place in C. difficile.  
Until genome sequencing data is available for the mutants constructed, any other genomic 
alterations which may have occurred during the ClosTron mutation process are unknown. A 
dominant negative approach was therefore taken, to see if sortase cysteine protease 
activity could be masked in a time frame that would prevent natural genetic mutations. 
Dominant negative enzyme expression has been used successfully in C. difficile for other 
genes that are essential or difficult to produce mutants of (de la Riva et al. 2011; Fagan and 
Fairweather 2011). The rationale of dominant negative systems is that over expression on a 
plasmid usually produces a larger quantity of protein than from the genome alone, 
producing a dominant protein. Additionally it may act to trap the substrate with the 
mutated enzyme. Plasmid expression of a mutated (negative) protein should therefore mask 
the effects of the wild type protein. In this way, the catalytic cysteine 208 was mutated to 
an alanine by inverse PCR and expressed under the inducible tetracycline promoter. 
Expression was detectable by western blot and localisation was the same as for expression 
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of wild type SrtB, suggesting the dominant negative sortase was tolerated by the cell. This 
was supported by the observation that there was also no growth defect from expression 
(data not shown). Cell wall extracts showed that there was a slight reduced level of CD0183 
in the cell wall of cells expressing the dominant negative SrtB compared with vector controls 
and complementation with wild type SrtB. This reduction of CD0183 was evident in all 
strains expressing the dominant negative SrtB; 630Δerm and ΔsrtB. It was interesting that 
this reduction was also evident in ΔsrtB, suggesting maybe another cysteine protease was 
performing at least the cleavage of CD0183 in the mutant. This experiment should be 
repeated in a longer time frame to determine whether a more altered phenotype of CD0183 
sorting is observed. Induction with increasing concentrations of ATc to saturation would be 
interesting to observe this dominant negative reaction. To truly determine whether there is 
a difference in the level of CD0183 in the cell wall, densitometry should be undertaken to 
quantify the level of CD0183 in the cell wall under these conditios. Additionally, a loading 
control should be determined for western blot analysis to confirm this is a true reduction in 
CD0183 in the cell wall when the dominant negative sortase is expressed. This experiment 
showed that in C. difficile, SrtB is indeed a membrane bound enzyme and potentially a 
cysteine protease, and that CD0183 is likely to be a cysteine protease substrate. 
 
  
173 
 
5Chapter 5 Dynamics of surface proteins Cwp2 and 
Cwp66 in C. difficile 
5.1 Introduction 
 
The dynamics of the C. difficile S-layer has long been under investigation. The role of Cwp84 
in the maturation of SlpA into high molecular weight (HMW) and low molecular weight 
(LMW) SLP proteins has been shown (Kirby et al. 2009; de la Riva et al. 2011), our 
understanding of the interactions of the HMW and LMW proteins in complex formation has 
been taken further (Fagan et al. 2009), while the S-layer protein CwpV has been 
characterised (Emerson et al. 2009; Reynolds et al. 2011) and its maturation understood 
(Dembek et al. 2012). The interactions between proteins within the S-layer and between the 
S-layer proteins and the cell wall is under investigation, but meanwhile the role of other 
surface proteins needs further investigation.  
The S-layer protein Cwp2 is the most abundant protein on the surface of C. difficile after the 
HMW and LMW SLPs. In Chapter 6 it is shown to be abundant on the surface of clinically 
relevant strains and could be useful in a multi-component vaccine to prevent episodes of 
diarrhoea from C. difficile infection. However, little is known of this protein or its 
interactions with other surface proteins. Additionally, little is known of the expression of 
these proteins. 12 of the S-layer proteins, SLPs and CWPs, are found within a cluster on the 
genome, with slpA, cwp84, cwp2 and cwp66 present amongst others, along with secA2 
which has been shown to be important for S-layer assembly (Fagan and Fairweather 2011). 
As there is such a close proximity between a number of these genes it is likely that there is 
some polycistronic expression, and possibly feedback mechanisms controlling expression.  
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In this chapter a ClosTron insertion mutant of cwp2 is created, and cwp2 is expressed from a 
plasmid for over-expression in wild type 630Δerm and complementation of the mutant. Cell 
interaction phenotypes are observed and the composition of the S-layer is studied. This is 
taken further with the relationship between cwp2 and cwp66 expression investigated.   
 
5.2 Results  
5.2.1 Creation of a cwp2 insertion mutant 
 
In order to characterise the S-layer protein Cwp2 an insertion mutant was created in 
630Δerm using the ClosTron mutagenesis system (Heap et al. 2007). The bacterial group II 
intron was targeted to position 670 of cwp2 in the sense orientation. Figure 5.1 shows 
insertion of the intron was successful by PCR across the insertion site, creating 
630Δerm::cwp2 (hereafter referred to as Δcwp2). Primers targeting the retrotransposition-
activated marker (RAM) show presence of the erythromycin cassette following excision of 
the group I intron.  
5.2.2 Plasmid mediated expression of cwp2  
 
Cwp2 was cloned in its entirety including its ribosome binding site from 630Δerm genomic 
DNA. This cwp2 DNA was inserted into pCBR004 (a pUC19 derivative containing Pcwp2) 
between EcoRI and BamHI restriction enzyme sites, placing cwp2 under control of its own 
promoter, creating pHAS001. Cwp2 and its promoter were then sub-cloned into pMTL960 
between the KpnI and BamHI restriction sites creating pHAS002 providing constitutive 
plasmid expression of Cwp2. This plasmid was conjugated into 630Δerm and Δcwp2 for wild 
type over expression and mutant complementation, respectively. Coomassie blue staining 
175 
 
 
and western blot analysis with antibodies against Cwp2 (Figure 5.2) show there was 
increased expression of Cwp2 from pHAS002 in both wild type and Δcwp2 strains and that in 
the Δcwp2 mutant Cwp2 was no longer detectable in S-layer extracts. Surface localisation of 
Cwp2 was also investigated using immunofluorescence on wild type 630Δerm alone, 
overexpressing Cwp2, the cwp2 mutant and the complemented mutant. As shown in Figure 
5.3, Cwp2 was detected on the surface of wild type 630Δerm while the cwp2 mutant shows 
loss of Cwp2 on the surface. Plasmid expression of cwp2 shows increased Cwp2 on the 
surface of C. difficile compared with wild type and successfully complements Δcwp2.  
5.2.3 Changes in Cwp2 in the S-layer causes slight changes in the dynamics of 
C. difficile 
 
Over expression and deletion of cwp2 could help to determine the function of Cwp2. 
Additionally, as Cwp2 is the most abundant surface protein after the HMW and LMW SLPs, it  
Figure 5.1 Creation of a cwp2 insertion mutant using ClosTron technology 
PCRs were conducted on genomic DNA extracted from the cwp2 mutant (Δcwp2) and wild 
type 630Δerm (WT), with water controls (-ve). Primers amplifying from within cwp2 coupled 
with the EBS primer within the intron confirmed orientation of the intron in the sense 
orientation. PCR for RAM confirms the presence of the erythromycin cassette (following 
group I intron excision) in this mutant and absent in wild type gDNA. Primers spanning the 
intron insertion site show the presence of an intron in the mutant which is absent in wild 
type gDNA, where a smaller PCR product is observed. 
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is likely that an increase in Cwp2 levels, or a removal of Cwp2, will provoke changes in the S-
layer and potentially alter cell surface dynamics. Cultures of C. difficile were plated on BHI, 
BHIS, Braziers and TY agar such that signal colonies could be isolated and grown under 
anaerobic conditions for 4 days. Figure 5.4a shows that strains show slightly different colony 
morphologies on the different agar plates. Wild type C. difficile with empty plasmid show 
tightest colony morphology on TY agar, and most spread out colony morphology on BHIS 
agar. BHI and Braziers agar show similar colony morphology. Meanwhile C. difficile 630Δerm 
expressing pHAS002 show similar colony morphology on each agar plate, with a slightly 
tighter colony morphology on TY agar. Additionally colonies appear darker on BHIS and TY 
agar. The opposite phenomenon occurs for Δcwp2 with empty plasmid where the tightest 
colony morphology is seen on BHI agar, and most spread out colony morphology on TY agar. 
BHIS and Braziers have similar intermediate colony morphology. As with 630Δerm 
expressing pHAS002, Δcwp2 expressing pHAS002 shows similar colony morphology on all 
Figure 5.2 Manipulation of cwp2 
S-layer extracts were prepared of wild type 630Δerm containing empty vector (WT), wild type 
containing pHAS002 for over expression of cwp2 (WT + pHAS002), the cwp2 mutant 
containing empty vector pMTL960 (Δcwp2) and the complemented cwp2 mutant (Δcwp2 + 
pHAS002). Extracts were Coomassie blue stained and probed with mouse anti-Cwp2. An 
~66.4 kDa protein representing Cwp2 is seen in WT and WT+pHAS002 (indicated with the 
black arrow). In the mutant there is an absence of Cwp2 expression, which is restored by 
complementation with pHAS002. 
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agar plates, with darker colonies observed on BHIS and TY agar.  
Comparing morphology between strains, colony morphology does not significantly change 
between wild type C. difficile and Δcwp2, except on TY agar where the mutant has a much 
larger colony size than wild type. However, increased Cwp2 expression causes a tighter 
colony morphology compared with wild type on all agars, most markedly in over expression 
of cwp2 in wild type cells where the colonies are smaller, and denser. The complemented 
Figure 5.3 Cwp2 on the surface of C. difficile following manipulation of cwp2 
C. difficile strains were grown to exponential or stationary phase in TY broth with 
thiamphenicol (15µg/ml). Cells were harvested, fixed and stained with antibodies raised 
against the full length protein of Cwp2. 
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mutants show a phenotype part way between wild type and over expression, as there is 
more Cwp2 expression from pHAS002 than in wild type genomic expression.   
It is possible that this tighter colony morphology in the wild-type over-expressing Cwp2 is 
due to increased interaction between cells. An aggregation assay was set up to determine 
whether increasing or removing cwp2 expression changed aggregation of C. difficile liquid 
cultures. However, as can be seen in Figure 5.4b no large difference in aggregation between 
these strains was observed, although there is a slight increase in aggregation when cwp2 is 
over expressed. It is therefore unlikely that Cwp2 is involved in an interaction between C. 
difficile cells which would cause aggregation. 
Western blot analysis was undertaken to determine whether changes in the level of Cwp2 
alter the composition of the S-layer, as observed in other mutants such as Δcwp84 (de la 
Riva et al. 2011). S-layer extracts and culture supernatants were prepared from 630Δerm 
and Δcwp2. Samples were analysed for levels of LMW and HMW SLP, Cwp84 and Cwp66 as 
these are important surface proteins and we had antibodies readily available. As Figure 5.5 
shows, all surface proteins are present at the same level in both strains, with the exception 
of Cwp66. In Δcwp2, Cwp66 is no longer detected on the S-layer extract. Analysis of the 
culture supernatants shows that Cwp66 is not present in higher levels in Δcwp2 than in wild 
type cultures, suggesting that in the mutant, Cwp66 is not shed from the cell surface. This 
suggests that expression of cwp66 or its transport to the cell surface is altered in the Δcwp2 
mutant.  
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Figure 5.4 Cell dynamics change following genetic manipulation of cwp2 
A: Cultures of C. difficile were plated onto BHI, BHIS, Braziers and TY agar. Plates were 
incubated under anaerobic conditions for 4 days and imaged from below the plates using a 
transmissive flat-bed scanner.  
B: C. difficile strains were grown under standard conditions. Cells were harvested by 
centrifugation and resuspended to OD 20 in round bottomed glass tubes. After 24 hours the 
tubes were photographed. Over-expression of Cwp2 promoted a slight increase in cellular 
aggregation.  
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5.2.4 Cwp66 protein expression is reduced in the cwp2 knockout 
The lack of Cwp66 on the surface in the cwp2 mutant was investigated further. S-layer 
extracts and supernatants were prepared from 630Δerm and Δcwp2 containing either 
empty vector (pMTL960) or over expressing Cwp2 (pHAS002) at exponential, early 
stationary and late stationary growth phases. Coomassie blue staining shows similar levels 
of proteins extracted from the S-layer in all growth phases (Figure 5.6a), with levels of 
Figure 5.5 Composition of the S-layer in the cwp2 mutant 
Cultures of C. difficile Δerm (wt) and Δcwp2 (Δ2) were grown to mid-log and S-layer 
preparations made with low pH glycine and culture supernatants concentrated. Samples 
were analysed by immunoblotting for Cwp2, Cwp66, Cwp84 and the HMW and LMW SLPs 
with the relevant antibodies. 
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proteins found in the supernatants increasing as growth progresses (Figure 5.6b). Cwp2 and 
Cwp66 were analysed by western blot to observe protein expression and localisation. As can 
be seen in Figure 5.6, levels of Cwp2 are as previously observed in all growth phases, with 
pHAS002 increasing levels of Cwp2, and complementing the loss of cwp2 in the mutant. As 
growth progresses, more Cwp2 is shed into the supernatants as is expected from a 
constitutively expressed protein. In wild type C. difficile 630Δerm expressing either empty 
vector or pHAS002, Cwp66 is clearly detectable in surface extracts of the bacterium in all 
growth phases. There is increased release of Cwp66 into the supernatant as growth 
progresses, with more degradation of Cwp66 visible in late stationary phase supernatants 
(Figure 5.6b). However, in Δcwp2 during exponential phase there is marked reduction of 
Cwp66 on the cell surface, without the protein being shed into the culture supernatant. 
Additionally Cwp66 is not restored to the cell surface by expression of cwp2 from pHAS002 
in the complemented mutant. This suggests that it is not simply expression of cwp2 that is 
required for Cwp66 to be found on the surface, but specifically expression of cwp2 at its 
genomic locus. There does appear to be a slight increase in Cwp66 on the surface in the 
complemented mutant, which was observed in other repeat experiments (data not shown). 
In later growth phases there does not seem to be an increase in Cwp66 on the cell surface in 
the cwp2 mutant in the western blot shown. Repeats, not shown, do sometimes show an 
increase in Cwp66 at stationary phase, but this is only slight, and not fully restored to wild 
type levels. The restoration of Cwp66 on the surface therefore does not seem to be strongly 
or consistently controlled.  
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Figure 5.6 Changes in Cwp66 on the surface of C. difficile 
Cultures of C. difficile were grown to exponential, early stationary and late stationary growth 
phases. S-layer preparations (A) and concentrated supernatants (B) were analysed for the 
presence of Cwp2 and Cwp66 with Coomassie Blue staining and immunostaining with either 
antibodies against Cwp2 or Cwp66 as indicated. Lanes: 1: 630Δerm + empty vector, 2: 
630Δerm + pHAS002, 3: Δcwp2 + empty vector, 4:  Δcwp2 + pHAS002. 
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Figure 5.7 Cwp66 on the surface of C. difficile following manipulation of cwp2 
C. difficile strains were grown to exponential or stationary phase in TY broth with 
thiamphenicol (15 µg/ml). Cells were harvested, fixed and stained with antibodies raised 
against the C-terminus of Cwp66. 
A: Stationary phase cultures of Δcwp66 containing empty vector (pMTL960) and 630Δerm 
over-expressing Cwp66 (pZLS002) 
B: C. difficile strains 630Δerm and Δcwp2 expressing empty vector (pMTL960) or Cwp2 
(pHAS002) at exponential and stationary phases of growth. 
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This phenotype was analysed further by surface immunostaining of C. difficile strains for 
Cwp66 (Figure 5.7). Exponential and stationary phase cultures were harvested, fixed and 
stained for Cwp66. These were compared to wild type cells over expressing cwp66 
(pZLS002) and a ClosTron mutant of cwp66 (Δcwp66) (both produced by Zoe Seager). As can 
be seen in Figure 5.7, this data confirms what was observed by gel analysis of the surface 
extracts. Cwp66 staining on the surface of Δcwp2 was absent in exponential phase cultures, 
and partial recovery can be seen in stationary phase. One bacterium stained with anti-
Cwp66 was seen in the Δcwp2 in exponential phase sample, which is possibly residual from 
when the overnight culture was sub-cultured. There appears to be more Cwp66 found on 
the surface of Δcwp2 when the mutant is complemented with plasmid expression of cwp2.  
To determine whether there was a block of cwp66 expression or of Cwp66 export from the 
cell, whole cell lysates were analysed for Cwp66 expression. As can be seen in Figure 5.8 
there is the same pattern of Cwp66 protein expression as found in glycine preps and surface 
immunostaining. This suggests that the variation in Cwp66 level on the surface is driven by 
alterations in genomic expression.  
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5.2.5 Genomic analysis of cwp2-CD2790-cwp66 
 
Following observation of changes in Cwp66 protein expression upon alterations in cwp2 
expression, genomic analysis was undertaken. The structure of the genome cluster 
comprising cwp2 and cwp66 is shown in Figure 5.9a. cwp2, CD2790 and cwp66 are present 
within a ~4.5 kb locus. The cwp2 promoter, which is believed to provide constitutive 
expression, is upstream of cwp2, while the cwp66 promoter is predicted to be within the 3’ 
region of CD2790. This promoter has recently been shown to be under control of the RNA 
polymerase sigma facter SigH, with stationary phase up-regulation of cwp66 expression 
(Saujet et al. 2011). The close proximity of these genes suggests that they may be expressed 
Figure 5.8 Changes in Cwp66 in whole cells of C. difficile 
Cultures of C. difficile were grown to exponential and late stationary growth phases. Whole 
cell lysates were prepared and analysed for the presence of Cwp2 and Cwp66 with Coomassie 
Blue staining and immunostaining with either antibodies against Cwp2 or Cwp66 as indicated. 
Lanes: 1: 630Δerm + empty vector, 2: 630Δerm + pHAS002, 3: Δcwp2 + empty vector, 4:  
Δcwp2 + pHAS002. 
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in a polycistronic manner, with additional cwp66 expression in stationary phase controlled 
by its native promoter. To investigate this hypothesis, semi-quantitative RT-PCR analysis was 
designed, as shown in Figure 5.9b.  
 
5.2.6 cwp2-CD2790-cwp66 form polycistronic RNA which is disrupted by the 
cwp2 mutation 
 
Transcriptomic analysis of the cwp2-CD2790-cwp66 cluster was undertaken using C. difficile 
strains analysed above. Primers were designed to amplify 400 bp of cwp2 before and after 
the ClosTron insertion site (a and b), cwp2-CD2790 intergenic region (c), CD2790-cwp66 
intergenic region (d) and cwp66 (d) as shown in Figure 5.9b, with the entire intergenic 
region between cwp2 and cwp66 amplified with a combination of the intergenic primers (f). 
RNA was extracted from wild type 630Δerm with empty vector, wild type over expressing 
Cwp2 (pHAS002), Δcwp2 with empty vector, and the complemented mutant at exponential, 
Figure 5.9 cwp2-CD2790-cwp66 gene cluster analysis 
A: The gene cluster compromising cwp2, CD2790 and cwp66. Structural genes are shown with 
white arrows, curved arrows demonstrate predicted promoter sites and black triangle shows 
ClosTron intron insertion site in cwp2. SigH has been previously shown to control Pcwp66 
(Saujet et al. 2011).  
B: PCR screening primer binding sites within this cluster used to analyse mRNA expression 
and determine the presence of polycistronic sequences. Black bars show predicted products 
from these primer pairings, labelled for convenience. a-e amplify approximately 400 bp of 
DNA, f amplifies approximately 1 kb of DNA.  
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early stationary and late stationary growth phases. cDNA was produced and analysed with 
semi-quantitative 24 cycle Taq PCR. As shown in Figure 5.10, 16S rRNA PCR confirms 
uniform production of cDNA from all samples. Primers targeting cwp2 pre and post intron (a 
and b) show transcription of cwp2 and increased transcription by the presence of pHAS002. 
A faint transcript post-intron is visible in Δcwp2 in exponential phase but this is absent by 
late stationary phase. The ClosTron type II intron contains multiple stop codons but no 
transcriptional terminator. Thus, the faint transcripts observed are probably due to 
transcriptional read through, but the stop codons prevent correct translation into Cwp2 and 
appear to destabilise the RNA transcript as transcription is completely lost by stationary 
phase. Transcripts for the complemented mutant come from the plasmid copy of cwp2. 
Primers for intergenic regions cwp2-CD2790 and CD2790-cwp66 show transcripts in wild 
type cells carrying both empty plasmid and pHAS002. This shows that in wild type 630Δerm 
there is polycistronic expression of cwp2-CD2790-cwp66, which is further verified with PCR 
spanning the region between cwp2 and cwp66. In Δcwp2 expressing either empty vector or 
pHAS002 there is a marked reduction in intergenic transcription between cwp2 and CD2790, 
with complete loss between CD2790 and cwp66, and thus complete removal of polycistronic 
RNA spanning cwp2 and cwp66.  
cwp66 is transcribed in wild type 630Δerm expressing empty vector and pHAS002, with 
slightly reduced levels of transcription in late stationary phase. In Δcwp2 containing empty 
vector or pHAS002, there is reduced transcription of cwp66 in all growth phases, with 
almost complete loss of cwp66 transcription in Δcwp2 + empty vector in late stationary 
phase. There appears to be an increase in cwp66 transcription in stationary phase cultures 
in Δcwp2 + pHAS002. 
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5.2.7 cwp66 expression is controlled by its own promoter and possibly the 
cwp2 promoter 
 
To determine where cwp66 transcription begins, 5’ RACE was undertaken. RNA was 
extracted from wild type 630Δerm and Δcwp2 at exponential and stationary phases of 
growth in TY media. The 5’ RACE (Invitrogen) protocol was followed (Figure 5.11); briefly, 
cDNA was produced using a specific primer within cwp66 and a dC tail added to the 3’ end 
of cDNA. A nested primer within cwp66 coupled with a primer binding to this “tail” were 
used in a standard Taq reaction, 35 cycles for 3 minutes 30 seconds to determine the length 
Figure 5.10 RT-PCR analysis of cwp2-CD2790-cwp66 cluster expression 
Cultures of wild type and mutant C. difficile were grown to exponential, early stationary and 
late stationary growth phases. RNA was extracted and cDNA generated. PCR was conducted 
with primer pairing shown in Figure 5.9, with 16S rRNA amplification to confirm cDNA 
production. Lanes: 1: 630Δerm + empty vector, 2: 630Δerm + pHAS002, 3: Δcwp2 + empty 
vector, 4:  Δcwp2 + pHAS002. 
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of mRNA upstream from cwp66.  Negative controls are performed with dC negative 
samples, where cDNA was not tailed, and therefore the tail-specific primer will not bind for 
PCR amplification of the transcript. From the predicted start site of Pcwp2, a band of 
approximately 3,030 bp is expected and from Pcwp66 a band of approximately 480 bp.  
 
As Figure 5.12 shows, there are only transcripts visible for wild type samples. There is a 
smear in exponential phase, possibly due to multiple lengths of DNA sequences, while there 
is a stronger band at approximately 400 bp in stationary phase. The 400 bp band probably 
represents transcription from Pcwp66, a stationary phase induced promoter, while the 
smear may represent transcripts from further upstream, possibly representing 
transcriptional readthrough from Pcwp2. The lack of any defined transcripts in the Δcwp2 
Figure 5.11 Overview of Invitrogen 5’ RACE procedure 
A gene specific primer (GSP1) anneals to a defined locus on mRNA transcript to synthesise 
cDNA. RNA is degraded and the purified single stranded cDNA is dC tailed. A primer 
recognising the dC tail (Abridged Anchor Primer) is coupled with a second gene specific 
primer (GSP2) nested within the transcript for amplification of cDNA. (From Invitrogen 5’ 
RACE manual).  
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mutant suggests either there is no transcription from either promoter, or that no cDNA was 
produced. 
 
 
 
 
Figure 5.12 5’ RACE shows cwp66 is under control of its own promoter, and possibly the 
cwp2 promoter 
A: Gene cluster and two possible transcripts for cwp66 from 5’ RACE analysis. The long 
transcript originates from the cwp2 promoter, while the shorter transcript originates from 
the cwp66 promoter under the control of SigH.  
B: Cultures of C. difficile were grown to exponential (E) and stationary (S) growth phases. RNA 
was extracted and cDNA generated with a primer within cwp66. cDNA was dC tailed and PCR 
was conducted with a primer binding to the dC tail and a primer nested within cwp66. 
Negative controls were not dC tailed. gDNA control shows PCR from the cwp2 ribosome 
binding site to the cwp66 nested primer. 
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5.3 Discussion  
 
Cwp2 is the most abundant S-layer protein after the HMW and LMW SLPs. As discussed in 
Chapter 6, Cwp2 has potential as a vaccine component to prevent symptoms of C. difficile 
infection but does not appear to affect the levels of colonisation in the gut in the mouse 
model of C. difficile colonisation compared with controls. The translated protein sequence 
of Cwp2 is highly conserved between strains, whereas proteins involved in colonisation or 
virulence often show variation to allow for evasion from the host immune system. It is 
therefore unlikely to have a role in colonisation, but any other role remains elusive. In this 
chapter a ClosTron insertion mutant of cwp2 was created (Δcwp2) and plasmid expression 
of cwp2 was achieved for wild type over expression and Δcwp2 complementation. Cwp2 null 
mutants were easily generated and Δcwp2 cultures grow as well as wild type cultures (data 
not shown), showing that Cwp2 is not essential for cell viability. Why then is there such an 
abundance of Cwp2 on the cell surface? Unfortunately from this study no answers could be 
found. Δcwp2 shows very similar colony morphology to wild type C. difficile. However, over 
expression of cwp2 does lead to“tighter” colony morphology, with an intermediate colony 
morphology observed in the complemented mutant. In this complemented stain, S-layer 
extracts contain higher levels of Cwp2 on the cell surface than in wild type. This suggests a 
possible role of Cwp2 in maintaining interactions between C. difficile cells, perhaps also 
preventing cell motility. However, when this was investigated further with an aggregation 
assay there was no significant difference between aggregation of wild type C. difficile 
containing empty vector or over expressing cwp2. A flagella motility assay could be 
undertaken to investigate any change in cell movement compared with wild-type cells, 
rather than a cell interaction difference between these strains.  It would be interesting to 
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take this further and analyse these strains in a biofilm assay in an attempt to investigate 
whether or not Cwp2 has a role in C. difficile – C. difficile interaction. However, these assays 
are artificial as cwp2 is constitutively expressed in laboratory growth conditions where it is 
found at the same level on the cell surface at all growth phases. Therefore any true role in 
cell interaction would be observed between wild type and the mutant and in this case 
colony morphology is almost identical. Biofilm data, however, may differ.  
Changes in expression within the S-layer cluster on the genome have been shown to affect 
the composition of the S-layer. Deletion of cwp84 showed lack of SlpA maturation and loss 
of proteins such as Cwp66 into the culture supernatant (de la Riva et al. 2011), while 
manipulation of secA2 expression affected the translocation of some surface proteins 
(Fagan and Fairweather 2011). Analysis of the surface of Δcwp2 and culture supernatant 
showed Cwp66 was no longer found in the S-layer yet was not released into the culture 
supernatant as observed in Δcwp84. Complementation of the mutant with plasmid 
expression of cwp2 did not restore Cwp66 to the surface. It was therefore unlikely to have 
been due to altered translocation that Cwp66 was not found on the surface, especially as 
analysis of whole cell lysates confirmed that total Cwp66 production was absent or reduced 
in Δcwp2 expressing either empty plasmid or pHAS002. Interestingly, as growth progresses, 
Cwp66 begins to be restored on the cell surface, so analysis of gene expression was 
undertaken to understand further how cwp66 expression is controlled.  
Analysis of the genome cluster around cwp2 and cwp66 showed that these genes are co-
linear, along with CD2790 a putative deacetylase. It has previously been suggested that 
these genes may be expressed in a polycistronic sequence (Savariau-Lacomme et al. 2003). 
In this chapter, polycistronic expression was confirmed in cells grown in exponential phase, 
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but was almost completely absent by stationary phase. This may reflect observations in 
other organisms that not all genes within polycistronic sequences are expressed to the same 
level (Hennecke et al. 2001). Additionally, this may explain why cwp66 has its own 
stationary phase induced promoter, potentially to compensate for loss of polycistronic 
expression. Cwp2 transcript levels were raised by expression from plasmid pHAS002, but 
genomic expression of cwp66 was unaffected by this increase, suggesting there is no 
feedback from cwp2 plasmid expression and the effect observed is due to transcriptional 
read through. Insertional inactivation of cwp2 caused a marked reduction in transcription of 
this locus. Faint transcripts can still be observed for cwp2 post intron insertion and for cwp2-
CD2790. This is likely due to the intron containing a large number of stop codons but no 
transcriptional terminator. Therefore, despite transcriptional read through, cwp2 would not 
be translated in its entirety due to the stop codons. Additionally the transcript would be less 
stable, with RT PCR products becoming completely absent in stationary phase cultures. In 
the Δcwp2 mutant, there is complete removal of the CD2790-cwp66 transcript and markedly 
reduced transcription products for cwp66. Interestingly, in stationary phase cells there is a 
recovery of cwp66 transcription in Δcwp2 only when pHAS002 is expressed. This could be 
due to feedback processes, or other stresses on the cell. Cwp66 has its own additional 
promoter which has been shown to be controlled by SigH (Saujet et al. 2011), which is 
activated in stationary phase. It would therefore have been expected that cwp66 expression 
would have increased in stationary phase for both Δcwp2 + empty vector and Δcwp2 + 
pHAS002. In Δcwp2 + pHAS002 there may therefore be more stress on the cells than in 
Δcwp2 + empty vector, causing increased SigH expression and activation of target genes, 
possibly due to the strain of over-expressing cwp2 from pHAS002. This could possibly be 
investigated further by measuring levels of SigH in these two strains to see if there is an 
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observable difference in SigH expression and activity. Toxin production could also be 
observed to see if for any reason this is altered between the mutant and complemented 
mutant, reflecting changes in stress levels. One thing certain, is that expression of cwp66 is 
highly reliant on transcriptional read through from the cwp2 promoter, as even activation of 
its own promoter does not bring levels of Cwp66 up to those of wild type C. difficile 
630Δerm and does not seem to be consistently activated under laboratory conditions. The 
activation of Pcwp66 in vivo remains to be understood.  
To determine whether this is the case, a silent mutation could be created (Cartman et al. 
2012; Heap et al. 2012) to remove Pcwp2, as this would show more clearly the effect of this 
promoter on cwp66 transcription. It would be interesting to observe whether Cwp66 
requires the presence of Cwp2 on the surface to be stably maintained on the cell surface by 
expressing Cwp66 from a plasmid in Δcwp2. Additionally it should be noted that for any 
future studies investigating the role of Cwp2, for example in animal models of infection, 
care should be taken to minimise the effects on cwp66 to rule out any phenotypes 
dependent on this protein. It would be interesting to create an in frame deletion of the 
majority of cwp2 and investigate whether this retains the polycistronic expression of cwp66, 
in contrast to what we see with the ClosTron mutant. If the polycistronic expression is 
unaffected, this would be a more interesting tool for determining the true phenotype and 
role of Cwp2.   
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6Chapter 6 Investigating Cwp2 as a potential vaccine 
candidate 
 
6.1 Introduction 
 
Vaccines against C. difficile infection currently in development are targeted against the 
toxins released by C. difficile during infection (Greenberg et al. 2012; Tian et al. 2012; Wang 
et al. 2012). However, despite prevention of death in the hamster model of C. difficile 
infection, animals vaccinated in this way still show symptoms of disease and are still highly 
colonised (Gill Douce, personal communication). It is therefore of interest to investigate 
whether another component could be added to a toxin-based vaccine which could prevent 
colonisation and thus enhance the efficacy of the vaccine.  This chapter investigates 
whether addition of surface proteins from C. difficile 630 can prevent symptoms of disease 
and colonisation in the hamster and mouse models of C. difficile infection.   
The surface of C. difficile is believed to be important for the initial colonisation of the 
intestine, with SLPs facilitating binding to host tissues (Calabi et al. 2002) and in strain C253, 
SLPs have been shown to induce the release of inflammatory cytokines from resting 
monocytes (Ausiello et al. 2006). The major surface proteins of C. difficile are the high 
molecular weight (HMW) and low molecular weight (LMW) S-layer proteins (SLPs) which 
form a complex (Fagan et al. 2009). The low molecular weight SLP is the surface exposed 
component of the protein complex, and elicits a strong immune response (Cerquetti et al. 
1992). An immunisation study using SLPs as antigens showed some protective effect in 
hamsters (Ni Eidhin et al. 2008). However, there is high sequence diversity between strains, 
and these proteins can show different migration patterns between strains by SDS PAGE 
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(McCoubrey and Poxton 2001). The LMW proteins from strains can be antigenically distinct, 
with no cross reaction occurring against LMW from one strain with antibodies raised in 
another, such as between R20291 and 630 (McCoubrey and Poxton 2001). This would 
prevent the SLPs from being vaccine antigens as they would not be expected to provide 
cross strain protection. This sequence variation and lack of immunological cross-reaction is 
also evident in other surface proteins, including Cwp66 (Savariau-Lacomme et al. 2003; 
Lemee et al. 2005) and CwpV (Reynolds et al. 2011). For a vaccine to be effective it must 
cover a broad, if not full, spectrum of C. difficile strains. In this chapter, Cwp2 is investigated 
as a candidate for inclusion in a multi-component vaccine. Bioinformatic analysis is 
undertaken, its characteristics described and its potential as a vaccine candidate is 
discussed.  
Purification of proteins is usually performed recombinantly using E. coli expression systems. 
However, expression of a heterologous protein in E. coli does have its complications and 
downfalls, for example mis-folding of proteins can occur. In the case of vaccine 
development it is of the utmost importance for proteins within the vaccine to be folded 
correctly such that they will generate an immune response against the protein upon 
infection in vivo. In this chapter, purification of Cwp2 from C. difficile is described, showing 
that native expression systems can be used to produce high levels of protein for purification 
and analysis. This is one of the first examples of recombinant protein purification from C. 
difficile.  
In vitro analysis of potential vaccine candidates only takes vaccine development so far. It is 
therefore necessary to investigate the potency of vaccine components in vivo in animal 
models of C. difficile infection. Both the hamster and mouse models of C. difficile infection 
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are used in this chapter to investigate whether a full S-layer preparation of C. difficile can 
reduce or prevent colonisation as well as investigating Cwp2 as a single vaccine candidate 
from this preparation. The hamster model of infection is a suitable model for observation of 
acute, severe diseases, whereas in the mouse model of infection one can more clearly 
observe changes in colonisation of the enteric system with C. difficile.  
6.2 Results 
6.2.1 Genome analysis indicates Cwp2 as a potential antigen  
 
Of the minor cell wall proteins, Cwp2 is the most abundant and can be easily seen in 
Coomassie blue stained S-layer extracts from vegetative cells (Figure 6.2). Its expression 
appears to be under control of a constitutive promoter, resulting in Cwp2 expression in all 
growth phases (see Chapter 5). It is also amongst the first surface proteins to be expressed 
upon germination of C. difficile spores (Marcin Dembek Plos One in press). There are 
currently 8 C. difficile genome sequences available for analysis at Sanger 
(www.sanger.ac.uk)  630, 196, 855, BI1, CF5, M68, M120 and R20291, plus several more at 
other institutes, e.g. QCD32G58 and VPI10463. The DNA sequence corresponding to cwp2 
was found in all strains, and bioinformatic analysis of these sequences was performed and 
showed high DNA sequence identities between strains of C. difficile which in turn leads to 
high translated protein sequence identity between strains (Figure 6.1). This contrasts the 
major SLPs which can show considerable heterogeneity between strains (Calabi and 
Fairweather 2002). Additionally, genome microarray analysis (Stabler et al. 2006) shows 
cwp2 to be present in all 75 C. difficile strains analysed. This cross strain presence and high 
sequence identity makes it an interesting candidate for a vaccine component.  
198 
 
 
 
6.2.2 Cwp2 is found on the surface of clinically relevant strains 
 
To determine whether the DNA microarray and bioinformatic analysis translated to true 
characteristics of Cwp2, its expression was analysed in a panel of 7 clinically relevant strains. 
These strains were ribotypes 001 (R13537), 012 (630), 017 (M9), 027 (R20291), 078 (M120), 
106 (NF2029) and a strain of unknown ribotype (AY1). S-layer extracts were prepared from 
each of these strains and analysed by Coomassie Blue Staining and immunoblotting with 
Figure 6.1 Alignment of Cwp2 protein sequence from a number of C. difficile strains 
Ten C. difficile genomes have been sequenced; 630, 855, BI1, CD196, CDM120, CDR20291, CF5, 
M68, QCD32g58 and VPI10463. The translated protein alignment of Cwp2 in these ten strains 
shows over 95% sequence identity. Green bar indicates sequence identity.  
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mouse anti-Cwp2 (α-Cwp2) antibodies. Mouse α-Cwp2 antibodies had previously been 
raised against recombinant Cwp2 cloned from strain 630. As can be seen in Figure 6.2, 
under Coomassie Blue staining a band at 66 kDa corresponding to Cwp2 can be seen in all 
strains in these S-layer preparations. This is further verified by Western Blot analysis with α-
Figure 6.2 Cwp2 is found in the S-layer of clinically relevant strains of C. difficile 
C. difficile strains were grown overnight in TY broth and S-layer extracts prepared in low pH 
glycine.  
A: Coomassie blue staining of S-layer extracts. Black arrow indicates band representing Cwp2. 
White arrow indicates LMW SLP. 
B: Western blot analysis with antibodies raised against Cwp2 from strain 630 (1:50,000 dilution). 
Black arrow indicates Cwp2.  
C: Western blot analysis with antibodies raised against Cwp66 from strain 630 (1:25,000 dilution). 
Black arrow indicates Cwp66.   
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Cwp2. This antibody successfully detects Cwp2 in all strains without any cross-reaction with 
other surface proteins. Meanwhile, western blot analysis with antibodies raised against the 
C-terminus of Cwp66 from C. difficile 630 detected Cwp66 only in strains 630 and M9. The 
LMW SLP can be seen by Coomassie staining to vary in size between strains, which 
corresponds with sequence diversity.  
 
 
As Cwp2 is known to be present in the S-layer, it was interesting to determine whether it is 
surface exposed in all these strains, which would enable its recognition by the immune 
system. Bacteria were therefore immunostained and observed at the cellular level.  Figure 
Figure 6.3 Cwp2 is present on the surface of clinically revelant strains of C. difficile 
C. difficile strains were grown overnight in TY broth. Cells were harvested, fixed and stained with 
antibodies raised against the full length protein of Cwp2 from C. difficile 630 (ribotype 012). 
Strains are denoted with their ribotype and strain number in brackets.   
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6.3 shows that Cwp2 is surface exposed in these clinically relevant strains. This high 
sequence homology between strains, surface exposure and abundance suggest Cwp2 would 
be an attractive candidate for inclusion in vaccine trials.  
6.2.3 Preparation of protein antigens for vaccination trials 
Previous studies have shown that using non-toxic fragments of the C. difficile toxins A and B 
as antigens can confer protective properties in the hamster model of C. difficile infection 
(Lyerly et al. 1990); Gill Douce personal communication). However the animals are 
constantly colonised with C. difficile and shedding of bacteria in the faeces still occurs, along 
with episodes of diarrhoea (Gill Douce, personal communication). The rationale was to 
investigate Cwp2 as a candidate for prevention of colonisation in this multi-component 
vaccine. Animals would be immunised with receptor binding domain repeats of toxin A and 
toxin B alone, or with the addition of purified Cwp2 or an S-layer preparation (which 
contains all S-layer surface proteins).   
 E. coli containing plasmid p56HIS was obtained from Gill Douce in Glasgow. This expressed 
14 C-terminal binding repeats (25-38) of toxin A from C. difficile strain VPI 10463, N-
terminally His-Tagged (Figure 6.4a). To generate a toxin B antigen, all 24 C-terminal binding 
repeats of Toxin B were amplified from C. difficile 630 and cloned into pET28a between NcoI 
and XhoI sites such that the repeats had a C-terminal His-Tag, creating pHAS014 (Figure 
6.4b). These two fragments in combination have been shown to produce a protective effect 
from C. difficile infection in hamsters (Gill Douce, personal communication). Both plasmids 
are under the control of the inducible T7 promoter and were transformed separately into E. 
coli Rosetta to improve expression of the T-A rich C. difficile genes. Cultures were grown in 
Overnight Express Instant TB Media (an auto-induction media). Both toxin fragments were 
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Figure 6.4 Protein structures and cloned regions of Toxin A, Toxin B and Cwp2 
A-B, Toxin A and Toxin B showing N-terminal enzymatic domains (catalytic and cysteine protease 
for internal cleavage), translocation domain and C-terminal receptor binding domain. Lines 
indicate receptor binding repeats.  
A: Toxin A, C-terminal repeats 25 - 38 cloned with an N-terminal His-Tag 
B: Toxin B, entire C-terminal receptor binding domain cloned with a C-terminal His-Tag 
C: Cwp2, containing 3 C-terminal cell wall binding repeats, cloned in its entirety with a C-terminal 
His-Tag  
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expressed as soluble proteins and were purified on a Nickel His-Trap column using an ÄKTA-
FPLC. Toxin fragments showed very high purity, and only minor degradation of Toxin B was 
observed by western blot. This was possibly due to multiple freeze-thaw cycles of the 
sample as the earlier coomassie staining shows a single distinct band (Figure 6.5a-c).  
 
 
Figure 6.5 Purification of proteins for immunisation trials 
Fragments of Toxins A (TxA-R) and B (TxB-R), and Cwp2 were His-tag purified, and 1 µg purified 
proteins were loaded onto gels and analysed for purity.  
A: Coomassie blue staining purified proteins 
B: Western blot analysis with antibodies raised against each specific protein. Toxin B fragment 
shows slight sign of degradation 
C: Western blot analysis with antibody against His-Tag.   
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Full length Cwp2 was amplified from C. difficile 630 genomic DNA using primers encoding a 
C-terminal 6 x His-Tag (Figure 6.4c). This was cloned into the E. coli – C. difficile shuttle 
vector pRPF144 between SacI and BamHI sites under its native constitutive promoter and 
expressed in C. difficile 630Δerm. This host was chosen to ensure correct folding of the 
protein as we have previously observed incorrect folding and degradation of cell wall 
proteins expressed in E. coli. Cultures were grown in TY to maximise cell density, cells were 
harvested and frozen at -20°C. The pellets were lysed by freeze-thawing, a procedure shown 
in our lab to effectively lyse C. difficile. After two cycles of freeze-thawing the samples were 
incubated at 37°C for 45 minutes with DNase. The lysed suspension was centrifuged and 
soluble proteins filtered and purified using the ÄKTA-FPLC. Preliminary results indicated that 
imidazole concentrations higher than 10 mM were effective at releasing Cwp2 from the 
nickel column, thus the column was washed with 10 mM immidazole to prevent loss of 
Cwp2 before elution. The protein was successfully purified and did not show any 
degradation (Figure 6.5a-c). From a 2 litre culture of C. difficile, approximately 3 mg of 
Cwp2-His of high purity was obtained. This was the first attempt to use C. difficile to express 
and purify recombinant proteins in our laboratory, and our success means that this system 
is now used to purify other C. difficile proteins for analysis, including preparation of proteins 
for X-ray crystallography.  
In addition, S-layer proteins from C. difficile 630 were extracted using low pH glycine to 
obtain an S-layer preparation for immunisation studies. All proteins were dialysed into 10 
mM HEPES 150 mM NaCl for storage at -80°C.  
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6.2.4 Hamster immunisation protocol 
 
Following discussions with Dr Gill Douce, Glasgow University, an immunisation protocol was 
developed and the proteins were sent to her laboratory for immunisation of hamsters. 
Female golden Syrian hamsters were immunised intraperitoneally (IP) four times over two 
week intervals, each dose containing 50 µg each protein. Antigens were delivered in MF59 
adjuvant (Novartis proprietary adjuvant). Following vaccination, hamsters were left for 3 
weeks before challenge with 103 C. difficile 630 spores (Figure 6.6). C. difficile spores were 
administered by oral gavages. Hamsters were divided into four groups, with 6 hamsters in 
each immunisation group, 3 in the non-immunised controls: 
1) Toxin A and toxin B fragments 
2) Toxin A and toxin B fragments; Cwp2 
3) Toxin A and toxin B fragments; S-Layer preparation 
4) Non-immunised controls 
Disease symptoms were followed by recording body temperature of the hamsters, and 
observing whether they experienced an episode of diarrhoea. A drop below 35°C in body 
temperature of a hamster determined the humane end point of the experiment, unless 
animals remained well, in which case they were culled 14 days post challenge (Douce and 
Goulding 2010). Faeces were collected to determine the level of colonisation during the 
experiment, and any episodes of diarrhoea noted. The caecum and colon were analysed for 
C. difficile vegetative cells and spores, either lumen associated or tissue associated, 
following the experiment. Toxin titre of caecum and colon washes were analysed at the end 
point of each experiment also.  
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6.2.5 Immunisation with Cwp2 or an S-layer preparation reduces symptoms 
in the hamster model of infection but does not affect colonisation levels 
 
The hamster model of C. difficile infection shows an acute disease phenotype, with hamsters 
challenged with C. difficile spores succumbing to the disease after approximately 36 hours of 
infection (Figure 6.7). It has previously been shown that immunisation with fragments of 
toxin A and toxin B prevent death in this hamster model of C. difficile infection; however the 
hamsters still have an episode of diarrhoea and are highly colonised with C. difficile (Figure 
6.7 and Gill Douce, personal communication). It was therefore of interest to determine 
whether S-layer proteins could be incorporated into a vaccine to prevent disease symptoms 
and reduce colonisation of the hamster gut.  
Survival 
Representative temperature thermograms are shown in Figure 6.7 for each group of 
hamsters, showing that all vaccinated groups maintained healthy temperatures (with 
Figure 6.6 Hamster vaccination programme 
Diagram showing the vaccination schedule for hamsters. Numbers show relevant dates respective 
of challenge Day 0. Three doses of antigens were given, two weeks apart, before hamsters were 
left for three weeks. On Day 0 hamsters were challenged with C. difficile spores and infection was 
followed for 14 days, with temperature monitoring and collection of faeces. All animals were 
culled at Day 14.   
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exceptions discussed below). In contrast, the non-vaccinated animals succumb to the 
infection after 36 hours and were culled.  
 
Colonisation 
Analysis of C. difficile in the faeces of hamsters vaccinated with toxin fragments alone, toxin 
fragments with Cwp2 or toxin fragments with an S-layer extract show that there is little 
difference in colonisation levels between vaccination programmes, Figure 6.8d. Animals  
Figure 6.7 Representative temperature graphs for each hamster vaccination group 
Graphs show changes in temperature of an individual hamster over time (hours). Black lines 
indicate temperature, and red bars indicate when disease symptoms, such as an episode of 
diarrhoea, occurred. Thermograms shown are representative for the majority of hamsters in each 
group.  
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Figure 6.8 Colonisation profiles of vaccinated hamsters 
Hamsters were vaccinated with toxin fragments alone (txA-R txB-R), with addition of Cwp2 (txA-R 
txB-T Cwp2) or with addition of an S-layer preparation (txA-R txB-R S-layer). Hamsters were 
challenged with 103 C. difficile spores by oral gavage. Faeces were collected across 12 days and C. 
difficile spores present quantified.  
A-C: Colonisation profiles of each hamster within each vaccination group as indicated 
D: Colonisation means for each group plotted with error bars showing standard error for each 
data point.   
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vaccinated with the addition of an S-layer extract appeared to reduce colonisation earlier, 
but this plateaued with little further reduction over the following 8 days. However, this data 
point only represents two of the six hamsters from this group (Figure 6.8c). Unfortunately 
the data sets vary wildly, with large standard deviations from the mean for all vaccination 
programmes on all days. This can be seen more clearly in the data for individual hamsters 
within each vaccination group (Figure 6.8a-c). Additionally, the data sets were taken over 
two experiments, where the data sampling was not conducted on all the same days 
between these experiments.  
Analysis of C. difficile vegetative cells and spores in the caecum and colon of hamsters 
showed high variability and no correlation to the vaccination programme followed (data not 
shown). Therefore little information can be drawn from the hamster model as to whether 
colonisation was reduced in animal immunised additionally with bacterial surface proteins. 
Toxin levels  
Toxin levels were analysed by ELISA and showed animals that succumbed to infection had 
higher levels of toxin in their gut than those who survived including those who succumbed 
to infection from vaccination groups (data not shown). All vaccination groups showed equal 
lack of toxin in the caecum and colon.  
Disease phenotype 
Immunisation of hamsters with toxin fragments A and B has previously been shown to 
prevent severe disease and death, but symptoms of disease are still seen, notably one or 
more episodes of diarrhoea (Gill Douce, personal communication). In this experiment, 
similar results were seen, as the group immunised with toxin fragments alone still showed 
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some symptoms of disease, with all hamsters in this group suffering one episode of 
diarrhoea, Table 6.1. The groups vaccinated with toxin fragments plus either Cwp2 or the S-
layer extract exhibited markedly reduced symptoms of disease, with only one animal in each 
group suffering from an episode of diarrhoea. In the Cwp2 group the temperature of this 
animal dropped below 35°C and had to be culled. These immunisation studies were 
repeated with antigens delivered by the oral route, but this experiment was unsuccessful as 
no group was immune from infection (data not shown).  
Table 6.1 Disease phenotype for vaccinated hamsters 
 Vaccination 
programme 
 Hamster 
Time to 
<35°C 
Time to cull Temp at cull Symptoms 
txA-R 
txB-R 
H1   14 days   Y 
H2   14 days   Y 
H3   14 days   N 
H4   14 days   Y 
H5   14 days   Y 
H6   14 days   N/A 
txA-R 
txB-R  
Cwp2 
H7   14 days   N 
H8   14 days   N 
H9   14 days   N 
H10 160h 3m 160h 17m 33.11°C Y 
H11   14 days   N 
H12   14 days   N 
txA-R 
txB-R  
S-layer 
H13   14 days   N 
H14   14 days   N 
H15   14 days   N 
H16   14 days   N 
H17   14 days   N 
H18   14 days   Y 
Non-
vaccinated 
H19 36h 37m  39h 36m 30.98°C Y 
H20 34h 27m 37h 0m 28.58°C Y 
Adjuvant 
only 
H21 36h 33m 36h 58m 34.02°C Y 
txA-R – toxin A fragment, txB-R – toxin B fragment, H denotes hamster number 
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6.2.6 Mouse immunisation protocol 
The clindamycin mouse model of C. difficile infection is a more suitable model for studying 
colonisation because mice do not develop severe symptoms of disease and survive 
throughout the infection. Following discussions with Miss Zoe Seager, Dr Ana Arbeloa Del 
Moral and Mr Mark Hession an immunisation protocol was developed. Dr Ana Arbeloa Del 
Moral and Mr Mark Hession conducted these mouse experiments at Imperial College 
London. Female C57BL/6 mice were immunised intraperitoneally (IP) with three doses of 5 
µg/dose each protein at days 61, 46 and 34 pre-challenge with C. difficile spores. Antigens 
were delivered with 5 mg/ml aluminium hydroxide (Sigma) adjuvant. Following the final 
vaccination, mice were left for 4 weeks before treatment with 250 µg/ml clindamycin by 
oral gavages (6 days pre-challenge). Clindamycin is known to alter the microbiota of mice, 
simplifying its composition and to sensitise them to infection by C. difficile (Lawley et al. 
2009a). Mice were challenged with C. difficile 630 spores on experiment Day 0 by a transfer 
of infected bedding from mice infected with C. difficile. Infected mice shed high levels of 
spores in their faeces into cages and their contaminated bedding can be used to reliably 
infect antibiotic treated animals. Mice were divided into the same four groups as the 
hamsters, with 5 mice in each group: 
1) Toxin A and B fragments 
2) Toxin A and B fragments; Cwp2 
3) Toxin A and B fragments; S-Layer preparation 
4) Adjuvant control – no vaccination 
Shedding of C. difficile into the faeces allows for colonisation to be quantified (Lawley et al. 
2009a). Colonisation was quantified for each group post challenge and followed for 17 days, 
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when shedding tailed off. The mice were left for 2 weeks before a second dose of 
clindamycin on Day 33. A second peak of shedding was followed for 22 days before a third 
induction of shedding on Day 61 (Figure 6.9).  
 
6.2.7 Vaccinations produce strong immune responses in mice 
 
Serum samples were taken before vaccination, after the final vaccination before challenge, 
and at the end point of the study.   
ELISAs were conducted on serum from Day -26, after vaccination but before challenge with 
C. difficile spores. Plates were coated with Cwp2, S-layer extracts, Toxin A fragment, or Toxin 
B fragment. Serum from each vaccination group was diluted on the plate and binding was 
recorded. As Figure 6.1 shows, all vaccinated animals showed an immune response against 
Figure 6.9 Mouse vaccination programme 
Diagram showing the vaccination schedule for mice. Numbers show relevant dates respective of 
challenge Day 0. Three doses of antigens were given, two weeks apart, before mice were left for 
four weeks. 6 days prior to challenge, mice were treated with clindamycin. On Day 0 mice were 
challenged with C. difficile spores through a bedding transfer from infected mice. Shedding of C. 
difficile vegetative cells and spores was quantified over 72 days, with two more inductions of 
shedding with clindamycin at Days 33 and 61. Colonisation was observed until Day 72 post 
challenge.   
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toxin A fragments and toxin B fragments, with no immune response mounted by non-
vaccinated controls. Interestingly, only animals vaccinated with Cwp2 showed an immune 
response against Cwp2 or the S-layer extract. Animals vaccinated with the S-layer extract 
did not produce antibodies that reacted with immobilised S-layer proteins on an ELISA plate.  
 
6.2.8 Vaccination of mice reduces the level of colonisation of C. difficile 
 
Colonisation was measured over 72 days, during which time mice were given clindamycin 
three times (Days -6, 33 and 61). Data for each vaccination group and a combination are 
shown in Figure 6.11. After the first clindamycin treatment, all groups of animals became 
infected with C. difficile, as shown by counts of up to 108 total cfu/g faeces. Mice vaccinated 
Figure 6.10 Mice mount immune responses to protein vaccinations 
Serum from post-vaccination pre-challenge mice was used in ELISA analyses against immobilised 
proteins as indicated above each graph: Cwp2, S-layer extract, toxin A repeats and toxin B 
repeats. Serum analysed was from the following groups: Toxin A repeats and toxin B repeats 
alone (A B), toxin A repeats, toxin B repeats and Cwp2 (A B C), toxin A repeats, toxin B repeats and 
an S-layer preparation (A B S) and non-vaccinated controls (Alum).  n = 5 mice 
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with toxin fragments alone show prolonged shedding of both C. difficile vegetative cells and 
spores until Day 17. Animals vaccinated with toxin fragments plus Cwp2 show a lower level 
of total C. difficile colonisation, but despite spores no longer being shed after Day 13, 
vegetative cells continue to be shed until Day 17. Animals vaccinated with toxin fragments 
plus the S-layer extract show a higher number of total C. difficile colonisation than the other 
two vaccination groups, but this contains lower levels of spores. However, shedding ceases 
for both vegetative cells and spores more swiftly than in the other vaccination groups, with 
no detectable shedding after Day 13 for either. All animals showed a spike in colonisation at 
Day 2 and by Day 17 all animals had ceased to shed C. difficile cells. 
After the second clindamycin treatment, shedding returned in all groups except those 
vaccinated with toxin fragments plus the S-layer extract. There were no detectable spores or 
vegetative cells shed for any of the mice in this group. Non-vaccinated mice and those 
vaccinated with toxin fragments plus Cwp2 show a delayed peak for shedding of both 
vegetative cells and spores, which ceases by Day 57.  
After the third clindamycin treatment, no C. difficile shedding was seen in the control (alum) 
group or the groups immunised with toxin fragments plus either S-layer extract or Cwp2. 
However, animals vaccinated with toxin fragments alone began the second cycle of 
shedding 3 days before the other groups, and had not ceased to shed C. difficile vegetative 
cells or spores before the third treatment with clindamycin, when an increase in shedding 
was again observed.   
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Figure 6.11 Colonisation profiles of vaccinated mice 
Mice were vaccinated with toxin fragments alone (txA-R txB-R), with addition of Cwp2 (txA-R txB-
T Cwp2) or with addition of an S-layer preparation (txA-R txB-R S-layer). C. difficile was 
administered by bedding transfer containing spores from separately infected mice. Faeces were 
collected across 72 days and C. difficile vegetative cells and spores present quantified. Blue bars 
indicate the second and third treatment with clindamycin. N = 5 mice 
A-D: Colonisation profiles of each mouse within each vaccination group as indicated with error 
bars showing standard deviation for each data point.  
E: Colonisation means for each group plotted for total counts and spore counts.   
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6.3 Discussion  
 
Studies have already shown that vaccination with toxin fragments can prevent death in the 
hamster model of disease (Lyerly et al. 1990; Torres et al. 1995; Tian et al. 2012). However, 
these animals still show disease symptoms, suffering from an episode of diarrhoea, and are 
still highly colonised. The aim of this work was to determine whether surface proteins could 
be used in combination with toxin fragments to prevent symptoms of disease and reduce 
the level of colonisation by C. difficile.  
Bioinformatic analysis indicated Cwp2 as a strong candidate for inclusion in a vaccine against 
C. difficile. As shown, the protein sequence is highly conserved between strains, antibodies 
raised in C. difficile 630 show cross reaction between strains, and it is abundant on the cell 
surface, yet not the predominant surface protein. Other surface proteins studied thus far 
show a large degree of variation in their protein sequences (McCoubrey and Poxton 2001; 
Savariau-Lacomme et al. 2003; Lemee et al. 2005; Reynolds et al. 2011). The function of 
Cwp2 is not known, and knock-out shows no obvious defects (Chapter 5). Cwp2 therefore 
had all the characteristics of a protein which would be an ideal vaccine candidate (Pizza et 
al. 2000). 
Cwp2 was purified from a lysate of C. difficile 630, to hopefully ensure correct folding of the 
protein for inclusion in the vaccine. From 2 litre of TY broth, 3 mg of protein could be 
purified using the expression vector pMTL960 under control of the cwp2 promoter. This was 
an encouraging result, and with enrichment of media, such as the addition of glucose, the 
yield could perhaps be increased further. The tetracycline inducible promoter, Ptet (Fagan 
and Fairweather 2011), is a stronger promoter than the cwp2 promoter, so it would be 
interesting to investigate whether the use of Ptet could also increase protein yields from C. 
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difficile. This system can now be used to purify other future vaccine candidates, and also to 
purify proteins for crystallisation as the proteins will potentially be folded correctly, 
removing the potential for uncertainty following purification from E. coli.  
Hamsters were vaccinated IP with toxin fragments alone (comprising 14 C-terminal repeats 
of Toxin A, and the entire C-terminal binding domain of Toxin B), toxin fragments with 
Cwp2, or toxin fragments with an S-layer extract. The S-layer extract was used to determine 
whether surface proteins as a whole could protect hamsters from colonisation. Additionally, 
if Cwp2 did not achieve the vaccination goals, this would indicate whether there is 
potentially another surface protein that could be studied. Both Cwp2 and the S-layer extract 
prevented disease symptoms in 5/6 of the hamsters immunised in each group, whereas 
hamsters vaccinated with toxin fragments alone still suffered an episode of diarrhoea. 
Faeces were collected and analysed for C. difficile. There was little overall difference 
between the three vaccination groups, except that those vaccinated with the addition of the 
S-layer extract appeared to show a drop in colonisation earlier than the other vaccination 
groups, however this drop in colonisation at Day 7 is not significant as it only represents 2 of 
the 6 hamsters within this group. As this study was conducted over two experiments and 
data was not collected on exactly the same days between experiments only Days 1, 4 and 9 
can truly be analysed for differences in colonisation as they comprise full data sets. Another 
point to note is that the degree of variation between hamsters on each day is very great 
(Figure 6.8a-c), such that some error bars show 100 fold variation from the mean.  
The continued colonisation and lack of symptoms with Cwp2 and S-layer extracts may be 
due to difficulties in measuring colonisation in hamsters or due to these surface proteins 
performing another function. They may be down regulating immune system recognition 
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strategies, as seen with commensal bacteria. The HMW and LMW SLPs are the most 
abundant proteins released into the extracellular environment (Mukherjee et al. 2002). SLPs 
have been shown to stimulate TLR4 and NFκB signalling (Ryan et al. 2011) and to induce 
immunomodulatory cytokines from monocytes (Bianco et al. 2011), thus by perturbing the 
immune system and inducing inflammation they may contribute to the pathogenesis of 
infection. Therefore, immunisation could produce antibodies against these proteins, such 
that upon infection the interaction of SLPs with the immune system is reduced and 
therefore potentially prevents inflammation in the gut. One study suggests that this 
induction of the immune system, especially their induction of monocyte derived dendritic 
cells (MDDC) driving a Th1/Th2 profile, may highlight the SLPs as interesting adjuvants 
(Ausiello et al. 2006). Thus, in the hamster model of C. difficile infection the presence of S-
layer proteins, whether Cwp2 or an S-layer preparation, may be acting to enhance the 
vaccination, thus removing the symptoms of infection, yet not be involved in clearing 
colonisation.  
Oral administration of vaccines was attempted as it was thought this may stimulate the 
mucosal immune system but showed no protective effect for any vaccination group. Other 
immunisation routes which have been shown to be effective in hamsters could be assessed, 
such as rectal immunisation and intramuscular immunisation (Giannasca et al. 1999) or 
intranasal immunisation (Torres et al. 1995) to observe whether these confer a 100% 
protective effect from symptoms with surface protein antigens. 
Overall the hamster data is very encouraging and further experiments should be planned to 
determine whether the surface proteins have a real role in protection from disease, and if 
so, what the molecular and immunological basis of that protection is. The variability in 
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colonisation data indicates that a larger group size would be needed to appropriately power 
these experiments. However, the number of hamsters required for a smaller standard 
deviation in colonisation would be impractical and potentially unethical. Thus the analysis of 
colonisation should be undertaken with a different model of C. difficile infection, while 
disease phenotype observed in hamsters.  
Attentions were turned to the mouse model of C. difficile infection as it is the model used to 
study colonisation due to its reproducible and consistant spore shedding pattern (Lawley et 
al. 2009a). Mice were again vaccinated with the same three groups or an adjuvant control 
and colonisation monitored. Mice do not succumb to C. difficile infection, so colonisation 
could be compared not just between different vaccinations, but also with the non-
vaccinated animals. Results of this first experiment indicate that immunisation with toxin 
fragments plus Cwp2 did not decrease the level of colonisation compared with the controls. 
Immunisation with toxin fragments plus an S-layer preparation however did decrease 
colonisation, with no return of C. difficile shedding after the second clindamycin treatment. 
This is expected as the S-layer is known to be highly immunogenic, and as the preparation 
contains many surface proteins it provides multiple antigens with which the immune system 
can target the infection. It is interesting to note, however, that immunisation with the S-
layer preparation did not seem to induce production of antibodies that would bind to an 
immobilised S-layer preparation on ELISA plates. There were also no antibodies raised 
against Cwp2 in the S-layer extract, despite Cwp2 being known to induce an immune 
response in mice. Cwp2 vaccinated mice however did produce strong antibodies against 
Cwp2 which reacted with both immobilised Cwp2 and S-layer extracts. It should be noted 
that this experiment has only been performed once. The experiment should be repeated to 
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ensure the samples represent the correct immunisation groups, especially as antibodies 
from Cwp2 immunised mice seem to have a stronger binding to the S-layer ELISA than the 
Cwp2 ELISA, despite lower levels of Cwp2 found in the S-layer compared with purified Cwp2 
alone.  
In the first peak of shedding, mice vaccinated with either Cwp2 or S-layer extracts showed 
10 fold fewer spores shed than those vaccinated with toxin fragments alone and non-
vaccinated mice. Additionally, despite having higher numbers of vegetative cells shed, those 
animals vaccinated with the S-layer extract ceased shedding earlier than other vaccination 
groups. Spores are the infectious agent of C. difficile (Lawley et al. 2009b), therefore the 
lower spore levels following the inclusion of surface proteins is an encouraging result.  
Those vaccinated with Cwp2 showed a similar profile to the non-vaccinated animals, 
suggesting that in mice, Cwp2 vaccination has little or no effect on colonisation. It should be 
noted however that the non-vaccinated controls were found to have been colonised prior to 
the experimental challenge, thus the pattern of shedding should not be analysed too closely 
as this prior colonisation could have affected the dynamics of the controls. What is 
interesting to note is that mice vaccinated with toxin fragments alone remained highly 
colonised after the second clindamycin treatment. The reason for this is unclear due to its 
difference from the non-vaccinated animals. It could suggest a tolerance of the mouse gut 
for C. difficile, with neutralisation of any toxin production allowing C. difficile to become a 
more permanent member of the microflora. This has been observed in hospitals, where 
patients had antibodies against toxin B upon admission to the hospital, but not all 
developed the symptoms of CDI, and instead remained asymptomatically colonised (Loo et 
al. 2011).  
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The most important result of the mouse experiment is that vaccination with an S-layer 
preparation cleared colonisation swiftly. It is essential to repeat this experiment and 
particularly to clearly analyse the serum responses to the surface proteins. If the S-layer 
extract can indeed provide immunological protection against colonisation, then individual 
proteins can be purified and tested separately to determine which surface proteins are 
important for this protective effect. 
Protection from colonisation could also be studied using C. difficile mutants. There are a 
number of surface protein deletion mutants already constructed which could be used to 
investigate the role of individual proteins in colonisation. Any mutant that failed to colonise 
might be defective in a protein that is essential for colonisation. Antibodies raised against 
this protein could potentially be used in a vaccine experiment similar to those described 
here. There are limitations to this approach, as some mutants are sickly and do not colonise 
the mouse well for reasons beyond their protein function, or the mutant affects the 
composition of the surface, such as removal of Cwp84 preventing formation of the SLP 
complex (Kirby et al. 2009; de la Riva et al. 2011). It has also been observed that some 
ClosTron mutants are more sensitive to clindamycin, and thus are cleared from the gut for 
this reason, rather than due to the loss of this protein (Zoe Seager, personal 
communication). Also, the combination of proteins in the S-layer extract may have been 
necessary for a reduction in colonisation, with a multifaceted attack on C. difficile by the 
mouse immune system.  
Another experiment that should be undertaken is to determine whether this vaccination 
with C. difficile 630 proteins can prevent colonisation with other strains of C. difficile. 
“Hypervirulent” strain R20291 is antigenically distinct from 630 for a number of key surface 
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proteins, so it would be interesting to observe whether immunisation with the 630 S-layer 
extract could still prevent long term colonisation after challenge with R20291. If it does, 
then the surface proteins involved in prevention of colonisation could be more easily 
identified with genome analysis for conserved protein sequences between these two 
strains. Following this, hamster experiments could be repeated to determine whether or not 
challenge with R20291 resulted in symptoms of disease following immunisation with 630 
Cwp2 or S-layer preparations.  
What is clear from this study is that surface proteins have the potential for inclusion in a 
multi-component vaccine. Cwp2 did prevent symptoms of disease in the hamster which 
means that patients would not suffer from infection, and transmission could be reduced. 
However, animals vaccinated with Cwp2 still showed a high level of colonisation, and 
therefore there could still be the possibility of the spread of infection (McFarland et al. 
1989). With the prevention of death and symptoms however, this is an encouraging step in 
the right direction. However, recent studies have found strains of C. difficile which contain a 
putative glycosylation gene cluster inserted into cwp2, rendering this gene inactive (Dingle 
et al. 2013). These strains therefore do not contain Cwp2, and due to the recombination 
event they also may not express Cwp66. Therefore a Cwp2 vaccine would no longer show 
complete cross-strain specificity, although these strains are currently in a minority.  
Other surface proteins in the S-layer of C. difficile could be investigated to determine which 
are important for the reduction in C difficile colonisation. It may be found that multiple 
proteins are required to prevent colonisation as there is great redundancy amongst the 
potential colonisation factors of C. difficile. There are also other surface proteins which are 
not part of the S-layer. Proteins covalently bound to the peptidoglycan cell wall of Gram 
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positive bacteria have been shown to be important in colonisation and virulence 
(Mazmanian et al. 2000), so the presence and role of these proteins in C. difficile should be 
investigated to determine whether non-S-layer surface proteins could be included in a 
vaccine. Bioinformatic analysis should be undertaken to ensure that new potential targets 
identified would have broad cross-strain activity.   
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Chapter 7 Discussion 
C. difficile causes a severe enteric infection, leading to thousands of deaths per year in the 
UK alone, and a high risk of recurrent infection. CDI is a burden on healthcare systems, due 
to further patient treatment, longer hospital stays and its high risk of transmission of 
infection. The majority of vaccines under investigation target the toxins produced by C. 
difficile, therefore removing the toxicity of disease but not preventing initial colonisation. 
This could potentially cause at least a short symptomatic period in vaccinated patients and 
lead to transmission to non-vaccinated patients. The surface of C. difficile contains a large 
number of proteins, but many of these have not yet been characterised. This includes a 
family of sortase substrates, which have been shown to be necessary for virulence in other 
Gram positive bacteria. We need a better understanding of these surface proteins to assess 
whether they could potentially be exploited to prevent colonisation in a toxin based multi-
component vaccine.  
In the following chapter the main conclusions of this thesis, questions raised and 
suggestions for further investigation are discussed. 
 7.1 Sortase substrates in C. difficile 
 
There is only one study to date which has investigated a sortase substrate from C. difficile 
which includes work from this study (Tulli et al. 2013). The study presented here has 
identified 7 potential sortase substrates in the genome of C. difficile 630, 4 of which are also 
found in strain R20291. RT-PCR shows that these proteins and the srtB gene are transcribed 
in both exponential and stationary growth phases, suggesting that this system is active in C. 
difficile.  Initial investigation into the phenotypes of these potential sortase substrates has 
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proved difficult due to the limitations of cell binding assays and redundancy of surface 
proteins of C. difficile. CD2831, CD3145 and CD3392/CD0386 could have roles in cell-cell 
interactions similar to those seen with CwpV (Reynolds et al. 2011) as they show tight 
colony morphology and are similarly predicted to be ECM binding proteins. A simple cell 
aggregation assay could be used to determine whether they are involved in clumping of 
cells, or a bacteria biofilm assay could determine their involvement in cell-cell interactions in 
this system (Dawson et al. 2012).  
Initial investigation in CD0183 suggests it to be a true sortase substrate, but this is 
contradicted by the lack of cleavage of a fusion protein with CwpV. This assay may have 
affected the folding of the protein, or the presence of a large C-terminal domain may have 
acted to “push” this protein through the membrane as it has a weakly predicted 
hydrophobic helix, especially as both domains were found in the cell wall. An optimisation 
of this assay would be to utilise a C-terminal Strep-tag, such that the presence of the small 
tag would show a lack of cleavage, but the absence would suggest a cleavage event has 
occurred. This is still an interesting assay though, and should be attempted with another 
sortase substrate to determine whether it could be viable for studying sortase substrates in 
C. difficile. An assay to investigate cell wall attachment of a secreted protein proved difficult 
as the protein used was not a completely secreted protein. Further analysis of the C. difficile 
secretome could highlight superior candidates for use in this proof of principle experiment 
for cell wall attachment.  
An important study which must be undertaken is the use of FRET technology. A short 
peptide consisting of the LPXTG like domain of a potential substrate is linked to an N-
terminal Dabcyl molecule, and a C-terminal Edans molecule (Matayoshi et al. 1990; Wang et 
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al. 1990). Dabcyl is a fluorescent molecule and Edans its quencher. When in close proximity 
there is no fluorescence, but upon cleavage of the LPXTG motif there is no longer quenching 
action on the Dabcyl molecule and fluorescence is observed. This can determine whether a 
cleavage event occurs when purified recombinant sortase is incubated with the peptide, and 
the rate of cleavage can also be determined.  
7.2 Sortase substrates and the cell wall of C. difficile 
 
The development of a cell wall protein extraction protocol has opened the way for future 
studies of these proteins. This study has shown that at least 4 of these 7 potential sortase 
substrates are found in cell wall fractions following digestion of the peptidoglycan. However, 
it is yet to be ascertained whether they are truly within the cell wall and not associated with 
the non-covalently attached S-layer. It would be beneficial to distinguish between those 
proteins found non-covalently attached to the cell wall within the S-layer and those which 
are truly covalently attached the cell wall. This could involve combining low pH glycine 
extraction methods for removal of the S-layer with digestion of the cell wall. Regardless of 
this, the localisation of these proteins beyond the cytoplasmic membrane suggests that they 
have been “sorted” as their predicted hydrophobic helix and charged tail should retain them 
in the membrane if no cleavage of their C-terminal cell wall sorting signal occurs. This is the 
first suggestion that the sortase system of cell wall anchoring of proteins is active in C. 
difficile.  
CD0183 is often shown to have laddering migration patterns through SDS-PAGE gels, which 
potentially is due to attachment to increasing sizes of incompletely digested cell wall 
fragments. CD0183 can be cleaved with cyanogen bromide at the methionine near its LPXTG 
like motif and analysed by mass spectrometry to determine whether cleavage has occurred 
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and what the cell wall anchor structure is. Additionally peptidoglycan sacculi could be 
purified, digested and analysed by mass spectrometry. This may identify all the proteins 
covalently attached to the cell wall, but would have to be optimised to ensure they are not 
lost during the rigorous purification.   
7.3 Sortase in C. difficile  
 
This study has begun the characterisation of sortase in C. difficile. SrtB has been shown to be 
membrane bound, as typically seen in other Gram-positive bacteria, and initial investigation 
has suggested it to potentially be a cysteine protease. The use of dominant negative sortase 
expression could yield further interesting information about the sorting process in C. difficile 
and investigate the effects on other potential sortase substrates. It has also helped to 
overcome the ambiguous data from the ClosTron mutant of srtB.   
This study has further clarified CD0183 to be a true sortase substrate, but when srtB 
expression is removed by insertion mutation, CD0183 is still found in the cell wall. This could 
either be due to the weak hydrophobic helix of CD0183 preventing retention in the 
membrane long term, or due to another cysteine protease performing a similar cleavage 
action, as sortase substrates in Listeria have been shown to still be sorted in sortase 
mutants (Mariscotti et al. 2012). Antibodies need to be raised to determine whether the 
genomic transcription shown in Chapter 3 translates to protein expression of srtB, and that 
the ClosTron mutation removes this expression. Further, a silent mutation on the 
chromosome with new technologies (Cartman et al. 2012; Heap et al. 2012) would be 
beneficial to remove any discrepancies from insertion mutations. These allele exchange 
technologies could be used to mutate key residues within the srtB gene to determine their 
significance in sortase action in C. difficile.  
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More surface protein localisation needs to be clarified under these mutation conditions to 
determine the significance of sortase in C. difficile, and following this to determine the 
significance of sortase and its substrates in C. difficile pathogenesis animal models of 
infection should be used.  
7.4 Cwp2 and the C. difficile S-layer 
 
The export and processing of numerous S-layer proteins is now understood (Fagan et al. 
2009; Kirby et al. 2009; de la Riva et al. 2011; Dembek et al. 2012). However, little is known 
of the transcriptional control of surface proteins. Early studies have shown SigH controls the 
expression of many important genes, including the S-layer protein Cwp66 (Saujet et al. 
2011). This study has drawn light on the transcriptional control of cwp66 expression, such 
that polycistronic expression from the cwp2 promoter is essential for cwp66 expression in 
exponential growth. By stationary phase its own promoter is activated. This could prove to 
be significant in the strains recently isolated in Oxford where a glycosylation cluster has 
been shown to have been inserted into the cwp2 locus with removal of this gene (Dingle et 
al. 2013). This insertion event alters the genomic localisation of cwp66 also, such that it is no 
longer in the vicinity of the cwp2 promoter, or the predicted site of its own promoter which 
is located within CD2790. It would be interesting to determine whether cwp66 is transcribed 
in these strains, and whether this translates to Cwp66 localisation on the surface. 
Cwp2 itself is not essential to C. difficile viability, and to understand its role in C. difficile 
pathogenesis further mutation studies would need to be undertaken. An allele exchange 
mutant of cwp2 should be constructed to determine whether CD2790 or cwp66 expression 
is affected by this system before any studies to understand the true role of Cwp2 can be 
undertaken. Due to its potential role in cell-cell interactions it could be studied in a biofilm 
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model (Dawson et al. 2012) as cell binding assays are still in their infancy as useful tools of C. 
difficile colonisation. Under laboratory conditions it is expressed in all growth phases, but its 
expression in vivo is unknown and should be understood. It is the most abundant surface 
protein after the HMW SLP and LMW SLP and therefore could be important in C. difficile 
pathogenesis, although its highly conserved sequence suggests it may not be as important 
as other virulence factors. Animal models of C. difficile pathogenesis are therefore useful 
tools to determine whether Cwp2 is involved in colonisation and disease.  
7.5 S-layer proteins in a multi-component vaccine 
 
Most vaccine studies to date have focused on toxins or surface proteins in isolation. It is 
clear that neutralisation of toxin activity and prevention of colonisation is needed to ensure 
a multi-faceted attack on C. difficile by the host immune system. In this study, the 
combination of toxin fragments and an S-layer preparation markedly reduced colonisation 
by C. difficile in the mouse model of C. difficile infection compared with alum controls and 
other antigen combinations. Additionally, the combination of toxin fragments with either an 
S-layer preparation or purified Cwp2 prevented diarrhoea from C. difficile infection in the 
hamster model of C. difficile infection, compared with toxins alone. All antigen combinations 
provided protection from death in hamsters compared with adjuvant controls. These were 
significant advances in vaccine development and should be repeated to ensure these are 
true and reproducible vaccine responses.  
It is encouraging that Cwp2 prevented diarrhoea in the hamster model and is still a strong 
candidate to be included in a vaccine, though multiple surface proteins may be needed to 
target colonisation. The S-layer results were also encouraging but should be investigated 
further as many proteins within the S-layer are antigenically distinct between strains of C. 
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difficile, such as SlpA, Cwp66 and CwpV. Further investigation should be undertaken to 
determine whether the reduction in colonisation with a C. difficile 630 S-layer antigen is 
observed upon challenge with a highly antigenically distinct strain such as R20291. This 
would shed light onto whether the proteins important within the S-layer for preventing 
colonisation would provide cross-strain specificity.  
7.6 Overall conclusions 
 
The surface of C. difficile is a dynamic structure, with a non-covalently attached S-layer, and 
proteins covalently attached to the cell wall beneath. With this sheer volume of different 
proteins there is likely to be redundancy in the function of these proteins, especially as we 
only known of one niche in which C. difficile flourishes. However, in the future it may 
become clear that these surface proteins provide roles varying from mucus attachment, 
host cell attachment, C. difficile attachment and avoidance of other strains and pathogens. It 
is therefore likely that a vaccine targeting colonisation should include multiple surface 
antigens for multi-faceted action. The sortase mechanism of cell wall protein attachment 
appears to be active in this pathogen, and could have an important role in C. difficile 
pathogenesis. Historically it may have been more important with two sortases sorting 
proteins as many strains contain a second copy of a sortase gene which has an inframe stop 
codon, rendering it inactive. Further investigation into this system could shed light on the 
success of C. difficile as an opportunistic pathogen.  
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Abstract 
Clostridium difficile is the leading cause of antibiotic-associated diarrhea and 
pseudomembranous colitis. While the role of toxins in pathogenesis has been extensively 
described, the contribution of surface determinants to intestinal colonization is still poorly 
understood. We focused our study on a novel member of the MSCRAMM family, named 
CbpA (Collagen binding protein A), for its adhesive properties towards collagen. We 
demonstrate that CbpA, which carries an LPXTG-like cell wall anchoring domain, is 
expressed on the bacterial surface of C. difficile and that the recombinant protein binds at high 
affinity to collagen I and V (apparent Kd  in the order of 10
-9
M). These findings were 
validated by confocal microscopy studies showing the co-localization of the protein with type 
I and V collagen fibers produced by human fibroblasts and mouse intestinal tissues. However, 
the collagen binding activity of the wild-type C. difficile 630 strain was indistinguishable to 
the cbpA knock-out strain. To overcome this apparent clostridial adherence redundancy, we 
engineered a Lactococcus lactis strain for the heterologous expression of CbpA. When 
exposed on the surface of L. Lactis, CbpA significantly enhances the ability of the bacterium 
to interact with collagen and to adhere to ECM-producing cells. The binding activity of L. 
lactis-CbpA strain was prevented by an antiserum raised against CbpA, demonstrating the 
specificity of the interaction. These results suggest that CbpA is a new surface-exposed 
adhesin contributing to the C. difficile interaction with the host. 
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Introduction  
Clostridium difficile is a Gram-positive, spore-forming, obligate anaerobe that is the most 
common cause of nosocomial diarrhea and pseudomembranous colitis (Carroll et al., 2011, 
Kelly et al., 2008, Rupnik et al., 2009). Disruption of the normal intestinal microbiota, 
normally through antibiotic treatment, allows C. difficile to colonize the enteric system; other 
risk factors that may contribute to C. difficile infections include insufficient anti-toxin 
antibody response due to immunological senescence, use of proton-pump inhibitors and other 
gastric acid suppressants and severe underlying disease (Viswanathan et al., 2010, Kelly, 
2012, Vedantam et al., 2012). C. difficile produces two large toxins, TcdA and TcdB, which 
are responsible for the disease manifestations associated with the infection. These toxins act 
as glycosyltransferases and modify small GTPases of the Rho protein family within the host 
cell, leading to alterations of cytoskeleton, activation of apoptosis and disruption of tight 
junctions. The resulting impairment of intestinal barrier function leads to fluid accumulation, 
inflammation and severe intestinal damage (Voth et al., 2005, Genth et al., 2008, Shen, 2012). 
In addition to toxins, other factors are likely to be important during the colonization process. 
Indeed, after germination, the adherence of C. difficile to the mucus layer is considered as the 
first step for the settlement of the pathogen in the gut (Deneve et al., 2009). Once the niche is 
occupied, C. difficile is thought to penetrate the mucosa and initiate a cognate interaction with 
epithelial cells and ECM components, likely employing a complex array of virulence factors.  
The interaction between bacteria and epithelial cells at host surface is a multi-factorial process 
and requires the involvement of surface-displayed adhesins and eukaryotic cellular targets. 
Gram-positive bacteria exploit a complex array of adhesins to attach to host cells (Talay, 
2005).  
A small number of C. difficile proteins involved in pathogen-host interaction have been 
characterized including S-layer proteins (Calabi et al., 2002), the flagellar components FliC 
and FliD (Tasteyre et al., 2001, Dingle et al., 2011), the GroEL chaperone (Hennequin et al., 
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2001), the Cwp66 adhesin (Waligora et al., 2001), the fibronectin binding protein Fbp68 
(Hennequin et al., 2003, Lin et al., 2011) and the cysteine protease Cwp84 (Janoir et al., 
2007). However, the general strategy whereby C. difficile colonizes the host is unclear, as are 
the roles of extracellular proteome of C. difficile in adhesion and colonization.  
In other Gram-positive bacteria, several proteins belonging to the family of microbial surface 
components recognizing adhesive matrix molecules (MSCRAMMs) have been characterized 
for their ability to bind ECM components (Patti et al., 1994, Chagnot et al., 2012). 
MSCRAMMs have a common surface localization that in Gram-positive bacteria is usually 
mediated by a cell wall sorting signal through which they are covalently anchored to the cell 
wall peptidoglycan by sortase. Examples are ClfA from Staphylococcus aureus with binding 
activity toward fibrinogen (Foster et al., 1998), FnbpA from Staphylococcus aureus (Foster et 
al., 1998) and PavB from Streptococcus pneumoniae (Jensch et al., 2010) which bind 
fibronectin, Cna from Staphylococcus aureus (Foster et al., 1998) and SdrF from 
Staphylococcus epidermidis (Arrecubieta et al., 2007) with collagen binding activity. There is 
redundancy in the MSCRAMM family with regards to host bacterial protein recognition; 
ECM components have the ability to bind several bacterial MSCRAMMs and MSCRAMMs 
can bind to multiple host proteins (Patti et al., 1994). 
In this study, we characterize a cell wall anchored protein of C. difficile, termed CbpA 
(Collagen binding protein A), having features of typical MSCRAMMs. We verified by 
immunofluorescence that CbpA is exposed on the bacterial surface and demonstrated that the 
recombinant protein is able to bind collagens with high affinity to type I and V and has 
adhesive properties toward ECM-producing human fibroblasts and gut tissues. To overcome 
clostridial adherence redundancy, we engineered a Lactococcus lactis strain for the 
heterologous expression of CbpA. We demonstrated that, when exposed on the surface of L. 
Lactis, CbpA confers an increased ability to target collagen V with a resulting potentiated 
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adhesiveness to ECM-producing cells. Overall these data suggest that CbpA is a new 
colonization factor contributing to C. difficile colonization of the gut. 
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Results 
Domain organization of CbpA/CD3145 protein 
Collagen binding protein A (CbpA), encoded by the CD3145 gene of C. difficile strain 630, is 
a predicted protein of 1190 amino acids annotated as serine-aspartate repeat-containing 
protein SdrF (Sebaihia et al., 2006, Monot et al., 2011). The protein has an N-terminal 
putative leader peptide and a C-terminus region comprising an NVQTG-motif followed by a 
hydrophobic membrane-spanning domain and a series of positively charged residues (Fig.1). 
These features suggest that CbpA could be putative substrate of C. difficile sortase B 
(Sebaihia et al., 2006). The mature polypeptide has a predicted molecular weight of 118,400 
Da. Sequence analysis revealed the presence of three distinct repeat types (Fig.1): type I 
(amino acids 34-314), type II (amino acids 315- 525) and type III (amino acids 841-1145); the 
latter comprise a central core of consecutive KPDPDNGGNS motifs flanked by DXDGDG 
signatures which are similar to the calcium-binding sequences found in the trombosphondin-
like proteins (Kvansakul et al., 2004, Rigden et al., 2004). All the three repeats are 
characterized by a relative high abundance of hydrophilic side chains like lysines, asparagines 
and aspartic acids, suggesting the exposure to the extracellular environment. Moreover, the 
presence of glycines can confer a marked conformational flexibility to these regions of the 
protein. 
 
Surface localization of CbpA 
The predicted cell surface localization of CbpA was investigated by confocal microscopy of 
630 strain using antibodies raised against the recombinant CbpAI-II protein, containing type I 
and II repeats (amino acids 29-841, Fig. 1). As shown in Fig. 2A, the protein was 
homogeneously detected on the bacterial surface of strain 630 (Fig. 2A). To further analyse 
the CbpA cellular distribution phenotype, we created an insertional mutant within cbp, 
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designated ∆cbpA, using ClosTron technology (Heap et al., 2010). The cbpA mutant did not 
express CbpA on its surface, showing the specificity of the labelling. Complementation of the 
mutant strain with a plasmid-encoded cbpA gene restored the surface expression of the protein 
(Fig. 2A). CbpA was present in the cell wall fraction as shown by Western blot analysis. 
Protein was detected in wild-type and complemented strains, but not in the cbpA mutant strain 
(Fig. 2B). 
 
Recombinant CbpAI-II binds to extracellular matrix components in vitro 
The presence of CbpA on the surface of C. difficile led us to hypothesize a contribution of the 
antigen in the interaction of the pathogen with host tissues. ECM components present at the 
basolateral surface of organs are important in maintaining tissue integrity and known to be 
target of several surface-exposed proteins contributing to bacterial colonization (Patti et al., 
1994, Chagnot et al., 2012). The propensity of CbpA to interact with ECM was evaluated by 
ELISA using a recombinant CbpAI-II polypeptide incubated in the presence of several ECM 
proteins including soluble fibronectin, laminin α1β1γ1 and multiple collagen types in their 
free form. By this approach, we observed that CbpAI-II was able to bind in a concentration-
dependent and saturable fashion only to collagen I and V (Fig 3A). No significant binding 
was reported for fibronectin, laminin and collagens II, IV and VI (Fig. S1-A).The Kd values, 
defined as the concentration able to saturate 50% of putative receptors, were 40 nM for 
collagen I and 16 nM for collagen V (as calculated by saturation curves in Fig. S1-B). 
To demonstrate that the binding of CbpA to collagens is relevant to the interaction of C. 
difficile to the ECM components produced by host cells, we used a human fibroblast cell line 
(IMR-90) presenting a complex fiber organization mainly composed by fibronectin and 
collagens (Fig. S2). As shown in Fig. 3B, confocal microscopy analysis of IMR-90 cells 
incubated with 20 µg/ml of recombinant CbpAI-II conjugated to Alexa-Fluor 488 dye, 
revealed a spatial co-localization of the protein with collagens I and V, supporting the 
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hypothesis of a cognate interaction of the antigen with such host determinants. The specificity 
of this interaction was confirmed by competition and serum-mediated inhibition experiments. 
We demonstrated that pre-incubation of cells with an excess of unlabelled CbpA I-II and pre-
treatment of the labeled CbpA I-II with anti-CbpA antibodies prevented the binding of the 
protein to collagens (Fig. 3B).  
To further strengthen the evidence that CbpA binding occurs via interaction to collagens, we 
extended binding studies to differentiated Caco-2 cells which do not express detectable ECM 
components (Fig. S3-A). We verified that recombinant CbpAI-II conjugated to Alexa Fluor 
488 dye is not able to bind Caco-2 cells (Fig. S3-B), confirming that the presence of collagens 
is essential for the binding.  
 
Recombinant CbpAI-II is able to bind to murine intestine 
In order to further investigate the intrinsic adhesive properties of the CbpA protein to host 
targets, we isolated different tracts of CD1 mouse intestine (ileum, jejunum, duodenum and 
colon) and prepared cryo-sections for examination in binding experiments. Briefly, sections 
were incubated with 20 µg/ml of recombinant CbpAI-II conjugated to Alexa Fluor 488 dye and 
collagens I/V were stained. BSA was used as control sample, while actin staining was used to 
monitor tissue morphology. Confocal microscopy analysis revealed that CbpAI-II localizes 
with collagen I and V in gut tissues, although the distribution differs between intestinal tracts 
(Fig. 4 and S4). In particular, magnification of longitudinal section of villi of small intestine 
showed a preferential localization of the protein in the sub-mucosa underlying the surface 
epithelium (Fig. 4). The specificity of the interaction was tested by competition experiments 
with unlabelled protein; the binding of the CbpAI-II was substantially reduced (Fig. 4, lower 
panel), although not fully abrogated due to the abundance of collagen in the intestinal tissues.  
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Engineering of L. lactis for surface-display of CbpA results in an increased adherence to 
collagen and ECM-producing human fibroblasts 
To understand the impact of CbpA protein on binding of C. difficile to collagens, the ability of 
the cbpA knock-out strain to bind immobilized collagen V and to adhere to IMR-90 cells was 
compared to the wild-type strain. As shown in Fig. 5, in both collagen and cell binding 
assays, we observed no significant difference between the wild type and ∆cbpA strain, 
suggesting that redundancy of bacterial proteins potentially interacting with ECM components 
may mask the contribution of CbpA to collagen V binding.  
To overcome the adherence redundancy and prove the role of CbpA as adhesin in a bacterial 
background, we employed Lactococcus lactis as a heterologous system for the constitutive 
expression of CbpA. Indeed, this bacterium is known to have been frequently used as a tool to 
express heterologous adhesins and show their functionality (Buccato et al., 2006, Arrecubieta 
et al., 2007, Sinha et al., 2000). Since the cell wall anchoring motif of CbpA is not predicted 
to be recognized by sortase A of L. lactis (Dieye et al., 2010), we substituted it with a 
previously described motif (Edwards et al., 2008), to ensure CbpA exposure on L. lactis 
surface. As shown in Fig. 6, the successful export of CbpA onto the lactococcal cell surface 
was then assessed by confocal immunofluorescence (Fig. 6A) and Western blot analysis (Fig. 
6B).  
Notably, surface expression of CbpA conferred to L. lactis a significant increased ability to 
adhere to immobilized solid-phase collagen V compared to L. lactis carrying the pAM401 
empty vector (L. lactis-pAM401) (Fig. 7). The binding was inhibited by the anti-CbpAI-II 
serum, demonstrating the specificity of the activity (Fig. 7). We also tested the ability of L. 
lactis-CbpA to adhere on IMR-90 cells by using both global quantification of viable adherent 
bacteria and confocal microscopy analysis. CFU counting of L. lactis-CbpA strain incubated 
with IMR-90 fibroblasts for 2h, clearly showed a 2.5 fold increase in cell adherence compared 
to control cells (Fig. 8A). As for the binding to collagen, the adhesion of L. lactis-CbpA strain 
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to fibroblasts was inhibited by pre-incubation of bacteria with anti-CbpA antibody (Fig. 8A). 
These data were confirmed by immunofluorescence confocal microscopy analysis, showing a 
larger number of L. lactis-CbpA bacteria associated to fibroblasts compared to control strain 
(Fig. 8B). 
Interestingly, adhesion of the L. lactis-CbpA strain to differentiated Caco-2 cells was identical 
to that of control bacteria, confirming that CbpA does not bind to cells not producing ECM 
(Fig S3-C). 
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Discussion 
Antibiotic-induced disruption of the normal intestinal flora is normally a prerequisite for C. 
difficile colonization of the gut and onset of disease (Rupnik et al., 2009), with toxins A and B 
being the major virulence factors responsible for the clinical symptoms and signs of infection 
(Thelestam et al., 2000, Shen, 2012). However, adhesion to host tissues is considered a 
crucial step which allows pathogenic bacteria to persist in specific niches and it has been 
proposed that surface-associated determinants are likely to be important in C. difficile 
pathogenesis (Rupnik et al., 2009).  
Bioinformatic analysis of predicted cell wall-anchored proteins led us to study the CD3145 
gene (cbpA) coding for a polypeptide carrying an NVQTG motif at its C-terminus. This 
sequence feature, combined with evidence of surface exposure, suggests that CbpA is a 
substrate of the putative sortase B in C. difficile (Sebaihia et al., 2006) and belongs to the 
family of Gram-positive proteins anchored to the peptidoglycan. However to date the activity 
of a sortase in C. difficile has not been demonstrated. We await further studies involving 
genetic manipulation of the C-terminal sorting sequence of putative substrates and the sortase 
B gene in C. difficile to determine whether CbpA is a bona fide sortase substrate. Based on 
functional evidence, CbpA can be ascribed to the MSCRAMM family, which includes 
bacterial adhesins that specifically interact with ECM components (Patti et al., 1994, Chagnot 
et al., 2012). Direct binding assays using recombinant CbpA on immobilized ECM 
components demonstrated the ability of the protein to bind with high affinity to collagen I and 
V. Of importance, ELISA affinity analysis of the binding of CbpA to collagen types was 
complemented with extensive confocal microscopy studies demonstrating that the protein 
displays binding activity toward collagen I and V in a cellular and tissutal context. Indeed, 
CbpA was co-localized with collagen fibers produced by human fibroblasts and showed a 
tropism to ex vivo gut tissues in accordance to the wide distribution of collagens in the sub-
mucosa. The binding was impaired by pre-incubation of cells and tissues with unlabeled 
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protein, indicating the specificity of the interaction. To further evaluate the role of CbpA as 
adhesin in the bacterial background, we employed L. lactis as heterologous system. This 
model has been used for expression of MSCRAMMs from several pathogens, such as 
Staphylococcus epidermidis and Staphylococcus aureus, to evaluate their adhesive capacity 
(Arrecubieta et al., 2007, Sinha et al., 2000). L. lactis displaying CbpA on its surface acquired 
increased ability to interact to immobilized collagen V and to adhere to human fibroblasts, 
and specific serum against the recombinant protein inhibits this capacity. 
Collagens are the major structural components of the ECM and participate in many cellular 
processes such as cell attachment, differentiation and migration (Gelse et al., 2003). There are 
more than 20 types of collagen of which types I and V account for the most common 
components of fibrils (Gelse et al., 2003, Chagnot et al., 2012). Type I collagen is the most 
abundant and is typically incorporated into composite fibers containing either type III or type 
V collagen, depending to tissue type (Gelse et al., 2003, Graham et al., 1988). Many bacteria 
have evolved to express adhesins to interact with collagens (Foster et al., 1998, Arrecubieta et 
al., 2007). In particular, type I and V collagens have been identified as the target of 
enteropathogenic E. coli (Ljungh et al., 1990), enterobacteria (Tarkkanen et al., 1990) and 
Bifidobacterium adolescentis (Mukai et al., 1997).  
As expected for a multi-factorial function such as the targeting of the ECM, when we studied 
the role of CbpA in the clostridial background we were not able to observe a significant 
contribution to the adhesion process. Indeed, CbpA is one of a number of clostridial proteins 
sharing the common function of binding to the ECM. Examples are the high-molecular-
weight subunit of SLP, which is able to mediate the attachment to collagen I, thrombospondin 
and vitronectin (Calabi et al., 2002) and the manganese-binding protein Fbp68, having 
binding activity toward fibronectin (Hennequin et al 2003; Lin et al, 2011). Moreover, several 
genes containing ECM–binding domains are predicted in the genome of C. difficile 630 as 
potential virulence factors (Sebaihia et al., 2006). Thus, the apparent common function of 
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predicted ECM adhesins highlights that, in C. difficile as in many other human pathogens, a 
diverse adhesive repertoire could be an added value in the competition for specific niches, in 
which affinity for specific substrates and their availability might be determinant to a 
successful colonization. On the other hand, the presence of multiple factors sharing functional 
similarity makes it difficult to determine the relative contribution of individual adhesin to the 
colonization processes. 
Moreover, the expression level of CbpA in our in vitro experimental conditions could affect 
the evaluation of the contribution of the protein in the adhesion process. It has been recently 
reported that CbpA is one of the proteins up-regulated in a pig ligated loop model, aimed at 
the identification bacterial genes involved in pathogenesis (Scaria et al., 2011). In this study, 
microarray analysis of C. difficile strain 630 transcriptome at different time points after 
infection, revealed the up-regulation of cbpA/CD3145 transcription at 8 and 12 hours. 
Interestingly, the up-regulation is shared with other putative collagen binding proteins (e.g. 
CD0386, CD2831 and CD3392) as well as with known proteins involved in host-pathogen 
interaction, such as fbp68 and slpA. We can then hypothesize that variable expression of the 
protein may modulate the binding characteristics of the bacterium in response to 
environmental changes encountered within the host during the colonization. 
The interaction of bacterial pathogens with the ECM is an important virulence mechanism 
contributing to host colonization. While the ECM is not accessible to pathogens under normal 
conditions, we could hypothesize that it may be exposed to pathogen as consequence of tissue 
damage. Based on the current knowledge of C. difficile molecular mechanisms of 
pathogenesis and the data reported in this study, we propose a model of gut colonization in 
which the disruption of tight junctions mediated by TcdA and B (Nusrat et al., 2001), together 
with the degradative activity toward ECM components displayed by Cwp84 (Janoir et al., 
2007) and other hydrolytic enzymes (Seddon et al., 1990, Seddon et al., 1992, Poilane et al., 
1998), could cause destabilization of intestinal mucosa and allow C. difficile to gain access to 
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ECM. This interaction may allow bacteria to use the submucosal matrix as a molecular bridge 
to increase their adherence to host tissues. The data reported in this study, propose that by the 
contribution of ECM-binding surface determinants, such as CbpA, the bacterium may take 
advantage to successfully compete for the occupancy of the intestinal niche. 
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Experimental procedures 
 
Bacterial strains and growth conditions 
L. lactis MG1363 strain was cultured statically at 30°C in M17 growth medium supplemented 
with 0.5% glucose and, when required, 20 ug ml
-1
 chloramphenicol.  
C. difficile strains were grown in anaerobiosis at 37°C in Brain-Heart Infusion (BHI) broth. 
Escherichia coli HK100 cells and BL21(DE3)T1
R
 strains, used to clone and express CbpAI-II, 
were cultured at 37°C in Luria-Bertani (LB) broth supplemented with 100 ug ml
-1 
ampicillin. 
 
Plasmid construction, DNA manipulation and mutant generation 
For the expression of recombinant CbpAI-II (amino acids 29-841), the corresponding sequence 
was amplified by PCR using chromosomal DNA from C. difficile 630 strain as template. The 
PCR products was cloned in pET15b+ expression vector (Novagen) using the PIPE cloning 
method (Klock et al., 2009). The PCR-amplified vector and the PCR-amplified CbpAI-II 
sequence were mixed and transformed in the HK100 E. coli strain (Klock et al., 2005). The 
correct transformant was then selected by PCR screening and DNA sequencing of the 
plasmids extracted from the PCR-positive clones. In order to express the cloned CbpAI-II 
protein, the plasmid was extracted from the selected HK100 clone and subcloned in 
chemically competent BL21-DE3T1
r
 cells (New England Biolabs). 
The C. difficile 630 erythromycin-sensitive strain (630∆erm) was used to make a cbpA mutant 
using the ClosTron technique (Heap et al., 2010).  More specifically, the cbpA mutant was 
generated by the targeted insertion into the cbpA gene of a bacterial group II intron containing 
a retrotransposition-activated marker (RAM) conferring erythromycin resistance. 
pMTL007C-E5 CD3145-18Ua (pHAS018) was generated to insert the group II intron 18 bp 
upstream of the transcriptional start site as no insertion sites were predicted within the gene 
sequence. E. coli CA434 transformed with pHAS018 was grown in LB with 15 µg ml
-1
 
Page 15 of 37 Cellular Microbiology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16 
 
chloramphenicol and conjugated with 630∆erm strain grown overnight in TY (Tryptone 
Peptone and Yeast extract) medium. The conjugation mixture was incubated overnight at 
37°C under anaerobic conditions on non-selective Brazier’s agar. C. difficile containing 
pHAS018 were selected with thiamphenicol (15 µg ml
-1
), with  cefoxitin and cycloserine 
(Bioconnection) counter-selection against E. coli. Transconjugates were tested for intron 
insertion by selection on Brazier’s agar containing erythromycin (5 µg ml
-1
) and for 
thiamphenicol sensitivity.  
For complementation of the cbpA mutant the CD3145 gene was amplified without its signal 
peptide from C. difficile 630 genomic DNA using Primer F: 5’-
GGGGCTCGAGGATACTATAGAAGAAAGTACTAATGCAG-3’ and Primer R: 5’-
GGGGACTAGTTTATTTACGTCTTAAGTATTTATTTGTTAGATTTTTAATTA-3’). 
pRPF144, a derivative of pMTL960 that contains the cwp2 promoter (Fagan et al., 2011) was 
modified to contain the slpA signal peptide followed by a Strep II tag and an XhoI restriction 
site, producing pHAS007. The amplified CD3145 was ligated between XhoI and SpeI sites of 
pHAS007 placing it under the control of the constitutive cwp2 promoter, with an N-terminal 
Strep II tag generating pHAS033.  
For the construction of L. lactis strain surface-expressing CbpA, the CD3145 gene was 
amplified by PCR from C. difficile 630 genomic DNA using primer 1: 5’-
GAGGTTAAGGCTAACGGTTCAAATACTTTCGCAGATACTATAGAAGAAAG-3’ and 
primer 2: 5’-ACCTGTTGATGGTAATTGACCTACATTACTATCTAAACTTTCATCTG-3’ 
and cloned in pAM401 expression vector (Buccato et al., 2006). The sequence coding for the 
leader peptide (1-72 bp) and the NVQTG-motif at C-terminal (3463-3573 bp) were 
substituted with the same regions of the GAS M1 gene (1-129 bp and 1348-1455 
respectively), to ensure the surface exposure in L. lactis as described by (Edwards et al., 
2008). pAM401-M1 was used as template to amplify the expression vector containing the 
leader peptide and the C-terminal of M1 protein  (Primer3: 5’-
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GATAGTAATGTAGGTCAATTACCATCAACAGGTGAAACAGCTAACCCA-3’; 
primer4:  
5’-GTATCTGCGAAAGTATTTGAACCGTTAGCCTTAACCTCTGTTTGATTCGC-3’). 
HK100 cells were used to clone the two PCR products using the PIPE method. The new 
assembled vector was used to transform L. lactis subspecies cremoris MG1363 strain by 
electroporation. 
 
Expression and purification of recombinant CbpAI-II 
A single colony of E. coli BL21(DE3)T1
R
 expressing CbpAI-II was inoculated in LB 
containing 100 µg ml
-1
 ampicillin and grown overnight at 37°C. The bacterial culture was 
diluted 1: 100 in Complex Medium (CM: yeast extract , KH2PO4 5,4 g/l, K2HPO4 15,6 g/l, 
MgSO4 250 mg/l, glycerol 15 g/l, pH 7.4) supplemented with 200 µg ml
-1 
ampicillin and 
grown for 30 h at 25°C. Recombinant CbpAI-II His-tagged protein was purified by affinity 
chromatography on Ni
2+
-NTA Superflow (Qiagen). The purity of the protein was checked by 
SDS-PAGE followed by Coomassie Blue staining and the protein concentration was 
determined by the BCA reagent (Thermo Scientific). 
 
Production of  polyclonal antibody against CbpAI-II 
5-week-old CD1 female mice were inoculated intraperitoneally three times (day 0, 21 and 35) 
with 10 µg of recombinant CbpAI-II in the presence of Aluminum hydroxide. The immune 
serum was obtained 14 days after the last inoculation. The procedures were performed in 
accordance with internal animal ethical committee and institutional guidelines. 
 
Cell fractionation and protein analysis 
To obtain cell wall-associated proteins of C. difficile strains, bacteria were grown until 
exponential phase, harvested by centrifugation at 3000 × g for 10 minutes and washed in Tris-
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sucrose buffer (TS: 10 mM Tris-HCl pH 6.9, 10 mM MgCl2, 0.5 M sucrose). Cells were 
resuspended in TS buffer (1/5 of initial volume), protease inhibitor cocktail (Complete Mini 
EDTA-free, Roche) and 250 µg ml
-1
 of mutanolysin (Sigma) and digestion was allowed to 
proceed for 2 h at 37°C with gentle agitation. The majority of intact protoplasts were removed 
by centrifugation at 3000 × g for 30 minutes. The supernatant was then subjected to 
microcentrifugation at 17 000 × g for 30 minutes to remove cell debris and any remaining 
protoplasts. The supernatant containing the solubilized cell surface proteins was recovered.  
To obtain cell wall-associated protein of L. lactis strains, bacteria were grown to exponential 
phase, centrifuged and resuspendend in protoplast buffer (0.1 M KPO4 pH 6.2, 40% sucrose, 
10 mM MgCl2 and protease inhibitor cocktail) with 100 U µl
-1
 mutanolysin for 1 h at 37°C. 
The majority of intact protoplasts were removed by centrifugation at 3000 × g for 30 minutes. 
The supernatant containing the solubilized cell surface proteins was recovered.  
Proteins were separated by SDS-PAGE electrophoresis using NuPAGE Gel System 
(Invitrogen), according to the manufacturer’s instructions. Samples were transferred to 
nitrocellulose membranes for Western blot analysis. Membranes transferred proteins were 
blocked with PBS containing 0.05% Tween 20 (PBST) and 10% skim milk powder (MERK). 
Proteins on nitrocellulose membranes were detected with anti-CbpAI-II serum followed by the 
HRP-conjugated secondary antibodies (DAKO) diluted in PBST and 3% skim milk powder. 
Bands were visualized with Super Signal® West Pico Chemiluminescent Substrate (Thermo 
Scientific). 
 
Cell culture 
IMR-90 cells (Human fibroblasts, ATCC) were maintained in Eagle’s Minimum Essential 
Medium (EMEM, ATCC) supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Gibco) and antibiotics. Cells were grown at 37°C with 5% CO2. 
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Caco-2 cells (Human epithelial colorectal adenocarcinoma, ATCC) were maintained in 
Eagle’s Minimum Essential Medium (EMEM, ATCC) supplemented with 20% heat-
inactivated fetal bovine serum (FBS, Gibco) and antibiotics. Cells were grown at 37°C with 
5% CO2. 
 
Immunofluorescence analysis 
To verify the presence of CbpA on bacterial surface of C. difficile and L. lactis strains, 
bacteria were grown until exponential phase, washed with PBS and, after centrifugation, 
resuspended in 3.7% paraformaldehyde (Sigma) for fixation. After multiple washings, 
bacteria were spread on polylisine-coated slides and blocked with PBS +3% Bovine Serum 
Albumin (BSA) (Sigma) for 1 h at room temperature. Samples were washed and incubated 
with anti-CbpAI-II serum (1:500) for 1 h at room temperature. Bacteria were washed several 
time with PBS and incubated with Alexa Fluor 568 goat anti-mouse IgG (1:500) (Molecular 
Probes). Labeled samples were mounted with ProLong
®
 Gold antifade reagent with DAPI 
(Molecular Probes) and analyzed with Zeiss LSM710 confocal microscope. 
 
Labeling of recombinant protein 
Purified recombinant CbpAI-II was labeled with Alexa Fluor® 488 Microscale Protein 
Labeling Kit (Molecular Probes), according to the manufacturer’s instructions. 
 
ECM labeling and binding assay on eukaryotic cells 
IMR-90 cells were seeded on 8-well chamber slides coated with collagen I (2.5 × 10
4
/ well) 
(BD BioCoat) and cultured for 3 days. Caco-2 cells were seeded on inserts coated with 
collagen I (10
5
/ well) (BD BioCoat) and cultured for 21 days changing the medium twice a 
week. Cells were then incubated with 20 µg ml
-1
 of recombinant CbpAI-II conjugated with 
Alexa Fluor 488 dye for 2 h at 37°C. After washing to remove unbound protein, cells were 
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fixed with 3.7% paraformaldehyde. Samples were washed extensively and incubated with the 
following rabbit anti-ECM components antibodies for 1 h at room temperature: anti-
fibronectin (SIGMA) 1:200, anti-collagen I (Abcam) 1:50, anti-collagen V (Santa Cruz) 1:50, 
anti-heparan sulfate (Millipore) 1:50. After multiple washings, samples were incubated with 
Alexa Fluor 568 goat anti-rabbit IgG (1:500) and Alexa Fluor 647-conjugated phalloidin 
(1:200) (Molecular Probes). To perform the competition assay, cells were incubated with 50 
µg ml
-1
 of unlabeled CbpAI-II for 2 h at 37°C; after pre-incubation, wells were washed with 
PBS and were used for the binding assay described above. To perform the serum-mediated 
inhibition assay, CbpAI-II conjugated with Alexa Fluor 488 dye was pre-incubated with anti-
CbpAI-II serum (1:10) for 1 h at 37°C and added to cells as above. As negative control, protein 
was incubated with the same concentrations of a pre-immune serum. Glass coverslips were 
mounted with ProLong
®
 Gold antifade reagent with DAPI and analyzed with Zeiss LSM710 
confocal microscope.  
 
Binding assay with recombinant protein on mouse gut cryo-sections 
Samples from different intestinal tracts (duodenum, jejunum, ileum and colon) were collected 
from CD1 mice and stored at -80°C. 8 µm cryo-sections were fixed with 3.7% 
paraformaldehyde and, after multiple washings, were incubated with 20 µg ml
-1
 of 
recombinant CbpAI-II conjugated with Alexa Fluor 488 dye for 2 h at room temperature. 
Samples were washed extensively and ECM and actin stained as described above. To perform 
the competition assay, sections were incubated with 50 µg ml
-1
 of unlabeled CbpAI-II for 2 h 
at room temperature; after pre-incubation, sections were washed with PBS and were used for 
the binding assay described above. Glass coverslips were mounted with ProLong
®
 Gold anti-
fade reagent with DAPI and analyzed with Zeiss LSM710 confocal microscope. 
 
Enzyme-linked Immunosorbent Assays  
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Flat bottom 96-well microtiter plates (Greiner Bio-One) were coated with 10 µg ml
-1
 of each 
ECM component (collagen I, II, III, IV, V, VI in free form, laminin α1β1γ1, fibrinogen and 
soluble fibronectin) or BSA overnight at 4°C. Wells were washed with PBS + 0.05% Tween 
and blocked them for 2 h at 37°C with Polyvinylpyrrolidone (PVP, SERVA); after several 
washings plates were incubated overnight at 4°C. CbpAI-II was serially diluted (from 4 to 480 
nM) and incubated for 2 h at 37°C. To detect the binding, plates were washed and incubated 
with anti-CbpAI-II serum for 1 h at 37°C followed by incubation with HRP-conjugated anti 
mouse antibodies. Wells were developed with o-Phenylenediamine dihydrochloride 
(SigmaFast OPD, Sigma). The reaction was stopped by adding 12.5% H2SO4 and finally the 
absorbance at 490 nm was measured. BSA coating was used as negative control. 
 
Bacterial adherence to immobilized collagen V 
Flat bottom 96-well microtiter plates were coated with 10 µg ml
-1
 of collagen V overnight at 
4°C. After several washings with PBS, wells were blocked with PBS containing 2% skimmed 
milk powder (MERK) for 1 h. L. lactis or C. difficile strains were grown to exponential phase, 
resuspended in DMEM medium to an OD600 of 1 and added to the microtiter wells. After 2 h 
of incubation at 37°C, plates were washed with PBS and adherent bacteria were collected by 
treatment with 0.25% trypsin/EDTA for 5 minutes at 37°C. Bacterial suspensions were 
serially diluted and plated for CFU enumeration. Wells coated with BSA were used as 
negative control. To perform the inhibition of adherence to Collagen V, L. lactis cells were 
pre-incubated with anti-CbpAI-II serum (1:500) for 1 h at 37°C. As negative control, bacteria 
were incubated with the same concentrations of a pre-immune serum. After pre-incubation, 
bacteria were centrifuged and resuspended in DMEM without glucose and were used for the 
adherence assay protocol described above. 
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Quantification of bacterial adhesion on eukaryotic cells by viable counting and 
immunofluorescence analysis 
IMR-90 cells were seeded on 96-well tissue culture plates coated with collagen I (10
4
 cells / 
well) and cultured for 3 days. One day before infection, cells were incubated for 24 h in an 
antibiotic-free medium. L. lactis or C. difficile strains were grown to exponential phase and 
added at multiplicity of infection (MOI) of 100:1 in DMEM without glucose for 2 h at 37°C 
in 5% CO2. After several washings to remove non-adherent bacteria, cells were lysed with 1% 
saponin (Sigma), bacterial suspensions were serially diluted and plated onto appropriated 
culture solid medium for CFU enumeration. To perform the inhibition of adhesion, L. lactis 
cells were pre-incubated with anti-CbpAI-II serum (1:500) for 1 h at 37°C. As negative control, 
bacteria were incubated with the same concentrations of a pre-immune serum. After pre-
incubation, bacteria were centrifuged and resuspended in DMEM without glucose and were 
used for the adhesion assay as described above. For immunofluorescence analysis, cells 
seeded on chamber slides coated with collagen I were incubated with bacteria as described 
above. After incubation, wells were washed with PBS and fixed with 3.7% paraformaldehyde. 
Subsequently, samples were blocked with PBS containing 3% BSA for 1 h at room 
temperature and incubated with mouse polyclonal serum against PFA-fixed whole bacteria 
(1:1000) for 1 h at room temperature. Wells were washed several time with PBS and 
incubated with Alexa Fluor 488 goat anti-mouse IgG (1:500) and Alexa Fluor 568-conjugated 
phalloidin (1:200). Labeled samples were mounted with ProLong
®
 Gold antifade reagent with 
DAPI and analyzed with Zeiss LSM710 confocal microscope. 
 
Statistical analysis 
Results were assessed by the Student t test for unpaired data. P ≤ .05 was considered 
statistically significant (*,P ≤ .05; **, P ≤ .01; ***, P ≤ .001). 
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Figure legends 
Fig. 1. Schematic representation of CbpA (CD3145) protein organization.  
Fig. 2. Surface exposure of CbpA protein in 630 strain. 
A: Confocal microscopy analysis of surface-expression using anti-CbpAI-II antibody and a 
secondary fluorescent antibody (red). DNA was stained with DAPI (blue). Scale bars 
represent 2 µm. 
B: Western blot analysis on cell wall fractions obtained by mutanolysin extraction from wild 
type strain (lane 1), ∆cbpA knockout mutant strain (lane 2) and complemented 
∆cbpA(pCbpA+) strain (lane 3). A 118 kDa protein was detected in the wild-type and 
complemented strains using anti-CbpAI-II antibody. 
 
Fig. 3. Interaction of CbpAI-II with immobilized ECM (A) and ECM-producing human 
fibroblasts (B). 
A: ELISA plates were coated with 10 µg ml
-1
of collagen I and V and incubated with serial 
dilutions of recombinant CbpAI-II protein (4 nM to 480 nM). Binding of the protein was 
detected by anti-CbpAI-II antibody followed by HRP-conjugated-secondary antibody. BSA 
was used as negative control. Values represent the mean ± SD from three experiments. 
B. Cells were incubated with 20 µg ml
-1
 of CbpAI-II protein conjugated with Alexa Fluor 488 
dye (green) for 2 h at 37°C. After fixation, collagens I and V were labelled using specific 
antibody (red). DNA and actin were stained with DAPI (cyan) and Phalloidin-Alexa Fluor 
647 (blue), respectively.  
In competition experiments, cells were pre-incubated with an excess of unlabelled CbpA 
before binding to CbpAI-II /488. In inhibition experiments, the protein was pre-treated with 
anti-CbpA serum before binding to cells. Scale bars represent 10 µm. 
 
Fig.4. Binding of recombinant CbpAI-II to mouse small intestine cryosections. 
Small intestine sections were incubated with the recombinant CbpAI-II conjugated to Alexa 
Fluor488 dye (green) for 2 h at room temperature. Collagens I and V were labelled using 
specific antibodies (red) and actin was stained with Phalloidin-647 dye (blue). In competition 
experiments, sections were pre-incubated with an excess of unlabelled CbpA before binding 
to CbpAI-II /488. Scale bars represent 100 µm. 
 
Fig.5. Binding activity of C. difficile strains on immobilized collagen V and on IMR-90. 
A: Plates were coated with collagen V and adherence of wild type (), ∆cbpA () and 
∆cbpA(pCbpA+) (▲) strains was measured by detaching bacteria with trypsin and plating. 
Adhesion was expressed as percentage of total bacteria applied. P-values of ∆cbpA strain 
compared with wild tye and ∆cbpA(pCbpA+) strains are 0.31 and 0.78, respectively. 
B: IMR-90 cells were incubated for 2 h with wild type (), ∆cbpA () and ∆cbpA(pCbpA+) 
(▲) strains at an MOI of 100:1. After washing and saponin treatment, lysates were plated and 
the number of total adherent bacteria was expressed as percentage of total bacteria applied. P-
values of ∆cbpA strain compared with wild type and ∆cbpA(pCbpA+) strains are 0.15 and 
0.07, respectively. 
 
Fig. 6. Expression of CbpA in L. lactis.  
A: Confocal microscopy analysis of surface-expression in L. lactis-CbpA strain using anti-
CbpAI-II  antibody and a secondary fluorescent antibody (red). DNA was stained with DAPI 
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(blue). An L. lactis strain carrying the empty vector (L. lactis-pAM401) was used as negative 
control. Scale bars represent 2 µm. 
B: Western blot analysis of cell-wall fractions from L.lactis-pAM401 (lane 1) and L. lactis-
CbpA strains (lane 2). 
 
Fig.7. Binding activity of L. lactis-CbpA strain to immobilized collagen V and inhibition 
by anti-CbpA antibodies. 
Plates were coated with collagen V and incubated with L. lactis-pAM401 (), L. lactis-CbpA 
(), L. lactis-CbpA pre-treated with pre-immune serum (▲) and L. lactis-CbpA pre-treated 
with anti-CbpA serum (▼). The binding was measured by detaching bacteria with trypsin and 
counting CFU after plating.  
Adhesion was expressed as percentage of total bacteria applied.  
Values represent the mean ± SE; ***p<0.001 
 
Fig. 8. Adhesion of L. lactis-CbpA strain to IMR-90 human fibroblasts and inhibition by 
anti-CbpA antibodies. 
A: IMR-90 cells were infected for 2 h with L. lactis-pAM401 (), L. lactis-CbpA (), L. 
lactis-CbpA pre-treated with pre-immune serum (▲) and L. lactis-CbpA pre-treated with anti-
CbpA serum (▼) at an MOI of 100:1. After washing and saponin treatment, lysates were 
plated and the number of total adherent bacteria was expressed as percentage of total bacteria 
applied. Values represent the mean ± SE; ***p<0.001 
B: IMR-90 cells were infected for 2 h with L. lactis-pAM401, L. lactis-CbpA, L. lactis-CbpA 
pre-treated with anti-CbpA serum and, after washing, were fixed and stained for confocal 
immunoflurescent microscopy. Bacteria were labeled by an anti-whole bacteria serum and a 
secondary fluorescent antibody (green). DNA and cellular actin were stained with DAPI 
(blue) and Phalloidin-Alexa Fluor 568 (red), respectively. Scale bars represent 10 µm. 
 
 
Fig. S1. Interaction of CbpAI-II with immobilized ECM and saturation curves of CbpAI-II 
binding to collagen I and V. 
A: ELISA plates were coated with 10 µg ml
-1
of purified ECM components and incubated with 
serially diluted recombinant CbpAI-II protein (4 nM to 480 nM). Binding of the protein was 
detected by anti-CbpAI-II antibody followed by HRP-conjugated-secondary antibody. BSA 
protein was used as negative control. Values represent the mean ± SD from three independent 
experiments. 
B: Binding of CbpAI-II protein to collagen I and V was expressed as percentage of saturation 
of putative receptors. Kd values were calculated as intercept of 50% of saturation on the x-
axis. 
 
Fig. S2. Expression of ECM components by human fibrolasts. 
Human fibroblasts IMR-90 were cultured for 3 days and collagens I and V, fibronectin and 
heparan sulfate were labelled using specific antibody (red). Actin was stained with Phalloidin-
Alexa Fluor 647 (blue). Scale bars represent 10 µm. 
 
Fig. S3. Expression of ECM components (A) and binding of CbpAI-II to differentiated 
Caco-2 cells (B). 
A: Caco-2 cells were cultured for 21 days and collagens I and V and fibronectin were labelled 
using specific antibody (red). Actin was stained with Phalloidin-Alexa Fluor 647 (blue). 
B. Cells were incubated with 20 µg ml
-1
 of CbpAI-II protein conjugated with Alexa Fluor 488 
dye (green) for 1 h at 37°C. After fixation, actin was stained with Phalloidin-Alexa Fluor 647 
(blue). Scale bars represent 10 µm. 
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C: Cells were infected for 2 h with L. lactis-pAM401 () and L. lactis-CbpA () at an MOI 
of 100:1. After washing and saponin treatment, lysates were plated and the number of total 
adherent bacteria was expressed as percentage of total bacteria applied. Values represent the 
mean ± SE. 
 
Fig. S4. Binding of recombinant CbpAI-II to mouse colon cryosections. 
Colon sections were incubated with the recombinant CbpAI-II conjugated to Alexa Fluor488 
dye (green) for 2 h at room temperature. Collagens I and V were labelled using specific 
antibodies (red) and actin was stained with Phalloidin-647 dye (blue). Scale bars represent 
100 µm. 
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